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Guidelines for Preventing Opportunistic
Infections Among Hematopoietic Stem
Cell Transplant Recipients
Recommendations of CDC, the Infectious Disease
Society of America, and the American Society of Blood
and Marrow Transplantation
SUMMARY
CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation have cosponsored these guidelines
for preventing opportunistic infections (OIs) among hematopoietic stem cell transplant (HSCT) recipients. The guidelines were drafted with the
assistance of a working group of experts in infectious diseases, transplantation, and public health. For the purposes of this report, HSCT is defined as
any transplantation of blood- or marrow-derived hematopoietic stem cells, regardless of transplant type (i.e., allogeneic or autologous) or cell source (i.e.,
bone marrow, peripheral blood, or placental or umbilical cord blood). Such OIs as bacterial, viral, fungal, protozoal, and helminth infections occur with
increased frequency or severity among HSCT recipients. These evidence-based guidelines contain information regarding preventing OIs, hospital
infection control, strategies for safe living after transplantation, vaccinations, and hematopoietic stem cell safety. The disease-specific sections address
preventing exposure and disease for pediatric and adult and autologous and allogeneic HSCT recipients. The goal of these guidelines is twofold: to
summarize current data and provide evidence-based recommendations regarding preventing OIs among HSCT patients. The guidelines were
developed for use by HSCT recipients, their household and close contacts, transplant and infectious diseases physicians, HSCT center personnel, and
public health professionals. For all recommendations, prevention strategies are rated by the strength of the recommendation and the quality of the
evidence supporting the recommendation. Adhering to these guidelines should reduce the number and severity of OIs among HSCT recipients.
INTRODUCTION
In 1992, the Institute of Medicine (1 ) recommended that
CDC lead a global effort to detect and control emerging in-
fectious agents. In response, CDC published a plan (2 ) that
outlined national disease prevention priorities, including the
development of guidelines for preventing opportunistic infec-
tions (OIs) among immunosuppressed persons. During 1995,
CDC published guidelines for preventing OIs among persons
infected with human immunodeficiency virus (HIV) and re-
vised those guidelines during 1997 and 1999 (3–5 ). Because
of the success of those guidelines, CDC sought to determine
the need for expanding OI prevention activities to other im-
munosuppressed populations. An informal survey of hema-
tology, oncology, and infectious disease specialists at trans-
plant centers and a working group formed by CDC deter-
mined that guidelines were needed to help prevent OIs among
hematopoietic stem cell transplant (HSCT)* recipients.
The working group defined OIs as infections that occur
with increased frequency or severity among HSCT recipi-
ents, and they drafted evidence-based recommendations for
preventing exposure to and disease caused by bacterial, fun-
gal, viral, protozoal, or helminthic pathogens. During March
1997, the working group presented the first draft of these
guidelines at a meeting of representatives from public and
private health organizations. After review by that group and
other experts, these guidelines were revised and made avail-
able during September 1999 for a 45-day public comment
period after notification in the Federal Register. Public com-
ments were added when feasible, and the report was approved
by CDC, the Infectious Disease Society of America, and the
American Society of Blood and Marrow Transplantation. The
pediatric content of these guidelines has been endorsed also
by the American Academy of Pediatrics. The hematopoietic
stem cell safety section was endorsed by the International So-
ciety of Hematotherapy and Graft Engineering.
The first recommendations presented in this report are fol-
lowed by recommendations for hospital infection control,
strategies for safe living, vaccinations, and hema-topoietic stem
cell safety. Unless otherwise noted, these recommendations ad-
dress allogeneic and autologous and pediatric and adult HSCT
recipients. Additionally, these recommendations are intended
for use by the recipients, their household and other close con-
tacts, transplant and infectious diseases specialists, HSCT cen-
ter personnel, and public health professionals.
8*For this report, HSCT is defined as any transplantation of blood- or marrow-derived hematopoietic stem cells, regardless of transplant
type (e.g., allogeneic or autologous) or cell source (e.g., bone marrow, peripheral blood, or placental/umbilical cord blood). In addition,
HSCT recipients are presumed immunocompetent at ≈24 months after HSCT if they are not on immunosuppressive therapy and do not
have graft-versus-host disease (GVHD), a condition that occurs when the transplanted cells recognize that the recipient’s cells are not the
same cells and attack them.
Using These Guidelines
For all recommendations, prevention strategies are rated by
the strength of the recommendation (Table 1) and the quality
of the evidence (Table 2) supporting the recommendation. The
principles of this rating system were developed by the Infec-
tious Disease Society of America and the U.S. Public Health
Service for use in the guidelines for preventing OIs among HIV-
infected persons (3–6 ). This rating system allows assessments
of recommendations to which adherence is critical.
BACKGROUND
HSCT is the infusion of hematopoietic stem cells from a
donor into a patient who has received chemotherapy, which is
usually marrow-ablative. Increasingly, HSCT has been used to
treat neoplastic diseases, hematologic disorders, immunodefi-
ciency syndromes, congenital enzyme deficiencies, and autoim-
mune disorders (e.g., systemic lupus erythematosus or multiple
sclerosis) (7–10 ). Moreover, HSCT has become standard treat-
ment for selected conditions (7,11,12 ). Data from the Interna-
tional Bone Marrow Transplant Registry and the Autologous
Blood and Marrow Transplant Registry indicate that
approximately 20,000 HSCTs were performed in North
America during 1998 (Statistical Center of the International
Bone Marrow Transplant Registry and Autologous Blood and
Marrow Transplant Registry, unpublished data, 1998).
HSCTs are classified as either allogeneic or autologous on
the basis of the source of the transplanted hematopoietic pro-
genitor cells. Cells used in allogeneic HSCTs are harvested from
a donor other than the transplant recipient. Such transplants
are the most effective treatment for persons with severe aplastic
anemia (13 ) and offer the only curative therapy for persons
with chronic myelogenous leukemia (12 ). Allogeneic donors
might be a blood relative or an unrelated donor. Allogeneic
transplants are usually most successful when the donor is a hu-
man lymphocyte antigen (HLA)-identical twin or matched sib-
ling. However, for allogeneic candidates who lack such a donor,
registry organizations (e.g., the National Marrow Donor Pro-
gram) maintain computerized databases that store information
regarding HLA type from millions of volunteer donors
(14–16 ). Another source of stem cells for allogeneic candidates
without an HLA-matched sibling is a mismatched family mem-
ber (17,18 ). However, persons who receive allogeneic grafts
from donors who are not HLA-matched siblings are at a sub-
stantially greater risk for graft-versus-host disease (GVHD)
(19 ). These persons are also at increased risk for suboptimal
graft function and delayed immune system recovery (19 ). To
reduce GVHD among allogeneic HSCTs, techniques have been
developed to remove T-lymphocytes, the principal effectors of
GVHD, from the donor graft. Although the
recipients of T-lymphocyte–depleted marrow grafts generally
have lower rates of GVHD, they also have greater rates of graft
rejection, cytomegalovirus (CMV) infection, invasive fungal
infection, and Epstein-Barr virus (EBV)-associated
posttransplant lymphoproliferative disease (20 ).
The patient’s own cells are used in an autologous HSCT.
Similar to autologous transplants are syngeneic transplants,
among whom the HLA-identical twin serves as the donor. Au-
tologous HSCTs are preferred for patients who require high-
level or marrow-ablative chemotherapy to eradicate an under-
lying malignancy but have healthy, undiseased bone marrows.
Autologous HSCTs are also preferred when the immunologic
antitumor effect of an allograft is not beneficial. Autologous
HSCTs are used most frequently to treat breast cancer, non-
Hodgkin’s lymphoma, and Hodgkin’s disease (21 ). Neither au-
tologous nor syngeneic HSCTs confer a risk for chronic
GVHD.
Recently, medical centers have begun to harvest hemato-
poietic stem cells from placental or umbilical cord blood (UCB)
immediately after birth. These harvested cells are used prima-
rily for allogeneic transplants among children. Early results
demonstrate that greater degrees of histoincompatibility be-
tween donor and recipient might be tolerated without graft re-
jection or GVHD when UCB hematopoietic cells are used (22–
24 ). However, immune system function after UCB transplants
has not been well-studied.
HSCT is also evolving rapidly in other areas. For example,
hematopoietic stem cells harvested from the patient’s periph-
eral blood after treatment with hematopoietic colony-stimulat-
ing factors (e.g., granulocyte colony-stimulating factor [G-CSF
or filgastrim] or granulocyte-macrophage colony-stimulating
factor [GM-CSF or sargramostim]) are being used increasingly
among autologous recipients (25 ) and are under investigation
for use among allogeneic HSCT. Peripheral blood has largely
replaced bone marrow as a source of stem cells for autologous
recipients. A benefit of harvesting such cells from the donor’s
peripheral blood instead of bone marrow is that it eliminates
the need for general anesthesia associated with bone marrow
aspiration.
GVHD is a condition in which the donated cells recognize
the recipient’s cells as nonself and attack them. Although the
use of intravenous immunoglobulin (IVIG) in the
routine management of allogeneic patients was common in the
past as a means of producing immune modulation among pa-
tients with GVHD, this practice has declined because of cost
factors (26 ) and because of the development of other strategies
for GVHD prophylaxis (27 ). For example, use of cyclosporine
GVHD prophylaxis has become commonplace since its intro-
duction during the early 1980s. Most frequently, cyclosporine
or tacrolimus (FK506) is administered in combination with
other immunosuppressive agents (e.g., methotrexate or corti-
costeroids) (27 ). Although cyclosporine is effective in prevent-
ing GVHD, its use entails greater hazards for infectious com-
plications and relapse of the underlying neoplastic disease for
which the transplant was performed.
Although survival rates for certain autologous recipients
have improved (28,29 ), infection remains a leading cause of
death among allogeneic transplants and is a major cause of
morbidity among autologous HSCTs (29 ). Researchers from
the National Marrow Donor Program reported that, of 462
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persons receiving unrelated allogeneic HSCTs during Decem-
ber 1987–November 1990, a total of 66% had died by 1991
(15 ). Among primary and secondary causes of death, the most
common cause was infection, which occurred among 37% of
307 patients (15 ).*
Despite high morbidity and mortality after HSCT, recipi-
ents who survive long-term are likely to enjoy good health. A
survey of 798 persons who had received an HSCT before 1985
and who had survived for >5 years after HSCT, determined
that 93% were in good health and that 89% had returned to
work or school full time (30 ). In another survey of 125 adults
who had survived a mean of 10 years after HSCT, 88%
responded that the benefits of transplantation outweighed the
side effects (31 ).
Immune System Recovery After HSCT
During the first year after an HSCT, recipients typically
follow a predictable pattern of immune system deficiency and
recovery, which begins with the chemotherapy or radiation
therapy (i.e., the conditioning regimen) administered just be-
fore the HSCT to treat the underlying disease. Unfortunately,
this conditioning regimen also destroys normal hematopoiesis
for neutrophils, monocytes, and macrophages and damages
mucosal progenitor cells, causing a temporary loss of mucosal
barrier integrity. The gastrointestinal tract, which normally
contains bacteria, commensal fungi, and other bacteria-
carrying sources (e.g., skin or mucosa) becomes a reservoir of
potential pathogens. Virtually all HSCT recipients rapidly lose
all T- and B-lymphocytes after conditioning, losing immune
memory accumulated through a lifetime of exposure to infec-
tious agents, environmental antigens, and vaccines. Because
transfer of donor immunity to HSCT recipients is variable and
influenced by the timing of antigen exposure among donor and
recipient, passively acquired donor immunity cannot be relied
upon to provide long-term immunity against infectious diseases
among HSCT recipients.
During the first month after HSCT, the major host-defense
deficits include impaired phagocytosis and damaged mucocu-
taneous barriers. Additionally, indwelling intravenous catheters
are frequently placed and left in situ for weeks to administer
parenteral medications, blood products, and nutritional supple-
ments. These catheters serve as another portal of entry for op-
portunistic pathogens from organisms colonizing the skin (e.g.,
coagulase-negative Staphylococci, Staphylococcus aureus, Candida
species, and Enterococci ) (32,33 ).
Engraftment for adults and children is defined as the point
at which a patient can maintain a sustained absolute neutrophil
count (ANC) of >500/mm3 and sustained platelet count of
≈20,000, lasting ≈3 consecutive days without transfusions.
Among unrelated allogeneic recipients, engraftment occurs at
a median of 22 days after HSCT (range: 6–84 days) (15 ). In the
absence of corticosteroid use, engraftment is associated with
the restoration of effective phagocytic function, which results
in a decreased risk for bacterial and fungal infections. However,
all HSCT recipients and particularly allogeneic recipients, ex-
perience an immune system dysfunction for months after en-
graftment. For example, although allogeneic recipients might
have normal total lymphocyte counts within ≈2 months after
HSCT, they have abnormal CD4/CD8 T-cell ratios, reflecting
their decreased CD4 and increased CD8 T-cell counts (27 ).
They might also have immunoglobulin G (IgG)2, IgG4, and im-
munoglobulin A (IgA) deficiencies for months after HSCT and
have difficulty switching from immunoglobulin M (IgM) to IgG
production after antigen exposure (32 ). Immune system recov-
ery might be delayed further by CMV infection (34 ).
During the first ≈2 months after HSCT, recipients might
experience acute GVHD that manifests as skin, gastrointesti-
nal, and liver injury, and is graded on a scale of I–IV (32,35,36 ).
Although autologous or syngeneic recipients might occasion-
ally experience a mild, self-limited illness that is acute GVHD-
like (19,37 ), GVHD occurs primarily among allogeneic recipi-
ents, particularly those receiving matched, unrelated donor
transplants. GVHD is a substantial risk factor for infection
among HSCT recipients because it is associated with a delayed
immunologic recovery and prolonged immunodeficiency (19 ).
Additionally, the immunosuppressive agents used for GVHD
prophylaxis and treatment might make the HSCT recipient
more vulnerable to opportunistic viral and fungal
pathogens (38 ).
Certain patients, particularly adult allogeneic recipients,
might also experience chronic GVHD, which is graded as ei-
ther limited or extensive chronic GVHD (19,39 ). Chronic
GVHD appears similar to autoimmune, connective-tissue dis-
orders (e.g., scleroderma or systemic lupus erythematosus) (40 )
and is associated with cellular and humoral immunodeficien-
cies, including macrophage deficiency, impaired neutrophil
chemotaxis (41 ), poor response to vaccination (42–44 ), and
severe mucositis (19 ). Risk factors for chronic GVHD include
increasing age, allogeneic HSCT (particularly those among
whom the donor is unrelated or a non-HLA identical family
member) (40 ), and a history of acute GVHD (24,45 ). Chronic
GVHD was first described as occurring >100 days after HSCT
but can occur 40 days after HSCT (19 ). Although allogeneic
recipients with chronic GVHD have normal or high total se-
rum immunoglobulin levels (41 ), they experience long-lasting
IgA, IgG, and IgG subclass deficiencies (41,46,47 ) and poor
opsonization and impaired reticuloendothelial function. Con-
sequently, they are at even greater risk for infections (32,39 ),
particularly life-threatening bacterial infections from encapsu-
lated organisms (e.g., Stre. pneumoniae , Ha. influenzae , or Ne.
meningitidis ). After chronic GVHD resolves, which might take
years, cell-mediated and humoral immunity function are gradu-
ally restored.
Opportunistic Pathogens After HSCT
HSCT recipients experience certain infections at different
times posttransplant, reflecting the predominant host-defense
defect(s) (Figure). Immune system recovery for HSCT recipi-
ents takes place in three phases beginning at day 0, the day of
transplant. Phase I is the preengraftment phase (<30 days after
HSCT); phase II, the postengraftment phase (30–100 days af-
ter HSCT); and phase III, the late phase (>100 days after HSCT).
Prevention strategies should be based on these three phases and
the following information:
*Presently, no updated data have been published.                                                                 .
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• Phase I, preengraftment. During the first month
posttransplant, HSCT recipients have two critical risk
factors for infection — prolonged neutropenia and breaks
in the mucocutaneous barrier resulting from the HSCT
preparative regimens and frequent vascular access
required for patient care. Consequently, oral, gastro-
intestinal, and skin flora are sources of infection. Prevalent
pathogens include Candida  species, and as neutropenia
continues, Aspergillus  species. Additionally, herpes
simplex virus (HSV) reactivation can occur during this
phase. During preengraftment, the risks for infection are
the same for autologous or allogeneic patients, and OIs can
appear as febrile neutropenia. Although a recipient’s first
fever during preengraftment is probably caused by a
bacterial pathogen, rarely is an organism or site of
infection identified. Instead, such infections are usually
treated preemptively or empirically (48 ) until the
neutropenia resolves (49 ). Growth factors can be
administered during phase I to decrease neutropenia
duration and complications (e.g., febrile neutropenia)
(50 ).
• Phase II, postengraftment. Phase II is dominated by
impaired cell-mediated immunity for allogeneic or
autologous recipients. Scope and impact of this defect for
allogeneic recipients are determined by the extent of
GVHD and its immunosuppressive therapy. After
engraftment, the herpes viruses, particularly CMV, are
critical pathogens. At 30–100 days after HSCT, CMV
causes pneumonia, hepatitis, and colitis and potentiates
superinfection with opportunistic pathogens, particularly
among patients with active GVHD. Other dominant
pathogens during this phase include Pneumocystis carinii
and Aspergillus  species.
• Phase III, late phase. During phase III, autologous
recipients usually have more rapid recovery of immune
system function and, therefore, a lower risk for OIs than
do allogeneic recipients. Because of cell-mediated and
humoral immunity defects and impaired reticuloen-
dothelial system function, allogeneic patients with
chronic GVHD and recipients of alternate donor
allogeneic transplants are at risk for certain infections
during this phase. Alternate donors include matched
unrelated, UCB, or mismatched family-related donors.
These patients are at risk for infections that include
CMV, varicella-zoster virus (VZV), EBV-related
posttransplant lymphoproliferative disease, community-
acquired respiratory viruses (CRV), and infections with
encapsulated bacteria (e.g., Ha. influenzae and Stre.
pneumoniae). Risk for these infections is approximately
proportional to the severity of the patient’s GVHD during
phases II and III. Patients receiving mismatched allogeneic
transplants have a higher attack rate and severity of
GVHD and, therefore, a higher risk for OIs during phases
II and III than do patients receiving matched allogeneic
HSCTs. In contrast, patients undergoing autologous
transplantation are primarily at risk for infection during
phase I.
Preventing infections among HSCT recipients is preferable
to treating infections. However, despite recent technologic ad-
vances, more research is needed to optimize health outcomes for
HSCT recipients. Efforts to improve immune system reconstitu-
tion, particularly among allogeneic transplant recipients, and to
prevent or resolve the immune dysregulation resulting from do-
nor-recipient histoincompatibility and GVHD remain substan-
tial challenges for preventing recurrent, persistent, or progressive
infections among HSCT patients.
BACTERIAL INFECTIONS
General Recommendations
Preventing Exposure
Because bacteria are carried on the hands, health-care
workers (HCWs) and others in contact with HSCT recipients
should routinely follow appropriate hand-washing practices to
avoid exposing recipients to bacterial pathogens (AIII).
Preventing Disease
Preventing Early Disease (0–100 Days After HSCT).
Routine gut decontamination is not recommended for HSCT
candidates (51–53 ) (DIII). Because of limited data, no recom-
mendations can be made regarding the routine use of antibiot-
ics for bacterial prophylaxis among afebrile, asymptomatic neu-
tropenic recipients. Although studies have reported that using
prophylactic antibiotics might reduce bacteremia rates after
HSCT (51 ), infection-related fatality rates are not reduced
(52 ). If physicians choose to use prophylactic antibiotics
among asymptomatic, afebrile, neutropenic recipients, they
should routinely review hospital and HSCT center antibiotic-
*Since November 1997, the United States has had a shortage of intravenous immunoglobulin (IVIG) (Source: CDC. Availability of immune
globulin intravenous for treatment of immune deficient patients—United States, 1997–1998. MMWR 1999:48[8];159–162). Physicians
who have difficulty obtaining IVIG should contact the following sources:
• American Red Cross Customer Service Center, (800) 261-5772;
• Alpha Therapeutic Corporation, (800) 421-0008;
• Baxter Healthcare Corporation, (847) 940-5955;
• Bayer Pharmaceutical Division, (800) 288-8370;
• Aventis Behring Customer Support, (800) 683-1288;
• Novartis Pharmaceuticals Corporation, (973) 781-8300, or the IVIG Emergency Hotline, (888) 234-2520; or
• Immune Deficiency Foundation, (800) 296-4433.
Physicians who are unable to obtain IVIG for a licensed indication from one of these sources should contact the Product Shortage Officer
at the Food and Drug Administration’s Center for Biologics Evaluation and Research, Office of Compliance, (301) 827-6220, for assistance.
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susceptibility profiles, particularly when using a single anti-
biotic for antibacterial prophylaxis (BIII). The emergence
of fluoquinolone-resistant coagulase-negative Staphylococci
and Es. coli  (51,52 ), vancomycin-intermediate Sta. aureus
and vancomycin-resistant Enterococcus  (VRE) are increas-
ing concerns (54 ). Vancomycin should not be used as an
agent for routine bacterial prophylaxis (DIII). Growth fac-
tors (e.g., GM-CSF and G-CSF) shorten the duration of
neutropenia after HSCT (55 ); however, no data were found
that indicate whether growth factors effectively reduce the
attack rate of invasive bacterial disease.
Physicians should not routinely administer IVIG products to
HSCT recipients for bacterial infection prophylaxis (DII), al-
though IVIG has been recommended for use in producing
immune system modulation for GVHD prevention. Researchers
have recommended routine IVIG* use to prevent bacterial infec-
tions among the approximately 20%–25% of HSCT recipients
with unrelated marrow grafts who experience severe hypogamma-
globulinemia (e.g., IgG < 400 mg/dl) within the first 100 days
after transplant (CIII). For example, recipients who are
hypogammaglobulinemic might receive prophylactic IVIG to
prevent bacterial sinopulmonary infections (e.g., from Stre.
pneumoniae ) (8 ) (CIII). For hypogammaglobulinemic allogeneic
recipients, physicians can use a higher and more frequent dose of
IVIG than is standard for non-HSCT recipients because the IVIG
half-life among HSCT recipients (generally 1–10 days) is much
shorter than the half-life among healthy adults (generally 18–23
days) (56–58 ). Additionally, infections might accelerate IgG ca-
tabolism; therefore, the IVIG dose for a hypogammaglobulinemic
recipient should be individualized to maintain trough serum IgG
concentrations >400–500 mg/dl (58 ) (BII). Consequently, physi-
cians should monitor trough serum IgG concentrations among
these patients approximately every 2 weeks and adjust IVIG doses
as needed (BIII) (Appendix).
Preventing Late Disease (>100 Days After HSCT). Antibi-
otic prophylaxis is recommended for preventing infection with
encapsulated organisms (e.g., Stre. pneumoniae, Ha. influenzae, or
Ne. meningitidis ) among allogeneic recipients with chronic
GVHD for as long as active chronic GVHD treatment is admin-
istered (59 ) (BIII). Antibiotic selection should be guided by local
antibiotic resistance patterns. In the absence of severe demon-
strable hypogammaglobulinemia (e.g., IgG levels < 400 mg/dl,
which might be associated with recurrent sinopulmonary infec-
tions), routine monthly IVIG administration to HSCT recipi-
ents >90 days after HSCT is not recommended (60 ) (DI) as a
means of preventing bacterial infections.
Other Disease Prevention Recommendations. Routine use of
IVIG among autologous recipients is not recommended (61 )
(DII). Recommendations for preventing bacterial infections are
the same among pediatric or adult HSCT recipients.
Recommendations Regarding Stre. pneumoniae
Preventing Exposure
Appropriate care precautions should be taken with hospital-
ized patients infected with Stre. pneumoniae  (62,63 ) (BIII) to pre-
vent exposure among HSCT recipients.
Preventing Disease
Information regarding the currently available 23-valent pneu-
mococcal polysaccharide vaccine indicates limited immunogenic-
ity among HSCT recipients. However, because of its potential
benefit to certain patients, it should be administered to HSCT
recipients at 12 and 24 months after HSCT (64–66 ) (BIII). No
data were found regarding safety and immunogenicity of the 7-
valent conjugate pneumococcal vaccine among HSCT recipients;
therefore, no recommendation regarding use of this vaccine can
be made.
Antibiotic prophylaxis is recommended for preventing infec-
tion with encapsulated organisms (e.g., Stre. pneumoniae , Ha.
influenzae , and Ne. meningitidis ) among allogeneic recipients with
chronic GVHD for as long as active chronic GVHD treatment is
administered (59 ) (BIII). Trimethoprim-sulfamethasaxole (TMP-
SMZ) administered for Pneumocystis carinii  pneumonia (PCP)
prophylaxis will also provide protection against pneumococcal
infections. However, no data were found to support using TMP-
SMZ prophylaxis among HSCT recipients solely for the purpose
of preventing Stre. pneumoniae  disease. Certain strains of Stre.
pneumoniae  are resistant to TMP-SMZ and penicillin. Recom-
mendations for preventing pneumococcal infections are the same
for allogeneic or autologous recipients.
As with adults, pediatric HSCT recipients aged ≈2 years
should be administered the current 23-valent pneumococcal
polysaccharide vaccine because the vaccine can be effective (BIII).
However, this vaccine should not be administered to children aged
<2 years because it is not effective among that age population
(DI). No data were found regarding safety and immunogenicity
of the 7-valent conjugate pneumococcal vaccine among pediatric
HSCT recipients; therefore, no recommendation regarding use
of this vaccine can be made.
Recommendations Regarding Streptococci viridans
Preventing Exposure
Because Streptococci viridans  colonize the oropharynx and gut,
no effective method of preventing exposure is known.
Preventing Disease
Chemotherapy-induced oral mucositis is a potential source of
Streptococci viridans  bacteremia. Consequently, before condition-
ing starts, dental consults should be obtained for all HSCT can-
didates to assess their state of oral health and to perform any
needed dental procedures to decrease the risk for oral infections
after transplant (67 ) (AIII).
Generally, HSCT physicians should not use prophylactic an-
tibiotics to prevent Streptococci viridans  infections (DIII). No data
were found that demonstrate efficacy of prophylactic antibiotics
for this infection. Furthermore, such use might select antibiotic-
resistant bacteria, and in fact, penicillin- and vancomycin-resis-
tant strains of Streptococci viridans  have been reported (68 ). How-
ever, when Streptococci viridans  infections among HSCT recipi-
ents are virulent and associated with overwhelming sepsis and
shock in an institution, prophylaxis might be evaluated (CIII).
Decisions regarding the use of Streptococci viridans  prophylaxis
should be made only after consultation with the hospital epide-
miologists or infection-control practitioners who monitor rates
of nosocomial bacteremia and bacterial susceptibility (BIII).
HSCT physicians should be familiar with current antibiotic
susceptibilities for patient isolates from their HSCT centers,
including Streptococci viridans  (BIII). Physicians should main-
     13B B & M T
tain a high index of suspicion for this infection among HSCT
recipients with symptomatic mucositis because early diagnosis
and aggressive therapy are currently the only potential means
of preventing shock when severely neutropenic HSCT recipi-
ents experience Streptococci viridans  bacteremia (69 ).
Recommendations Regarding Ha. influenzae type b
Preventing Exposure
Adults with Ha. influenzae  type b (Hib) pneumonia re-
quire standard precautions (62 ) to prevent exposing the
HSCT recipient to Hib. Adults and children who are in con-
tact with the HSCT recipient and who have known or sus-
pected invasive Hib disease, including meningitis, bacter-
emia, or epiglottitis, should be placed in droplet precau-
tions until 24 hours after they begin appropriate antibiotic
therapy, after which they can be switched to standard pre-
cautions. Household contacts exposed to persons with Hib
disease and who also have contact with HSCT recipients
should be administered rifampin prophylaxis according to
published recommendations (70,71 ); prophylaxis for house-
hold contacts of a patient with Hib disease are necessary if
all contacts aged <4 years are not fully vaccinated (BIII) (Ap-
pendix). This recommendation is critical because the risk
for invasive Hib disease among unvaccinated household
contacts aged <4 years is increased, and rifampin can be ef-
fective in eliminating Hib carriage and preventing invasive
Hib disease (72–74 ). Pediatric household contacts should
be up-to-date with Hib vaccinations to prevent possible Hib
exposure to the HSCT recipient (AII).
Preventing Disease
Although no data regarding vaccine efficacy among
HSCT recipients were found, Hib conjugate vaccine should
be administered to HSCT recipients at 12, 14, and 24
months after HSCT (BII). This vaccine is recommended
because the majority of HSCT recipients have low levels of
Hib capsular polysaccharide antibodies ≈4 months after
HSCT (75 ), and allogeneic recipients with chronic GVHD
are at increased risk for infection from encapsulated organ-
isms (e.g., Hib) (76,77 ). HSCT recipients who are exposed
to persons with Hib disease should be offered rifampin pro-
phylaxis according to published recommendations (70 )
(BIII) (Appendix).
Antibiotic prophylaxis is recommended for preventing
infection with encapsulated organisms (e.g. ,  Stre.
pneumoniae, Ha. influenzae, or Ne. meningitidis ) among allo-
geneic recipients with chronic GVHD for as long as active
chronic GVHD treatment is administered (59 ) (BIII). An-
tibiotic selection should be guided by local antibiotic-resis-
tance patterns. Recommendations for preventing Hib in-
fections are the same for allogeneic or autologous recipi-
ents. Recommendations for preventing Hib disease are the
same for pediatric or adult HSCT recipients, except that
any child infected with Hib pneumonia requires standard
precautions with droplet precautions added for the first 24
hours after beginning appropriate antibiotic therapy (62,70 )
(BIII). Appropriate pediatric doses should be administered
for Hib conjugate vaccine and for rifampin prophylaxis (71 )
(Appendix).
VIRAL INFECTIONS
Recommendations Regarding Cytomegalovirus
Preventing Exposure
HSCT candidates should be tested for the presence of se-
rum anti-CMV IgG antibodies before transplantation to deter-
mine their risk for primary CMV infection and reactivation af-
ter HSCT (AIII). Only Food and Drug Administration (FDA)
licensed or approved tests should be used. HSCT recipients
and candidates should avoid sharing cups, glasses, and eating
utensils with others, including family members, to decrease the
risk for CMV exposure (BIII).
Sexually active patients who are not in long-term monoga-
mous relationships should always use latex condoms during sexual
contact to reduce their risk for exposure to CMV and other sexu-
ally transmitted pathogens (AII). However, even long-time mo-
nogamous pairs can be discordant for CMV infections. There-
fore, during periods of immuno-
compromise, sexually active HSCT recipients in monogamous
relationships should ask partners to be tested for serum CMV
IgG antibody, and discordant couples should use latex condoms
during sexual contact to reduce the risk for exposure to this sexu-
ally transmitted OI (CIII).
After handling or changing diapers or after wiping oral and
nasal secretions, HSCT candidates and recipients should practice
regular hand washing to reduce the risk for CMV exposure (AII).
CMV-seronegative recipients of allogeneic stem cell transplants
from CMV-seronegative donors (i.e., R-negative or D-negative)
should receive only leukocyte-reduced or CMV-seronegative red
cells or leukocyte-reduced platelets (<1 x 106 leukocytes/unit) to
prevent transfusion-associated CMV infection (78 ) (AI). How-
ever, insufficient data were found to recommend use of leuko-
cyte-reduced or CMV seronegative red cells and platelets among
CMV-seronegative recipients who have CMV-seropositive do-
nors (i.e., R-negative or D-positive).
All HCWs should wear gloves when handling blood products
or other potentially contaminated biologic materials (AII) to pre-
vent transmission of CMV to HSCT recipients. HSCT patients
who are known to excrete CMV should be placed under standard
precautions (62 ) for the duration of CMV excretion to avoid pos-
sible transmission to CMV-seronegative HSCT recipients and
candidates (AIII). Physicians are cautioned that CMV excretion
can be episodic or prolonged.
Preventing Disease and Disease Recurrence
HSCT recipients at risk for CMV disease after HSCT (i.e.,
all CMV-seropositive HSCT recipients, and all CMV-seronega-
tive recipients with a CMV-seropositive donor) should be placed
on a CMV disease prevention program from the time of engraft-
ment until 100 days after HSCT (i.e., phase II) (AI). Physicians
should use either prophylaxis or preemptive treatment with
ganciclovir for allogeneic recipients (AI). In selecting a CMV dis-
ease prevention strategy, physicians should assess the risks and
benefits of each strategy, the needs and condition of the patient,
and the hospital’s virology laboratory support capability.
Prophylaxis strategy against early CMV (i.e., <100 days after
HSCT) for allogeneic recipients involves administering
ganciclovir prophylaxis to all allogeneic recipients at risk through-
out phase II (i.e., from engraftment to 100 days after HSCT).
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The induction course is usually started at engraftment (AI),
although physicians can add a brief prophylactic course during
HSCT preconditioning (CIII) (Appendix).
Preemptive strategy against early CMV (i.e., <100 days af-
ter HSCT) for allogeneic recipients is preferred over prophy-
laxis for CMV-seronegative HSCT recipients of seropositive
donor cells (i.e., D-positive or R-negative) because of the low
attack rate of active CMV infection if screened or filtered blood
product support is used (BII). Preemptive strategy restricts
ganciclovir use for those patients who have evidence of CMV
infection after HSCT. It requires the use of sensitive and spe-
cific laboratory tests to rapidly diagnose CMV infection after
HSCT and to enable immediate administration of ganciclovir
after CMV infection has been detected. Allogeneic recipients
at risk should be screened ≈1 times/week from 10 days to 100
days after HSCT (i.e., phase II) for the presence of CMV vire-
mia or antigenemia (AIII).
HSCT physicians should select one of two diagnostic tests
to determine the need for preemptive treatment. Currently, the
detection of CMV pp65 antigen in leukocytes (antigenemia)
(79,80 ) is preferred for screening for preemptive treatment
because it is more rapid and sensitive than culture and has good
positive predictive value (79–81 ). Direct detection of CMV-
DNA (deoxyribonucleic acid) by polymerase chain reaction
(PCR) (82 ) is very sensitive but has a low positive predictive
value (79 ). Although CMV-DNA PCR is less sensitive than
whole blood or leukocyte PCR, plasma CMV-DNA PCR is
useful during neutropenia, when the number of leukocytes/slide
is too low to allow CMV pp65 antigenemia testing.
Virus culture of urine, saliva, blood, or bronchoalveolar
washings by rapid shell-vial culture (83 ) or routine culture
(84,85 ) can be used; however, viral culture techniques are less
sensitive than CMV-DNA PCR or CMV pp65 antigenemia
tests. Also, rapid shell-viral cultures require ≈48 hours and rou-
tine viral cultures can require weeks to obtain final results. Thus,
viral culture techniques are less satisfactory than PCR or
antigenemia tests. HSCT centers without access to PCR or
antigenemia tests should use prophylaxis rather than preemp-
tive therapy for CMV disease prevention (86 ) (BII). Physicians
do use other diagnostic tests (e.g., hybrid capture CMV-DNA
assay, Version 2.0 [87 ] or CMV pp67 viral RNA [ribonucleic
acid] detection) (88 ); however, limited data were found regard-
ing use among HSCT recipients, and therefore, no recommen-
dation for use can be made.
Allogeneic recipients £100 days after HSCT (i.e., during
phase II) should begin preemptive treatment with ganciclovir if
CMV viremia or any antigenemia is detected or if the recipient
has ≈2 consecutively positive CMV-DNA PCR tests (BIII).
After preemptive treatment has been started, maintenance
ganciclovir is usually continued until 100 days after HSCT or
for a minimum of 3 weeks, whichever is longer (AI) (Appendix).
Antigen or PCR tests should be negative when ganciclovir is
stopped. Studies report that a shorter course of ganciclovir (e.g.,
for 3 weeks or until negative PCR or antigenemia occurs) (89–
91 ) might provide adequate CMV prevention with less toxic-
ity, but routine weekly screening by pp65 antigen or PCR test
is necessary after stopping ganciclovir because CMV reactiva-
tion can occur (BIII).
Presently, only the intravenous formulation of ganciclovir
has been approved for use in CMV prophylactic or preemptive
strategies (BIII). No recommendation for oral ganciclovir use
among HSCT recipients can be made because clinical trials
evaluating its efficacy are still in progress. One group has used
ganciclovir and foscarnet on alternate days for CMV preven-
tion (92 ), but no recommendation can be made regarding this
strategy because of limited data. Patients who are ganciclovir-
intolerant should be administered foscarnet instead (93 ) (BII)
(Appendix). HSCT recipients receiving ganciclovir should have
ANCs checked ≈2 times/week (BIII). Researchers report man-
aging ganciclovir-associated neutropenia by adding G-CSF
(94 ) or temporarily stopping ganciclovir for ≈2 days if the
patient’s ANC is <1,000 (CIII). Ganciclovir can be restarted
when the patient’s ANC is ≈1,000 for 2 consecutive days. Alter-
natively, researchers report substituting foscarnet for ganciclovir
if a) the HSCT recipient is still CMV viremic or antigenemic
or b) the ANC remains <1,000 for >5 days after ganciclovir has
been stopped (CIII) (Appendix). Because neutropenia accom-
panying ganciclovir administration is usually brief, such patients
do not require antifungal or antibacterial prophylaxis (DIII).
Currently, no benefit has been reported from routinely
administering ganciclovir prophylaxis to all HSCT recipients
at >100 days after HSCT (i.e., during phase III). However, per-
sons with high risk for late CMV disease should be routinely
screened biweekly for evidence of CMV reactivation as long as
substantial immunocompromise persists (BIII). Risk factors for
late CMV disease include allogeneic HSCT accompanied by
chronic GVHD, steroid use, low CD4 counts, delay in high
avidity anti-CMV antibody, and recipients of matched unre-
lated or T-cell–depleted HSCTs who are at high risk (95–99 ).
If CMV is still detectable by routine screening ≈100 days after
HSCT, ganciclovir should be continued until CMV is no longer
detectable (AI). If low-grade CMV antigenemia (<5 positive
cells/slide) is detected on routine screening, the antigenemia
test should be repeated in 3 days (BIII). If CMV antigenemia
indicates ≈5 cells/slide, PCR is positive, or the shell-vial culture
detects CMV viremia, a 3-week course of preemptive
ganciclovir treatment should be administered (BIII) (Appen-
dix). Ganciclovir should also be started if the patient has had ≈2
consecutively positive viremia or PCR tests (e.g., in a person
receiving steroids for GVHD or who received ganciclovir or
foscarnet at <100 days after HSCT). Current investigational
strategies for preventing late CMV disease include the use of
targeted prophylaxis with antiviral drugs and cellular immuno-
therapy for those with deficient or absent CMV-specific
immune system function.
If viremia persists after 4 weeks of ganciclovir preemptive
therapy or if the level of antigenemia continues to rise after 3
weeks of therapy, ganciclovir-resistant CMV should be sus-
pected. If CMV viremia recurs during continuous treatment
with ganciclovir, researchers report restarting ganciclovir in-
duction (100 ) or stopping ganciclovir and starting foscarnet
(CIII). Limited data were found regarding the use of foscarnet
among HSCT recipients for either CMV prophylaxis or pre-
emptive therapy (92,93 ).
Infusion of donor-derived CMV-specific clones of CD8+
T-cells into the transplant recipient is being evaluated under
FDA Investigational New Drug authorization; therefore, no
recommendation can be made. Although, in a substantial coop-
erative study, high-dose acyclovir has had certain efficacy for
preventing CMV disease (101 ), its utility is limited in a setting
where more potent anti-CMV agents (e.g., ganciclovir) are used
(102 ). Acyclovir is not effective in preventing CMV disease af-
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ter autologous HSCT (103 ) and is, therefore, not recom-
mended for CMV preemptive therapy (DII). Consequently,
valacyclovir, although under study for use among HSCT
recipients, is presumed to be less effective than ganciclovir
against CMV and is currently not recommended for CMV
disease prevention (DII).
Although HSCT physicians continue to use IVIG for
immune system modulation, IVIG is not recommended for
CMV disease prophylaxis among HSCT recipients (DI).
Cidofovir, a nucleoside analog, is approved by FDA for the
treatment of AIDS-associated CMV retinitis. The drug’s
major disadvantage is nephrotoxicity. Cidofovir is currently
in FDA phase 1 trial for use among HSCT recipients; there-
fore, recommendations for its use cannot be made.
Use of CMV-negative or leukocyte-reduced blood prod-
ucts is not routinely required for all autologous recipients
because most have a substantially lower risk for CMV dis-
ease. However, CMV-negative or leukocyte-reduced blood
products can be used for CMV-seronegative autologous re-
cipients (CIII). Researchers report that CMV seropositive
autologous recipients be evaluated for preemptive therapy
if they have underlying hematologic malignancies (e.g., lym-
phoma or leukemia), are receiving intense conditioning
regimens or graft manipulation, or have recently received
fludarabine or 2-chlorodeoxyadenosine (CDA) (CIII). This
subpopulation of autologous recipients should be monitored
weekly from time of engraftment until 60 days after HSCT
for CMV reactivation, preferably with quantitative CMV
pp65 antigen (80 ) or quantitative PCR (BII).
Autologous recipients at high risk who experience CMV
antigenemia (i.e., blood levels of ≈5 positive cells/slide)
should receive 3 weeks of preemptive treatment with
ganciclovir or foscarnet (80 ), but CD34+-selected patients
should be treated at any level of antigenemia (BII) (Appen-
dix). Prophylactic approach to CMV disease prevention is
not appropriate for CMV-seropositive autologous recipi-
ents. Indications for the use of CMV prophylaxis or pre-
emptive treatment are the same for children or adults.
Recommendations Regarding EBV
Preventing Exposure
All transplant candidates, particularly those who are
EBV-seronegative, should be advised of behaviors that could
decrease the likelihood of EBV exposure (AII). For example,
HSCT recipients and candidates should follow safe hygiene
practices (e.g., frequent hand washing [AIII] and avoiding
the sharing of cups, glasses, and eating utensils with others)
(104 ) (BIII), and they should avoid contact with potentially
infected respiratory secretions and saliva (104 ) (AII).
Preventing Disease
Infusion of donor-derived, EBV-specific cytotoxic T-
lymphocytes has demonstrated promise in the prophy-
laxis of EBV-lymphoma among recipients of T-cell–de-
pleted unrelated or mismatched allogeneic recipients
(105,106 ). However, insufficient data were found to rec-
ommend its use. Prophylaxis or preemptive therapy with
acyclovir is not recommended because of lack of efficacy
(107,108 ) (DII).
Recommendations Regarding HSV
Preventing Exposure
HSCT candidates should be tested for serum anti-HSV IgG
before transplant (AIII); however, type-specific anti-HSV IgG
serology testing is not necessary. Only FDA-licensed or
approved tests should be used. All HSCT candidates, par-
ticularly those who are HSV-seronegative, should be informed
of the importance of avoiding HSV infection while
immunocompromised and should be advised of behaviors that
will decrease the likelihood of HSV exposure (AII). HSCT re-
cipients and candidates should avoid sharing cups, glasses, and
eating utensils with others (BIII). Sexually active patients who
are not in a long-term monogamous relationship should always
use latex condoms during sexual contact to reduce the risk for
exposure to HSV as well as other sexually transmitted patho-
gens (AII). However, even long-time monogamous pairs can be
discordant for HSV infections. Therefore, during periods of
immunocompromise, sexually active HSCT recipients in such
relationships should ask partners to be tested for serum HSV
IgG antibody. If the partners are discordant, they should con-
sider using latex condoms during sexual contact to reduce the
risk for exposure to this sexually transmitted OI (CIII). Any
person with disseminated, primary, or severe mucocutaneous
HSV disease should be placed under contact precautions for
the duration of the illness (62 ) (AI) to prevent transmission of
HSV to HSCT recipients.
Preventing Disease and Disease Recurrence
Acyclovir. Acyclovir prophylaxis should be offered to all HSV-
seropositive allogeneic recipients to prevent HSV reactivation
during the early posttransplant period (109–113 ) (AI). Standard
approach is to begin acyclovir prophylaxis at the start of the con-
ditioning therapy and continue until engraftment occurs or until
mucositis resolves, whichever is longer, or approximately 30 days
after HSCT (BIII) (Appendix). Without supportive data from
controlled studies, routine use of antiviral prophylaxis for >30 days
after HSCT to prevent HSV is not recommended (DIII). Rou-
tine acyclovir prophylaxis is not indicated for HSV-seronegative
HSCT recipients, even if the donors are HSV-seropositive (DIII).
Researchers have proposed administration of ganciclovir prophy-
laxis alone (86 ) to HSCT recipients who required simultaneous
prophylaxis for CMV and HSV after HSCT (CIII) because
ganciclovir has in vitro activity against CMV and HSV 1 and 2
(114 ), although ganciclovir has not been approved for use against
HSV.
Valacyclovir. Researchers have reported valacyclovir use for
preventing HSV among HSCT recipients (CIII); however, pre-
liminary data demonstrate that very high doses of valacyclovir (8
g/day) were associated with thrombotic thrombocytopenic pur-
pura/hemolytic uremic syndrome among HSCT recipients (115 ).
Controlled trial data among HSCT recipients are limited (115 ),
and the FDA has not approved valacyclovir for use among recipi-
ents. Physicians wishing to use valacyclovir among recipients with
renal impairment should exercise caution and decrease doses as
needed (BIII) (Appendix).
Foscarnet. Because of its substantial renal and infusion-re-
lated toxicity, foscarnet is not recommended for routine HSV
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prophylaxis among HSCT recipients (DIII).
Famciclovir. Presently, data regarding safety and efficacy
of famciclovir among HSCT recipients are limited; therefore,
no recommendations for HSV prophylaxis with famciclovir can
be made.
Other Recommendations
HSV prophylaxis lasting >30 days after HSCT might be
considered for persons with frequent recurrent HSV (CIII)
(Appendix). Acyclovir can be used during phase I for
administration to HSV-seropositive autologous recipients who
are likely to experience substantial mucositis from the condi-
tioning regimen (CIII). Antiviral prophylaxis doses should be
modified for use among children (Appendix), but no published
data were found regarding valacyclovir safety and efficacy
among children.
Recommendations Regarding VZV
Preventing Exposure
HSCT candidates should be tested for the presence of se-
rum anti-VZV IgG antibodies (AIII). However, these tests are
not 100% reliable, particularly among severely immunosup-
pressed patients. Researchers recommend that a past history
of varicella accompanied by a positive titer is more likely to
indicate the presence of immunity to VZV than a low positive
titer alone. All HSCT candidates and recipients, particularly
those who are VZV-seronegative, should be informed of the
potential seriousness of VZV disease among
immunocompromised persons and advised of strategies to de-
crease their risk for VZV exposure (116–122 ) (AII).
Although researchers report that the majority of VZV dis-
ease after HSCT is caused by reactivation of endogenous VZV,
HSCT candidates and recipients who are VZV-
seronegative, or VZV-seropositive and immunocompromised,
should avoid exposure to persons with active VZV infections
(123 ) (AII). HCWs, family members, household contacts, and
visitors who are healthy and do not have a reported history of
varicella infection or who are VZV-seronegative should receive
VZV vaccination before being allowed to visit or have direct
contact with an HSCT recipient (AIII). Ideally, VZV-suscep-
tible family members, household contacts, and potential visi-
tors of immunocompromised HSCT recipients should be vac-
cinated as soon as the decision is made to perform HSCT. The
vaccination dose or doses should be completed ≈4 weeks
before the conditioning regimen begins or ≈6 weeks (42 days)
before the HSCT is performed (BIII).
HSCT recipients and candidates undergoing conditioning
therapy should avoid contact with any VZV vaccine recipient
who experiences a rash after vaccination (BIII). When this rash
occurs, it usually appears 14–21 days after VZV vaccination
(median: 22 days; range: 5–35 days) (personal communication
from Robert G. Sharrar, M.D., Merck & Co., Inc.). However,
to date, no serious disease has been reported among
immuno-compromised patients from transmission of VZV
vaccine virus, and the VZV vaccine strain is susceptible to
acyclovir.
All HSCT recipients with VZV disease should be placed
under airborne and contact precautions (62 ) (AII) to prevent
transmission to other HSCT recipients. Contact precautions
should be continued until all skin lesions are crusted. Airborne
precautions should be instituted 10 days after exposure to VZV
and continued until 21 days after last exposure or 28 days
postexposure if the patient received varicella-zoster immuno-
globulin (VZIG)* (62 ) (AI) because a person infected with
VZV can be infectious before the rash appears.
Preventing Disease
VZIG. VZV-seronegative HSCT recipients should be admin-
istered VZIG as soon as possible but ideally within 96 hours after
close or household contact with a person having either chickenpox
or shingles if the HSCT recipient is not immunocompetent (i.e.,
allogeneic patient <24 months after HSCT, ≈24 months after
HSCT and on immunosuppressive therapy, or having chronic
GVHD) (AII). Researchers report VZIG administration for VZV
exposure as described for HSCT recipients who were VZV-se-
ropositive before HSCT (CIII).
Because of the high morbidity of VZV-associated disease
among severely immunocompromised HSCT recipients and un-
til further data are published, HSCT physicians should adminis-
ter VZIG to all VZV-seronegative HSCT recipients or candi-
dates undergoing conditioning therapy who are exposed to a VZV
vaccinee having a varicella-like rash (BIII). Researchers also re-
port VZIG administration for this situation for VZV-seroposi-
tive HSCT recipients and candidates undergoing conditioning
therapy (CIII). These recommendations are made because the
vaccinee might be unknowingly incubating wild-type varicella,
particularly during the first 14 days after varicella vaccination, and
because vaccine-strain VZV has been rarely transmitted by VZV
vaccinees with vesicular rashes postvaccination (121 ).
If VZV-seronegative HSCT recipients or candidates un-
dergoing conditioning therapy are closely exposed to varicella
>3 weeks after receiving VZIG, they should be administered
another dose of VZIG (120 ) (BIII). Researchers also recom-
mend VZIG administration for this condition for VZV-serop-
ositive HSCT recipients and candidates undergoing condition-
ing therapy (CIII).
Antiviral Drugs. Any HSCT recipient or candidate under-
going conditioning therapy who experiences a VZV-like rash (par-
ticularly after exposure to a person with wild-type varicella or
shingles) should receive preemptive intravenous acyclovir until
≈2 days after all lesions have crusted (BIII) (Appendix). Any HSCT
recipient or candidate undergoing conditioning therapy who
experiences a VZV-like rash after exposure to a VZV vaccinee
*VZIG is distributed by FFF Enterprises, Inc., under contract with the American Red Cross, except in Massachusetts where it is distributed
by the Massachusetts Public Health Biologic Laboratories (now a unit of the University of Massachusetts) (19 ). FFF Enterprises, Inc., can
be contacted at
FFF Enterprises, Inc.
41093 County Center Drive
Temecula, CA 92591
Phone: (800) 522-4448
     17B B & M T
with a rash should be administered intravenous acyclovir preemp-
tively to prevent severe, disseminated VZV disease (BII). Acyclovir
should be administered until 2 days after all lesions have crusted.
Long-term acyclovir prophylaxis to prevent recurrent VZV
infection (e.g., during the first 6 months after HSCT) is not rou-
tinely recommended (124–126 ) (DIII); however, this therapy
could be considered for use among HSCT recipients with severe,
long-term immunodeficiency (CIII). When acyclovir resistance
occurs among patients, HSCT physicians should use foscarnet
for preemptive treatment of VZV disease (127 ) (BIII). Research-
ers report valacyclovir use for preventing HSV among HSCT
recipients (CIII). However, preliminary data demonstrate that
very high doses of valacyclovir (8 g/day) were associated with
thrombotic thrombocytopenic purpura/hemolytic uremic syn-
drome among HSCT recipients (115 ). Controlled trial data
regarding HSCT recipients are limited (115 ), and the FDA has
not approved valacyclovir for use among HSCT recipients. Phy-
sicians wishing to use valacyclovir among HSCT recipients with
renal impairment should exercise caution and decrease doses as
needed (BIII) (Appendix). No data were found demonstrating
safety and efficacy of preemptive treatment of famciclovir against
herpes zoster among HSCT recipients. Consequently, no rec-
ommendation for its use can be made.
Live-Attenuated VZV Vaccine. VZV vaccine use is contrain-
dicated among HSCT recipients <24 months after HSCT (128 )
(EIII). Use of VZV vaccine among HSCT recipients is restricted
to research protocols for recipients ≈24 months after HSCT who
are presumed immunocompetent. Further research is needed to
determine the safety, immunogenicity, and efficacy of VZV vac-
cine among HSCT recipients.
Other Recommendations
An inactivated VZV vaccine has been used investigationally
among HSCT recipients (129 ); however, more studies are needed
before a recommendation regarding its use can be made. Recom-
mendations for VZV prevention are the same for allogeneic or
autologous recipients. Recommendations for preventing VZV
disease among pediatric or adult HSCT recipients are the same,
except that appropriate dose adjustments for VZIG should be
made for pediatric HSCT recipients (AIII) (Appendix).
Recommendations Regarding CRV Infections: Influenza,
Respiratory Syncytial Virus, Parainfluenza Virus, and
Adenovirus
Preventing Exposure
Preventing CRV exposure is critical in preventing CRV dis-
ease (130,131 ). To prevent nosocomial CRV transmission,
HSCT recipients and their HCWs should always follow
HSCT infection control guidelines (AIII). To minimize the
risk for CRV transmission, HCWs and visitors with upper res-
piratory infection (URI) symptoms should be restricted from
contact with HSCT recipients and HSCT candidates under-
going conditioning therapy (AIII). At a minimum, active clini-
cal surveillance for CRV disease should be conducted on all
hospitalized HSCT recipients and candidates undergoing
conditioning therapy; this clinical surveillance should include
daily screening for signs and symptoms of CRV (e.g., URI or
lower respiratory infection [LRI]) (AIII). Viral cultures of
asymptomatic HSCT candidates are unlikely to be useful.
HSCT recipients with URI or LRI symptoms should be placed
under contact precautions to avoid transmitting infection to
other HSCT candidates and recipients, HCWs, and visitors
until the etiology of illness is identified (62 ) (BIII). Optimal
isolation precautions should be modified as needed after the
etiology is identified (AIII). HSCT recipients and candidates,
their family members and visitors, and all HCWs should be
informed regarding CRV infection control measures and the
potential severity of CRV infections among HSCT recipients
(130–140 ) (BIII). Physicians have routinely conducted culture-
based CRV surveillance among HSCT recipients; however, the
cost effectiveness of this approach has not been evaluated.
Influenza vaccination of family members and close or
household contacts is strongly recommended during each in-
fluenza season (i.e., October–May) starting the season before
HSCT and continuing ≈24 months after HSCT (141 ) (AI) to
prevent influenza exposure among the recipients or candidates.
All family members and close or household contacts of HSCT
recipients who remain immunocompromised ≈24 months af-
ter HSCT should continue to be vaccinated annually as long
as the HSCT recipient’s immuno-compromise persists (141 )
(AI). Seasonal influenza vaccination is strongly recommended
for all HCWs of HSCT recipients (142,143 ) (AI).
If HCWs, family members, or other close contacts of
HSCT recipients receive influenza vaccination during an in-
fluenza A outbreak, they should receive amantadine or
rimantadine chemoprophylaxis for 2 weeks after influenza vac-
cination (BI) while the vaccinee experiences an immunologic
response to the vaccine. Such a strategy is likely to prevent
transmission of influenza A to HCWs and other close contacts
of HSCT recipients, which could prevent influenza A trans-
mission to HSCT recipients themselves. However, if a noso-
comial outbreak occurs with an influenza A strain that is not
contained in the available influenza vaccine, all healthy family
members, close and household contacts, and HCWs of HSCT
recipients and candidates should be administered influenza A
chemoprophylaxis with amantadine or rimantadine until the
end of the outbreak (141 ) (BIII).
In 1999, two neuroaminidase inhibitors (zanamivir and
oseltamivir) were approved for treatment of influenza, but are
not currently approved for prophylaxis. To date, experience is
limited regarding use of zanamivir or oseltamivir in the treat-
ment or prophylaxis of influenza among HSCT settings. How-
ever, HCWs, family members, or other close contacts can be
offered a neuroaminidase inhibitor (e.g., zanamivir or
oseltamivir) using the same strategies outlined previously, if a)
rimantadine or amantadine cannot be tolerated, b) the out-
break strain of influenza A is amantadine or rimantadine-re-
sistant, or c) the outbreak strain is influenza B (144–147 ) (BI).
Zanamivir can be administered to persons aged ≈12 years, and
oseltamivir can be administered to persons aged ≈18 years.
Patients with influenza should be placed under droplet and
standard precautions (AIII) to prevent transmission of influ-
enza to HSCT recipients. HCWs with influenza should be
excused from patient care until they are no longer infectious
(AIII).
Preventing Disease
HSCT physicians should determine the etiology of a URI
in an HSCT recipient or candidate undergoing conditioning
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therapy, if possible, because respiratory syncytial virus (RSV),
influenza, parainfluenza, and adenovirus URIs can progress to
more serious LRI, and certain CRVs can be treated (BIII). Ap-
propriate diagnostic samples include nasopharyngeal washes,
swabs or aspirates, throat swabs, and bronchoalveolar lavage
(BAL) fluid. HSCT candidates with URI symptoms at the time
conditioning therapy is scheduled to start should postpone their
conditioning regimen until the URIs resolve, if possible, be-
cause certain URIs might progress to LRI during immunosup-
pression (131,133,137,138 ) (BIII).
Recommendations Regarding Influenza. Life-long seasonal
influenza vaccination is recommended for all HSCT candidates
and recipients, beginning during the influenza season before
HSCT and resuming ≈6 months after HSCT (142 ) (BIII). Influ-
enza vaccinations administered to HSCT recipients <6 months
after HSCT are unlikely to be beneficial and are not recom-
mended (142 ) (DII). HSCT recipients <6 months after HSCT
should receive chemoprophylaxis with amantadine or rimantadine
during community or nosocomial influenza A outbreaks (BIII).
These drugs are not effective against influenza B. Additionally,
antiviral-resistant strains of influenza can emerge during treat-
ment with amantadine or rimantadine and transmission of resis-
tant strains can occur (148,149 ). During such outbreaks, HSCT
recipients 6–24 months after HSCT, or
>24 months after HSCT and still substantially
immunocompromised (i.e., receiving immunosuppressive therapy,
have had a relapse of their underlying disease, or have GVHD)
and who have not yet received a current influenza vaccination,
should be vaccinated against influenza immediately (BIII). Addi-
tionally, to allow sufficient time for the patient to experience an
immunologic response to influenza vaccine, chemoprophylaxis
with amantadine or rimantadine can be used for these HSCT
recipients for 2 weeks after vaccination during a nosocomial or
community influenza A outbreak (CIII). Influenza A chemopro-
phylaxis with amantadine or rimantadine has been recommended
for all influenza A-exposed HSCT recipients <24 months after
HSCT or ≈24 months after HSCT and substantially
immunocompromised regardless of vaccination history, because
of their likely suboptimal immunologic response to influenza vac-
cine (142,143 ). However, no recommendation regarding such
chemoprophylaxis can be made because of lack of data.
To prevent severe disease, early preemptive therapy with
amantadine or rimantadine has been reported for HSCT recipi-
ents with unexplained acute URI or LRI symptoms during a com-
munity or nosocomial outbreak of influenza A (141 ). However,
the effectiveness in preventing influenza-related complications
and the safety of this strategy have not been evaluated among
HSCT recipients. Therefore, data are insufficient to make a rec-
ommendation.
Neuroaminidase inhibitors (zanimivir and oseltamivir), intra-
venous and aerosol ribavirin, and combination drug therapy (e.g.,
rimantadine or amantadine with ribavirin or interferon) (143,150–
153 ) have been proposed for investigational, preemptive treat-
ment to prevent severe influenza disease among HSCT recipi-
ents. However, because of lack of data, no recommendation for
use of these strategies among HSCT recipients can be made.
Recommendations Regarding RSV. Respiratory secretions of
any hospitalized HSCT candidate or recipient who experiences
signs or␣ symptoms of CRV infection should be tested promptly
by viral culture and rapid diagnostic tests for RSV (BIII). If two
diagnostic samples taken ≈2 days apart do not identify a respi-
ratory pathogen despite persistence of respiratory symptoms,
BAL and further testing are advised (BIII). This testing is criti-
cal because of the high morbidity and case fatality of RSV dis-
ease among HSCT recipients (154,155 ). HSCT recipients, par-
ticularly those who are preengraftment and at highest risk for
severe RSV pneumonia, should have their illness diagnosed
early (i.e., during RSV URI), and their illness should be treated
aggressively to prevent fatal RSV disease (BIII).
Although a definitive, uniformly effective preemptive
therapy for RSV infection among HSCT recipients has not
been identified, certain strategies have been proposed, includ-
ing use of aerosolized ribavirin (155,156 ), RSV antibodies (i.e.,
passive immunization with high RSV-titered IVIG or RSV im-
munoglobulin) in combination with aerosolized ribavirin
(137,157 ), and RSV monoclonal antibody (158 ). Clinical trials
are currently underway to evaluate the efficacy of these strate-
gies. No recommendation regarding the optimal method for
RSV prevention and preemptive therapy can be made because
of limited data. Further, current data do not support use of in-
travenous ribavirin for preemptive therapy for RSV pneumo-
nia among HSCT recipients (60 ) (DIII), and nocommercially
licensed vaccines against RSV are currently available.
Recommendations Regarding Parainfluenza Virus and
Adenovirus. Immuno-prophylaxis, chemoprophylaxis, and pre-
emptive treatment for parainfluenza virus and adenovirus in-
fections among HSCT recipients have been proposed
(159,160 ). However, no recommendation can be made in these
guidelines because of insufficient data. No commercially li-
censed vaccines against parainfluenza or adenovirus are cur-
rently available.
Other Disease Prevention Recommendations
The recommendations for preventing CRV infections and
their recurrence are the same for allogeneic or autologous re-
cipients. Generally, these recommendations apply to children
or adults (161–164 ), but with appropriate adjustments in anti-
viral drug and influenza vaccine doses for children (Appendix).
For pediatric HSCT recipients and candidates aged >6
months, annual seasonal influenza vaccination is recommended
HSCT (BIII). Children aged <9 years who are receiving influ-
enza vaccination for the first time require two doses adminis-
tered ≈1 months apart (AI). Healthy children who receive in-
fluenza vaccination for the first time might not generate pro-
tective antibodies until 2 weeks after receipt of the second dose
of influenza vaccine. Therefore, during an influenza A outbreak,
pediatric recipients aged <9 years, ≈6 months after HSCT, and
receiving their first influenza vaccination, should be administered
≈6 weeks of influenza A chemoprophylaxis after the first dose of
influenza vaccine (141 ) (BIII) (Appendix). Amantadine and
rimantadine are not FDA-approved for children aged <1 year
(141,161 ) (DIII).
To prevent RSV disease, researchers report substituting
RSV-IVIG for IVIG during RSV season (i.e., November–April)
for pediatric recipients (i.e., children aged <18 years) who receive
routine IVIG therapy (164 ) (i.e., those with
hypogammaglobulinemia) (CIII) (Appendix). Other researchers
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report that pediatric recipients with RSV can be considered for
preemptive therapy (e.g., during URI or early LRI) with aero-
solized ribavirin (CIII), although this therapy remains controver-
sial (164 ) (Appendix). Droplet and contact precautions for the
duration of illness are required for pediatric recipients for the
duration of adenovirus (62 ) (AIII).
FUNGAL INFECTIONS
General Recommendations
Preventing Exposure
Limited data were found that demonstrate to what extent pre-
venting fungal exposures is effective in preventing infection and
disease. However, HSCT recipients and candidates undergoing
conditioning therapy have been advised to avoid contact with cer-
tain areas and substances, including foods, that might increase a
patient’s risk for fungal exposures (CII). Specific precautions have
included avoiding areas of high dust exposure (e.g., excavation
sites, areas of building construction or renovation, chicken coops,
and caves), occupations involving soil, and foods that contain
molds (e.g., blue cheese).
Preventing Disease
Growth factors (e.g., GM-CSF and G-CSF) shorten the
duration of neutropenia after HSCT (165 ); however, no data were
found that indicate which growth factors effectively reduce the
attack rate of invasive fungal disease. Therefore, no recommen-
dation for use of growth factors solely for prophylaxis against
invasive fungal disease can be made.
Topical antifungal drugs, which are applied to the skin or
mucosa (e.g., nystatin or clotrimazole), might reduce fungal colo-
nization in the area of application. However, these agents have
not been proven to prevent generation of locally invasive or dis-
seminated yeast infections (e.g., candidiasis) or mold infections
(e.g., aspergillosis) and are not recommended for their prophy-
laxis (DII). Performing fungal surveillance cultures is not indi-
cated for asymptomatic HSCT recipients (166,167 ) (DII), but
cultures should be obtained from symptomatic HSCT recipients
(BIII).
Recommendations Regarding Yeast Infections
Preventing Exposure
Invasive candidiasis is usually caused by dissemination of
endogenous Candida  species that have colonized a patient’s gas-
trointestinal tract (168 ). Consequently, methods of preventing
exogenous yeast exposure usually do not prevent invasive yeast
infections after HSCT. However, because Candida  species can be
carried on the hands, HCWs and others in contact with HSCT
recipients should follow appropriate hand-washing practices to
safeguard patients from exposure (AIII).
Preventing Disease
Allogeneic recipients should be administered fluconazole pro-
phylaxis to prevent invasive disease with fluconazole-susceptible
Candida  species during neutropenia, particularly among centers
where Can. albicans  is the predominant cause of invasive fungal
disease preengraftment (AI) (Appendix). Because candidiasis
occurs during phase I (169 ), fluconazole (400 mg/day by mouth
or intravenously) should be administered (169,170 ) from the day
of HSCT until engraftment (AII). However, fluconazole is not
effective against certain Candida  species, including Can. krusei
(171 ) and Can. glabrata  and is, therefore, not recommended for
their prevention (DI). Further studies are needed to determine
the optimal duration of fluconazole prophylaxis. Preliminary stud-
ies have reported that low-dose fluconazole prophylaxis (100–200
mg/day by mouth) among neutropenic patients has variable effi-
cacy in preventing candidiasis (172 ). Therefore, this therapy is
not recommended for HSCT recipients (DII). Oral, nonabsorb-
able antifungal drugs, including oral amphotericin B (500 mg sus-
pension every 6 hours), nystatin, and clotrimazole troches, might
reduce superficial colonization and control local mucosal candidi-
asis, but have not been demonstrated to reduce invasive candidi-
asis (CIII).
Other Recommendations
HSCT candidates with candidemia or invasive candidiasis can
safely receive transplants (173 ) if a) their infection was diagnosed
early and treated immediately and aggressively with amphoteri-
cin B or alternatively with appropriate doses of fluconazole if the
organism is susceptible; and b) evidence of disease control is re-
ported (e.g., by serial computed tomography scans) before the
transplant (BIII). Such patients should continue receiving thera-
peutic doses of an appropriate antifungal drug throughout phase
I (BII) and until a careful review of clinical, laboratory, and serial
computed tomography scans verifies resolution of candidiasis
(BII).
Because autologous recipients generally have an overall lower
risk for invasive fungal infection than allogeneic recipients, cer-
tain autologous recipients do not require routine antiyeast pro-
phylaxis (DIII). However, researchers recommend administering
antiyeast prophylaxis to a subpopulation of autologous recipients
with underlying hematologic malignancies (e.g., lymphoma or
leukemia) and who have or will have prolonged neutropenia and
mucosal damage from intense conditioning regimens or graft
manipulation, or have received fludarabine or 2-CDA recently
(BIII). Recommendations regarding preventing invasive yeast
infections among pediatric or adult HSCT recipients are the
same, except that appropriate dose adjustments for prophylactic
drugs should be made for pediatric recipients (Appendix).
Recommendations Regarding Mold Infections
Preventing Exposure
Nosocomial mold infections among HSCT recipients result
primarily from respiratory exposure to and direct contact with
fungal spores (174 ). Ongoing hospital construction and renova-
tion have been associated with an increased risk for nosocomial
mold infection, particularly aspergillosis, among severely
immunocompromised patients (175–177 ). Therefore, whenever
possible, HSCT recipients who remain immunocompromised
should avoid hospital construction or renovation areas (AIII).
When constructing new HSCT centers or renovating old ones,
hospital planners should ensure that rooms for HSCT patients
have an adequate capacity to minimize fungal spore counts
through use of
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• high-efficiency (>90%) particulate air (HEPA) filtration
(140,178,179 ) (BIII);
• directed room airflow (i.e., positive air pressure in
patient rooms in relation to corridor air pressure) so that
air from patient rooms flows into the corridor (180 )
(BIII);
• correctly sealed rooms, including correctly sealed
windows and electrical outlets (140 ) (BIII);
• high rates of room air exchange (i.e., >12 air changes/
hour) (140,178 ) (BIII); and
• barriers between patient care and renovation or
construction areas (e.g., sealed plastic) that prevent dust
from entering patient care areas and that are
impermeable to Aspergillus  species (175,179 ) (BIII).
Additionally, HSCT centers should be cleaned with care,
particularly after hospital renovation or construction, to avoid
exposing HSCT recipients and candidates to mold spores
(174,176 ) (BIII).
Preventing Disease
No regimen has been reported to be clearly effective or
superior in preventing aspergillosis, and therefore, no recom-
mendation can be made. Further studies are needed to deter-
mine the optimal strategy for aspergillosis prevention. Moder-
ate-dose (0.5 mg/kg/day) amphotericin B (181–184 ), low-dose
(0.1–0.25 mg/kg/day) amphotericin B (185–187 ), intranasal
amphotericin B spray (188 ), lipid formulations of amphoteri-
cin B (182,189 ), and aerosolized amphotericin B (190 ) have
been administered for aspergillosis prophylaxis, but data are
limited regarding the safety and efficacy of these formulations
among HSCT recipients. Additionally, itraconazole capsules
are not recommended for fungal prophylaxis among HSCT
recipients (191 ) (DII) for three reasons. First, itraconazole
capsules are poorly absorbed gastrointestinally, particularly
among patients who are fasting (192 ) or receiving cytotoxic
agents (193 ). Second, persons taking itraconazole capsules do
not achieve steady-state serum levels for 2 weeks (188,194 ),
and when achieved, these levels are lower than the average
Aspergillus  species minimum inhibitory concentration
(MIC) among HSCT recipients (195 ). Third, itraconazole
has adverse interactions with other drugs (e.g., antiepileptics,
rifampin, oral hypoglycemics, protease inhibitors, vinca alka-
loids, cyclosporine, methylprednisolone, and warfarin-like
anticoagulants) (196 ). Trials assessing the efficacy of the
recently licensed cyclodextrin oral solution and intravenous
formulations of itraconazole in preventing invasive fungal
disease among HSCT recipients are in progress; however, no
recommendations regarding its use for Aspergillus  species
infection prophylaxis can be made. For HSCT recipients
whose respiratory specimens are culture positive for Aspergil-
lus  species, acute invasive aspergillosis should be diagnosed
presumptively (197 ) and treated preemptively and aggres-
sively (e.g., with intravenous amphotericin) (AIII).
The risk for aspergillosis recurrence has been high among
allogeneic recipients with preexisting invasive aspergillosis.
Previously, allogeneic HSCTs were avoided among persons
with uncontrolled, proven aspergillosis. However, HSCT cen-
ter personnel have recently reported successful allogeneic or
autologous HSCT among a limited number of persons
who have had successfully treated, prior invasive pulmo-
nary aspergillosis (198–200 ). Because of limited data, no rec-
ommendations regarding strategies for preventing aspergillosis
recurrence can be made.
PROTOZOAL AND HELMINTHIC INFECTIONS
Recommendations Regarding PCP
Preventing Exposure
Although a possible cause of PCP is reactivation of latent
infection among immunocompromised persons, cases of per-
son-to-person transmission of PCP have been reported (201–
206 ). Generally, standard precautions should be used for pa-
tients with PCP (62 ) (BIII), but researchers have reported pa-
tients with PCP being isolated (201,204 ) and contact precau-
tions being used if evidence existed of person-to-person trans-
mission in the institution (CIII). This subject remains contro-
versial, and until further data are published, HSCT recipients
should avoid exposure to persons with PCP (62 ) (CIII).
Preventing Disease and Disease Recurrence
Physicians should prescribe PCP prophylaxis for alloge-
neic recipients throughout all periods of immunocompromise
(207 ) after engraftment. Prophylaxis should be administered
from engraftment until 6 months after HSCT (AII) for all
patients, and >6 months after HSCT for the duration of im-
munosuppression for those who a) are receiving immunosup-
pressive therapy (e.g. prednisone or cyclosporine) (AI), or b)
have chronic GVHD (BII). However, PCP prophylaxis can be
initiated before engraftment if engraftment is delayed (CIII).
Researchers report an additional 1- to 2-week course of PCP
prophylaxis before HSCT (i.e., day –14 to day –2) (CIII).
Preferred PCP prophylaxis is TMP-SMZ (AII); however,
if TMP-SMZ is administered before engraftment, the associ-
ated myelosuppression could delay engraftment, and patients
might experience sensitivity to the drug. Every effort should
be made to keep such patients on the drug, including assess-
ment of desensitization therapy, although data regarding this
technique among HSCT recipients are limited. For patients
who cannot tolerate TMP-SMZ, physicians can choose to use
alternative PCP prophylaxis regimens (e.g., dapsone) (208 )
(BIII). Use of aerosolized pentamidine (209 ) is associated with
the lowest PCP prevention rates and should only be used if
other agents cannot be tolerated. Atovaquone is a possible
alternative drug for PCP prophylaxis among dapsone intol-
erant persons with HIV infection (210 ); however, no recom-
mendation regarding use of atovaquone among HSCT recipi-
ents can be made because of lack of data. Although data are
limited, concomitant use of leucovorin (folinic acid) and TMP-
SMZ is not recommended (211,212 ) (DIII). A patient’s his-
tory of PCP should not be regarded as a contraindication to
HSCT (213 ) (DIII).
Recurrent PCP among HSCT recipients is rare; how-
ever, patients with continued immunosuppression should
remain on PCP prophylaxis until their immunosuppression
is resolved (AI). The regimen recommended for preventing
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toxoplasmosis recurrence among HSCT recipients (i.e.,
TMP-SMZ) will also prevent PCP recurrence.
Other Recommendations
PCP prophylaxis should be considered for autologous
recipients who have underlying hematologic malignancies
(i.e., lymphoma or leukemia), are receiving intense condi-
tioning regimens or graft manipulation, or have recently
received fludarabine or 2-CDA (207,214 ) (BIII). PCP pro-
phylaxis should be administered ≈6 months after HSCT if
substantial immunosuppression or immunosuppressive
therapy (e.g., steroids) persists (CIII). Use of PCP prophy-
laxis among other autologous recipients is controversial
(CIII). Generally, indications for PCP prophylaxis are the
same among children or adults, but pediatric doses should
be used (Appendix).
Recommendations Regarding Toxoplasma gondii
Preventing Exposure
All HSCT recipients should be provided information
regarding strategies to reduce their risk for Toxoplasma  spe-
cies exposure. Researchers report that potential donors for
allogeneic HSCT be tested for To. gondii  antibodies
(215,216 ) by using FDA-licensed or -approved screening
tests that include IgG antibody testing because To. gondii
has been reported to be transmitted by leukocyte transfu-
sion (217 ) and HSCT (218,219 ) (CIII).
Preventing Disease and Disease Recurrence
Because most toxoplasmosis among HSCT recipients is
caused by disease reactivation, researchers report that can-
didates for allogeneic HSCT can be tested for IgG anti-
body to determine whether they are at risk for disease reac-
tivation after HSCT (215,216,218 ) (CIII). However, the
value of such testing is controversial because a limited
number of patients who were seronegative for To. gondii
pretransplant experienced the infection posttransplant
(220 ). If testing is performed, only FDA-licensed or
approved screening tests should be used.
 Researchers recommend toxoplasmosis prophylaxis for
seropositive allogeneic  recipients with active GVHD or a
prior history of toxoplasmic chorioretinitis (221,222 ), but
data demonstrating efficacy are limited (CIII). The optimal
prophylactic regimen for toxoplasmosis among HSCT
recipients has not been determined, but a proposed drug is
TMP-SMZ (BII), although allogeneic recipients have ex-
perienced break-through clinical disease despite TMP-SMZ
prophylaxis (218 ). For patients who are TMP-SMZ–intol-
erant, a combination of clindamycin, pyramethamine, and
leucovorin can be substituted for To. gondii  prophylaxis
(Appendix). After therapy for toxoplasmosis, HSCT recipi-
ents should continue receiving suppressive doses of TMP-
SMZ or an alternate regimen for the duration of their im-
munosuppression (BIII) (Appendix).
Other Recommendations
Recipients of autologous transplants are at negligible risk
for toxoplasmosis reactivation (218 ). No prophylaxis or
screening for toxoplasmosis infection is recommended for
such patients (DIII). Indications for toxoplasmosis prophy-
laxis are the same among children or adults, but pediatric
doses should be used among children (Appendix).
Recommendations Regarding Strongyloides stercoralis
Preventing Exposure
Allogeneic recipients should avoid contact with out-
houses and cutaneous exposure to soil or other surfaces that
might be contaminated with human feces (223 ) (AIII).
Allogeneic recipients who work in settings (e.g., hospitals
or institutions) where they could be exposed to fecal matter
should wear gloves when working with patients or in areas
with potential fecal contamination (AIII).
Preventing Disease and Disease Recurrence
Travel and residence histories should be obtained for all
patients before HSCT to determine any exposures to high-
risk areas (e.g., such moist temperate areas as the tropics,
subtropics, or the southeastern United States and Europe)
(223 ) (BIII). HSCT candidates who have unexplained
peripheral eosinophilia or who have resided in or traveled
to areas endemic for strongyloidiasis, even during the dis-
tant past, should be screened for asymptomatic strongyloidi-
asis before HSCT (BIII). Serologic testing with an enzyme-
linked immunosorbent assay is the preferred screening
method and has a sensitivity and specificity of >90%
(223,224 ) (BIII). FDA-licensed or -approved screening tests
should be used. Although stool examinations for strongy-
loidiasis are specific, the sensitivity obtained from ≈3 stool
examinations is 60%–70%; the sensitivity obtained from
concentrated stool exams is, at best, 80% (223 ). A total of
≈3 stool examinations should be performed if serologic tests
are unavailable or if strongyloidiasis is clinically suspected
in a seronegative patient (BIII).
HSCT candidates whose screening tests before HSCT
are positive for Strongyloides  species, and those with an
unexplained eosinophilia and a travel or residence his-
tory indicative of exposure to Strongyloides stercoralis  should
be empirically treated before transplantation (225,226 ),
preferably with ivermectin (BIII), even if seronegative or
stool-negative (Appendix).
To prevent recurrence among HSCT candidates with parasi-
tologically confirmed strongyloidiasis, cure after therapy should
be verified with ≈3 consecutive negative stool examinations be-
fore proceeding with HSCT (AIII). Data are insufficient to rec-
ommend a drug prophylaxis regimen after HSCT to prevent re-
currence of strongyloidiasis. HSCT recipients who had strongy-
loidiasis before or after HSCT should be monitored carefully for
signs and symptoms of recurrent infection for 6 months after treat-
ment (BIII).
Other Recommendations
Hyperinfection strongyloidiasis has not been reported after
autologous HSCT; however, the same screening precautions
should be used among autologous recipients (BIII). Indications
for empiric treatment for strongyloidiasis before HSCT are
the same among children or adults except for children weighing
<15 kg, for whom the preferred drug is thiabendazole (BIII)
(Appendix).
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Recommendations Regarding Trypanosoma cruzi
Preventing Exposure
HSCT physicians should be aware that Trypanosoma
cruzi , the etiologic agent of Chagas’ disease, can be trans-
mitted congenitally, through blood transfusion (227 ), and
possibly through HSCT. Additionally, treatment for persons
infected with Tr. cruzi  is not always effective, even dur-
ing the acute stage of infection (227 ). Therefore, poten-
tial donors who were born, received a blood transfusion, or
ever lived for ≈6 months in a Chagas’ disease endemic area
(e.g., parts of South and Central America and Mexico)
should be screened serologically for anti-Tr. cruzi  serum
IgG antibody (228 ) (BIII). Persons who lived <6 months in
a Chagas’-endemic area but who had high-risk living con-
ditions (e.g., having had extensive exposure to the Chagas’
disease vector — the reduviid bug — or having lived in
dwellings with mud walls, unmilled logs and sticks, or a
thatched roof) should also be screened for evidence of Tr.
cruzi  infection (BIII). Because Chagas’ disease can be
transmitted congenitally, researchers report that any per-
son with extensive multigenerational maternal family histo-
ries of cardiac disease (e.g., cardiomegaly and arrhythmias)
should be screened serologically for serum IgG anti-Tr.
cruzi  antibodies (227 ) (CIII). To decrease the risk for mis-
diagnosis by false-positive or false-negative serologic tests,
Tr. cruzi  screening should consist of ≈2 conventional sero-
logic tests (e.g., enzyme immunoassay, indirect hemaggluti-
nation, indirect fluorescent antibody) or ≈1 conventional
serologic tests, followed by a confirmatory serologic test
(e.g., radioimmunoprecipitation assay) (229 ) (BIII). Persons
with active Chagas’ disease should not serve as HSCT
donors (DIII). Researchers also recommend deferral of
HSCT donation for a past history of Chagas’ disease (CIII).
Preventing Disease
HSCT candidates who are at risk for being infected with
Tr. cruzi  should be screened for serum IgG anti-Tr. cruzi
antibody (228 ) (BIII). Tr. cruzi  seropositivity is not a con-
traindication to HSCT (228,230 ). However, if an acute ill-
ness occurs in a Tr. cruzi-seropositive HSCT recipient, par-
ticularly during neutropenia, Tr. cruzi  reactivation should
be included in the differential diagnosis (230 ) (BIII).
Researchers have proposed use of beznidazole or nifurtimox
for preemptive therapy or prophylaxis of recurrent Tr. cruzi
among seropositive HSCT recipients (230,231 ), but insuf-
ficient data were found to make a recommendation.*
Other Recommendations
Recommendations are the same for autologous or allo-
geneic recipients. However, recurrence of Chagas’ disease
is probably less likely to occur among autologous recipi-
ents because of the shorter duration of immunosuppres-
sion. Recommendations are the same among children or
adults.
HOSPITAL INFECTION CONTROL
Room Ventilation
HSCT center personnel should follow published guidelines
for hospital room design and ventilation (140,180 ) (BIII).
HSCT centers should also prevent birds from gaining access
to hospital air-intake ducts (140,174 ) (AII). All allogeneic
recipients should be placed in rooms with >12 air exchanges/
hour (232,233 ) and point-of-use HEPA filters that are capable
of removing particles ≈0.3 µm in diameter
(140,178,180,233 ) (AIII). Correct filtration is critical in
HSCT centers with ongoing construction and renovation
(179 ). When portable HEPA filters are used as adjuncts to the
primary ventilation system, they must be placed centrally in
patient rooms so that space is available around all surfaces to
allow free air circulation (BIII). The need for environmental
HEPA filtration for autologous recipients has not been estab-
lished. However, HEPA-filtered rooms should be evaluated for
autologous recipients if they experience prolonged neutrope-
nia, a substantial risk factor for nosocomial aspergillosis (CIII).
A laminar air flow (LAF) room contains filtered air that
moves in parallel, unidirectional flow — the air enters the room
from one wall and exits the room on the opposite wall (232 ).
Although LAF has been demonstrated to protect patients from
infection during aspergillosis outbreaks related to hospital con-
struction (234,235 ), the value of routine LAF room use for all
HSCT recipients is doubtful because substantial overall sur-
vival benefit has not been reported (236 ). During 1983, LAF
rooms were preferred for allogeneic recipients with aplastic
anemia and HLA-identical sibling donors because use of regu-
lar rooms was associated with a mortality rate that was approxi-
mately four times higher than for those recipients treated in
LAF rooms (237 ). However, the survival of aplastic anemia
HSCT recipients during the late 1990s exceeds that reported
during the early 1980s, and no studies have been done to de-
termine whether HSCT recipients with aplastic anemia still
have an improved survival rate when treated in an LAF room.
Therefore, HSCT centers need not construct LAF rooms
for each HSCT recipient. Use of LAF rooms, if available, is
optional (CII).
Hospital rooms should have directed airflow so that air
intake occurs at one side of the room and air exhaust occurs
at the opposite side (140 ) (BIII). Each hospital room should
also be well-sealed (e.g, around windows and electrical out-
lets) (140 ) (BIII). To provide consistent positive pressure in
the recipient’s room, HSCT centers should maintain consis-
tent pressure differentials between the patient’s room and the
hallway or anteroom at >2.5 Pa (i.e., 0.01 inches by water
gauge) (232,233 ) (BIII). Generally, hospital rooms for HSCT
recipients should have positive room air pressure when com-
pared with any adjoining hallways, toilets, and anterooms, if
present.
Anterooms should have positive air pressure compared with
hallways (180 ). An exception is the HSCT recipient with an
active disease that has airborne transmission (e.g., pulmonary
*For additional information regarding the epidemiology of Chagas’ disease, contact CDC/National Center for Infectious Diseases/Division
of Parasitic Diseases, (770) 488-7760.
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or laryngeal Mycobacteria tuberculosis  [TB] or measles). These
HSCT patients should be placed in negative isolation rooms
(62 ) (BIII), and a room with an anteroom is recommended for
such patients (180 ) (BIII).
Whenever possible, HSCT centers should have self-clos-
ing doors to maintain constant pressure differentials among
the HSCT recipients’ room and anterooms, if available, and
hallways (233 ) (BIII). To enable the nursing staff to observe
the HSCT recipient even when the doors are closed, windows
can be installed in either the door or the wall of the HSCT
recipient’s room (233 ) (CIII).
HSCT centers should provide backup emergency power
and redundant air-handling and pressurization systems to
maintain a constant number of air exchanges and room pres-
surization in the center when the central ventilation system is
shut off for maintenance and repair (238 ) (BIII). Additionally,
infection control personnel should work with maintenance
personnel to develop protocols to protect HSCT centers at all
times from bursts of mold spores that might occur when air-
handling systems are restarted after routine maintenance shut-
downs (BIII).
Construction, Renovation, and Building Cleaning
Construction and Renovation
Hospital construction and renovation have been associated
with an increased risk for nosocomial fungal infection, par-
ticularly aspergillosis, among severely immuno-compromised
patients (175,176 ). Therefore, persons responsible for HSCT
center construction or renovation should consult published
recommendations regarding environmental controls during
construction (239,240 ) (AIII).
Whenever possible, HSCT recipients, HCWs, and visitors
should avoid construction or renovation areas (240 ) (AIII).
Also, equipment and supplies used by HSCT recipients or their
HCWs should not be exposed to construction or renovation
areas (240 ). When planning for construction or renovation,
the HSCT center should include plans for intensified
aspergillosis-control measures (AIII). Construction and
renovation infection control planning committees should
include engineers, architects, housekeeping staff, infection
control personnel, the director of the HSCT center, the
administration, and safety officers (241 ) (BIII).
When constructing new HSCT centers, planners should
ensure that patient rooms will have adequate capacity to mini-
mize fungal spore counts by following room ventilation rec-
ommendations. During outdoor construction and demolition,
the intake air should be sealed (BIII), if possible; if not, filters
should be checked frequently. Additionally, to protect HSCT
patient care areas during fire drills and emergencies, weather
stripping should be placed around stairwell doors, or alter-
natively, the stairwell air should be filtered to the level of
safety of the adjacent hospital air (BIII). False ceilings
should be avoided whenever possible (174 ) (BII). If use of
false ceilings cannot be avoided, the area above false ceilings
should be vacuumed routinely to minimize dust and, there-
fore, fungal exposure to patients (174 ) (BIII).
During hospital construction or renovation, hospitals
should construct rigid, dust-proof barriers with airtight seals
(242 ) between patient care and construction or renovation
areas to prevent dust from entering patient care areas; these
barriers (i.e., sealed drywall) should be impermeable to
Aspergillus  species (140,175,176,179,240 ) (BIII). If impervi-
ous barriers cannot be created around the construction or
renovation area, patients should be moved from the area until
renovation or construction is complete and the area has been
cleaned appropriately (176 ) (BIII). HSCT centers should
direct pedestrian traffic occurring near construction or
renovation areas away from patient care areas to limit the
opening and closing of doors or other barriers that might cause
dust dispersion, entry of contaminated air, or tracking of dust
into patient areas (140 ), particularly those in the HSCT cen-
ter (176 ) (BIII). If possible, specific corridors, entrances, and
exits should be dedicated to construction use only (240 ). An
elevator to which patients do not have access also should be
dedicated to construction use only (240 ). Construction work-
ers, whose clothing might be contaminated with Aspergillus
species spores, should use the construction elevator and avoid
contact with patients, patient care areas, other elevators, and
nonconstruction areas (BIII).
Hospital construction or renovation areas should have
negative air pressure relative to that in adjacent patient care
areas, if no contraindications exist for such pressure differen-
tial (140,176,179,240,242 ) (BIII). Ideally, air from the con-
struction or renovation areas should be exhausted to the out-
side of the hospital (176 ) (BIII) or if recirculated, it should be
HEPA-filtered first (BIII).
Researchers have proposed that HSCT recipients wear
the N95 respirator to prevent mold exposure during trans-
portation near hospital construction or renovation areas
(CIII) because the N95 respirators are regarded as effective
against any aerosol. However, to be maximally effective, N95
respirators must be fit-tested and all users must be trained.
With correct personnel fit-testing and training, N95 respira-
tors reliably reduce aerosol exposure by 90%. Without fit-
testing and training, aerosol exposure would be reduced but
not necessarily by 90% (243 ). For patients who cannot use
or tolerate an N95 respirator, researchers have proposed
using the powered air purifying respirator (244,245 ), which
can be used by patients in wheelchairs. Limitations of the
powered air purifying respirator include its cost and that it is
not appropriate for young children and infants. General limi-
tations of using respirators are that no commercially avail-
able respirator, including N95, has been tested specifically
for its efficacy in reducing exposure to Aspergillus  species in
hospital construction or renovation areas, and no studies have
been done that assess the usefulness and acceptability of us-
ing respirators among HSCT recipients. Standard surgical
masks provide negligible protection against mold spores and
are not recommended for this indication (DIII).
Newly constructed or renovated areas should be
cleaned before patients are allowed to enter them
(140,176 ) (AIII). Decontamination of fungal-contaminated
areas that cannot be extracted and replaced should be done
using copper-8-quinolate (179 ) (BIII). Also, areas above
false ceilings located under or adjacent to construction ar-
eas should be vacuumed (174 ) (BIII). Additionally, the ven-
tilation, direction of airflow, and room pressurization should
be tested and correctly adjusted before patients are allowed
to enter (BIII).
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Cleaning
HSCT centers should be cleaned ≈1 times/day with special
attention to dust control (BIII). Exhaust vents, window sills,
and all horizontal surfaces should be cleaned with cloths and
mop heads that have been premoistened with an FDA- or En-
vironmental Protection Agency (EPA)-registered hospital dis-
infectant (BIII). Thorough cleaning during and after any con-
struction activity, including minor renovation projects, is criti-
cal (BIII).
HSCT center personnel should prohibit exposures of pa-
tients to such activities as vacuuming or other floor or carpet
vacuuming that could cause aerosolization of fungal spores
(e.g., Aspergillus  species) (140 ) (AIII). Accordingly, doors to
patient rooms should be closed when vacuuming HSCT cen-
ter corridors. All vacuum cleaners used in the HSCT center
should be fitted with HEPA filters. An FDA- or EPA-regis-
tered disinfectant (246,247 ) should be used daily for environ-
mental disinfection and when wet vacuuming is performed in
the HSCT center (BIII). If an HSCT center provides care for
infants, phenolic disinfectants can be used to clean the floors
only if the compound is diluted according to the product label;
but phenolic compounds should not be used to clean basinets
or incubators (246 ) (DIII).
Water leaks should be cleaned up and repaired as soon as
possible but within 72 hours to prevent mold proliferation in
floor and wall coverings, ceiling tiles, and cabinetry in and
around all HSCT patients care areas (BIII). If cleanup and re-
pair are delayed ≈72 hours after the water leak, the involved
materials should be assumed to contain fungi and handled ac-
cordingly. Use of a moisture meter to detect water penetration
of walls should be used whenever possible to guide decision-
making (238 ) (BIII). For example, if the wall does not have
<20% moisture content ≈72 hours after water penetration, it
should be removed (BIII). Design and selection of furnishings
should focus on creating and maintaining a dust-free environ-
ment. Flooring and finishes (i.e., wall coverings, window
shades, and countertops) used in HSCT centers should be
scrubbable, nonporous, easily disinfected, and they should col-
lect minimal dust (BIII).
Isolation and Barrier Precautions
HSCT center personnel should follow published guidelines
for hospital isolation practices, including CDC guidelines for
preventing nosocomial infections (62,140,248 ) (AIII). How-
ever, the efficacy of specific isolation and barrier precautions
in preventing noso-comial infections among HSCT recipients
has not been evaluated.
HSCT recipients should be placed in private (i.e., single-
patient) rooms (BIII). If contact with body fluids is anticipated,
standard precautions should be followed (AIII). These precau-
tions include hand washing and wearing appropriate gloves,
surgical masks or eye and face protection, and gowns during
procedures and activities that are likely to generate splashes or
sprays of blood, body fluids, secretions or excretions, or cause
soiling of clothing (62 ). When indicated, HSCT recipients
should also be placed on airborne, droplet, or contact precau-
tions in addition to standard precautions (62 ) (AIII). Careful
observation of isolation precautions is critical in preventing
transmission of infectious agents among HSCT recipients,
HCWs, visitors, and other HSCT recipients. Physicians are
cautioned that HSCT recipients might have a prolonged or
episodic excretion of organisms (e.g., CMV).
Researchers have proposed that HSCT recipients wear sur-
gical mask and gloves when exiting their hospital rooms be-
fore engraftment (CIII). All HSCT recipients who are
immunocompromised (phases I–III of immune system recov-
ery) and candidates undergoing conditioning therapy should
minimize the time spent in crowded areas of the hospital (e.g.,
waiting areas and elevators) (BIII) to minimize potential expo-
sure to persons with CRV infections.
Hand Hygiene
Hand washing is the single-most critical and effective pro-
cedure for preventing nosocomial infection (62 ). All persons,
but particularly HCWs, should wash their hands before enter-
ing and after leaving the rooms of HSCT recipients and can-
didates undergoing conditioning therapy (62,249 ) or before
and after any direct contact with patients regardless of whether
they were soiled from the patient, environment, or objects (AI).
HSCT recipients should be encouraged to practice safe hand
hygiene (e.g., washing hands before eating, after using the toi-
let, and before and after touching a wound) (BIII). Hand wash-
ing should be done with an antimicrobial soap and water (AIII);
alternatively, use of hygienic hand rubs is another acceptable
means of maintaining hand hygiene (250,251 ). If gloves are
worn, HCWs should put them on in the patient’s room
after hand washing and then discard them in the same
patient’s room before washing hands again after exiting the
room. When worn, gloves should always be changed
between patients or when soiled before touching a clean
area (e.g., change gloves after touching the perineum and
before going to a “clean” area) (AIII). Appropriate gloves
should be used by all persons when handling potentially
contaminated biological materials (AII). Items worn on the
hands and fingers (e.g., rings or artificial nails [248,252 ])
and adhesive bandage strips, can create a nidus for patho-
genic organisms that is difficult to clean. Thus, HCWs
should avoid wearing such items whenever possible (BII).
Equipment
All HSCT center personnel should sterilize or disinfect and
maintain equipment and devices using only EPA-registered
compounds as directed by established guidelines
(140,180,246,247,253–256 ) (AIII). HSCT center personnel
should monitor opened and unopened wound-dressing sup-
plies (e.g., adhesive bandages [257,258 ] and surgical and elas-
tic adhesive tape [259 ]) to detect mold contamination and pre-
vent subsequent cutaneous transmission to patients (BII).
Monitoring should consist of discarding all bandages and
wound dressings that are out of date, have damaged packag-
ing, or are visually contaminated by construction debris or
moisture (BIII). When arm boards are used to provide support
for intravenous lines, only sterile dressing materials should be
used (260 ), and arm boards should be changed frequently (e.g.,
daily) (BIII). Additionally, unsterile tongue depressors in-
serted into a piece of foam tubing should not be used as
splints for intravenous and arterial catheter sites because
these have been associated with an outbreak of fatal inva-
sive nosocomial Rhizopus microsporus  among preterm (i.e.,
very low-birth–weight) infants (261 ) (DII). HSCT centers
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should not install carpeting in hallways outside (DII) or in
patient rooms (DIII) because contaminated carpeting has
been associated with outbreaks of aspergillosis among HSCT
recipients (262,263 ).
Plants, Play Areas, and Toys
Although to date, exposure to plants and flowers has not
been conclusively reported to cause fungal infections among
HSCT recipients, most researchers strongly recommend that
plants and dried or fresh flowers should not be allowed in the
rooms of hospitalized HSCT candidates undergoing condi-
tioning therapy and HSCT recipients (phases I–III of immune
system recovery) because Aspergillus  species have been isolated
from the soil of potted ornamental plants (e.g., cacti), the sur-
face of dried flower arrangements, and fresh flowers
(140,174,178,264 ) (BIII).
Play areas for pediatric HSCT recipients and candidates
undergoing conditioning therapy should be cleaned and disin-
fected ≈1 times/week and as needed (BIII). Only toys, games,
and videos that can be kept clean and disinfected should be
allowed in the HSCT center (BIII). HSCT centers should fol-
low published recommendations for washing and disinfecting
toys (265 ) (BIII). All HSCT center toys, games, and videos
should be routinely and thoroughly washed or wiped down
when brought into the HSCT center and thereafter ≈1 times/
week and as needed by using a nontoxic FDA- or EPA-regis-
tered disinfectant (246,247,265 ) followed by a water rinse
(BIII). Cloth or plush toys should be washed in a hot cycle of a
washing machine or dry-cleaned ≈1 times/week and as
needed (BIII). Alternatively, machine washing in a cold cycle
is acceptable if laundry chemicals for cold water washing are
used in proper concentration (265 ). Hard plastic toys should
be scrubbed with warm soapy water using a brush to clean crev-
ices, rinsed in clean water, immersed in a mild bleach solution,
which should be made fresh daily, for 10–20 minutes, rinsed
again, and allowed to air dry (246 ). Alternatively, hard plastic
toys can be washed in a dishwasher or hot cycle of a washing
machine (BIII). Broviac dolls* should be disassembled upon
completion of play and washed with a nontoxic FDA- or EPA-
registered disinfectant (246,247 ), rinsed with tap water, and
allowed to air dry before other children are allowed to play
with them (BIII). Toys that cannot be washed, disinfected, or
dry-cleaned after use should be avoided (BIII). Infants, tod-
dlers, and children who put toys in their mouths should not
share toys (265 ) (DIII). For children in isolation, researchers
recommend the following:
• Disposable play items should be offered whenever
possible (BIII).
• Before returning a washable toy used in an isolation
room to the pediatric play room for use by another
child, it should be cleaned again as previously described
(BIII).
• When a child is taken out of isolation, toys, games, and
videos used during the period of isolation and that
might serve as fomites for infection should be
thoroughly disinfected with a nontoxic FDA- or EPA-
registered disinfectant (246,247,265 ) (BIII). After use
in isolation rooms, cloth or plush toys should be placed
in a plastic bag and separated from unused toys. All cloth
or plush toys used in isolation rooms should be washed
in a washing machine or dry-cleaned before being used
in a nonisolation room (BIII). Toys that cannot be
disinfected or dry-cleaned after use in an isolation room
should be discarded (BIII).
Water-retaining bath toys have been associated with an
outbreak of Pseudomonas aeruginosa  in a pediatric oncology
ward (266 ); therefore, these toys should not be used by
immunocompromised HSCT recipients and candidates
(DII). Occupational and physical therapy items should be
cleaned and disinfected as previously described (BIII). Soil-
based materials (e.g., clay or potting soil) should be avoided
(BIII).
HCWs
HSCT center personnel should have a written compre-
hensive policy regarding their immunizations and vaccina-
tions, and that policy should meet current CDC, Advisory
Committee on Immunization Practices, and Healthcare
Infection Control Practices Advisory Committee recom-
mendations (267 ) (BIII). Immunizations are needed to pre-
vent transmission of vaccine-preventable diseases to HSCT
recipients and candidates undergoing conditioning therapy.
All HCWs with diseases transmissible by air, droplet, and
direct contact (e.g., VZV, infectious gastroenteritis, HSV
lesions of lips or fingers, and URIs) should be restricted
from patient contact and temporarily reassigned to other
duties (AI). HSCT center personnel should follow published
recommendations regarding the duration of work restric-
tions for HCWs with infectious diseases (268,269 ) (BIII).
HSCT center HCWs with bloodborne viruses (e.g., HIV
or hepatitis B or C viruses) should not be restricted from
patient contact (DIII) as long as they do not perform proce-
dures that pose a high risk for injury that could result in
patient exposure to the HCW’s blood or body fluids. Work
exclusion policies should be designed to encourage HCWs
to report their illnesses or exposures (AII).
HSCT Center Visitors
Hospitals should have written policies for screening
HSCT center visitors, particularly children, for potentially
infectious conditions. Such screening should be performed
by clinically trained HCWs (BII). Visitors who might have
communicable infectious diseases (e.g., URIs, flu-like ill-
nesses, recent exposure to communicable diseases, an active
shingles rash whether covered or not, a VZV-like rash within
6 weeks of receiving a live attenuated VZV vaccine, or a his-
tory of receiving an oral polio vaccine within the previous 3–6
weeks) should not be allowed in the HSCT center or allowed
to have direct contact with HSCT recipients or candidates
undergoing conditioning therapy (AII). No absolute minimum
age requirement for HSCT center visitors exists; however, all
visitors must be able to understand and follow appropriate hand
*Broviac dolls are used to demonstrate medical procedures (e.g., insertion of catheters) to children to lessen their fears.
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washing and isolation precautions (AIII). The number of
HSCT center visitors at any one time should be restricted to a
number that permits the nursing staff to perform appropriate
screening for contagious diseases and adequate instruction and
supervision of hand washing, glove and mask use, and biosafety
precautions (BIII).
Patient Skin and Oral Care
To optimize skin care, HSCT recipients should take daily
showers or baths during and after transplantation (BIII), using
a mild soap (BIII). Skin care during neutropenia should also
include daily inspection of skin sites likely to be portals of in-
fection (e.g., the perineum and intravascular access sites) (BIII).
HSCT recipients and candidates undergoing conditioning
therapy should maintain good perineal hygiene to minimize
loss of skin integrity and risk for infection (BIII). To facilitate
this precaution, HSCT center personnel should develop pro-
tocols for patient perineal care, including recommendations
for gentle but thorough perineal cleaning after each bowel
movement and thorough drying of the perineum after each
urination (BIII). Females should always wipe the perineum
from front to back after using the toilet to prevent fecal con-
tamination of the urethra and urinary tract infections (AIII).
Moreover, to prevent vaginal irritation, menstruating
immunocompromised HSCT recipients should not use tam-
pons (DIII) to avoid the risk for cervical and vaginal abrasions.
Additionally, the use of rectal thermometers, enemas, sup-
positories, and rectal exams are contraindicated among
HSCT recipients to avoid skin or mucosal breakdown (DIII).
All HSCT candidates and their caregivers should be edu-
cated regarding the importance of maintaining good oral and
dental hygiene for at least the first year after HSCT to reduce
the risk for oral and dental infections (AIII). For example,
HSCT candidates should be informed that establishment of
the best possible periodontal health before HSCT is a sub-
stantial step in avoiding short- and long-term oral infections
and that maintenance of safe oral hygiene after HSCT can
minimize the severity of infections and facilitate healing of
mucositis, particularly before engraftment (BIII).
All HSCT candidates should receive a dental evaluation
and relevant treatment before conditioning therapy begins
(270,271 ) (AIII). Likely sources of dental infection should be
vigorously eliminated (271 ) (AIII). For example, teeth with
moderate to severe caries should be restored; ill-fitting dental
prostheses should be repaired; and teeth compromised by mod-
erate to severe periodontal disease should be extracted (271 ).
Ideally, 10–14 days should elapse between the completion of
tissue-invasive oral procedures and onset of conditioning
therapy to allow for adequate healing and monitoring for post-
surgical complications (AIII).
HSCT recipients with mucositis and HSCT candidates
undergoing conditioning therapy should maintain safe oral
hygiene by performing oral rinses 4–6 times/day with sterile
water, normal saline, or sodium bicarbonate solutions (270 )
(AIII). HSCT recipients and candidates should brush their
teeth ≈2 times/day with a soft regular toothbrush (270 ) (BIII).
If the recipient cannot tolerate these brushings, use of an
ultrasoft toothbrush or toothette (i.e., foam swab on a stick),
can be used (CIII), but physicians should be aware that using
the latter products are less desirable than using soft regular or
ultrasoft toothbrushes because the toothettes remove less den-
tal debris (270 ). Using toothpaste is optional, depending on
the recipient’s tolerance (270 ) (CIII). HSCT recipients and
candidates undergoing conditioning therapy who are skilled at
dental flossing should floss daily if this can be done without
trauma (BIII). Routine dental supervision is advised to moni-
tor and guide the patient’s maintenance of oral and dental
hygiene (BIII). To decrease the risk for mechanical trauma and
infection of oral mucosa, fixed orthodontic appliances and
space maintainers should not be worn from the start of condi-
tioning therapy until preengraftment mucositis resolves, and
these devices should not be worn during any subsequent peri-
ods of mucositis (270 ) (DIII). Dental and transplant teams and
the patient’s community dentist should coordinate removal of
these appliances and long-term rehabilitation of any oral le-
sions (BIII). However, patients who normally wear removable
dental prostheses might be able to wear them during condi-
tioning therapy before HSCT and during mucositis after
HSCT, depending on the degree of tissue integrity at the den-
ture-bearing sites and the ability of the patient to maintain
denture hygiene on a daily basis (CIII).
Preventing Bacterial Intravascular Catheter-
Related Infections
HSCT center personnel are advised to implement pub-
lished guidelines for preventing intravascular device-related
infections (33 ) (AIII). Contact with tap water at the central
venous catheter site should be avoided (BIII). For long-term
central venous access among children, HSCT physicians can
use a totally implantable device among children aged <4 years
if the anticipated duration of vascular access is >30 days (CII).
However, such a device among children aged <4 years is not
generally used as the actual HSCT infusion site because a)
problems with skin fragility contraindicate repeated punc-
tures over the port site and b) the port device might have an
insufficient number of lumens for optimal patient manage-
ment immediately after HSCT.
To prevent bloodstream infections associated with
needleless intravenous access devices, HSCT recipients
should a) cover and protect the catheter tip or end cap during
bathing or showering to protect it from tap water contami-
nation, b) change the device in accordance with manufactur-
ers’ recommendations, if available, and c) have a caregiver
perform intravenous infusions whenever possible (272,273 )
(BII). Also, HSCT recipients and their caregivers should be
educated regarding proper care of needleless intravenous ac-
cess devices (272 ) (BII). No recommendation regarding the
use of antibiotic impregnated central venous catheters among
HSCT recipients can be made because of lack of data.
Control of Specific Nosocomial Infections
Recommendations Regarding Legionella Species
HSCT physicians should always include Legionnaires’
disease (LD) in the differential diagnosis of pneumonia
among HSCT recipients (140 ) (AIII). Appropriate tests to
confirm LD include a) culturing sputum, BAL, and tissue
specimens; b) testing BAL specimens for Legionellae  by di-
rect fluorescent antibody; and c) testing for Legionella
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pneumophila  serogroup 1 antigen in urine. The incubation
period for LD is usually 2–10 days; thus, laboratory-confirmed
legionellosis that occurs in a patient who has been hospitalized
continuously for ≈10 days before the onset of illness is regarded
as a definite case of nosocomial LD, and a laboratory-con-
firmed infection that occurs 2–9 days after hospital admission
is a possible case of nosocomial LD (140 ). When a case of
laboratory confirmed nosocomial LD (274,275 ) is identified
in a person who was in the inpatient HSCT center during all
or part of the 2–10 days before illness onset, or if two or more
cases of laboratory-confirmed LD occur among patients who
had visited an outpatient HSCT center, hospital personnel
should
• report the case(s) to the local or state health department
if the disease is reportable in that state or if assistance is
needed (140 ) (AIII); and
• in consultation with the hospital infection control team,
conduct a thorough epidemiologic and environmental
investigation to determine the likely environmental
source(s) of Legionella  species (e.g., showers, tap water
faucets, cooling towers, and hot water tanks) (274,276 )
(AI).
The source of Legionella  infection should be identified and
decontaminated or removed (AIII). Extensive hospital investi-
gations of an isolated case of possible nosocomial LD might
not be indicated if the patient has had limited contact with the
inpatient center during most of the incubation period (CIII).
Because HSCT recipients are at much higher risk for disease
and death from legionellosis compared with other hospital-
ized persons (274 ), periodic routine culturing for Legionellae
in water samples from the center’s potable water supply could
be regarded as part of an overall strategy for preventing LD in
HSCT centers (CIII). However, the optimal methodology (i.e.,
frequency or number of sites) for environmental surveillance
cultures in HSCT centers has not been determined, and the
cost-effectiveness of this strategy has not been evaluated. Be-
cause HSCT recipients are at high risk for LD and no data
were found to determine a safe concentration of Legionellae
organisms in potable water, the goal, if environmental sur-
veillance for Legionellae  is undertaken, should be to maintain
water systems with no detectable organisms (AIII). Physicians
should suspect legionellosis among HSCT recipients with
nosocomial pneumonia even when environmental surveillance
cultures do not yield Legionellae  (AIII). If Legionella  species
are detected in the water supplying an HSCT center, the fol-
lowing should be done until Legionella  species are no longer
detected by culture:
• The water supply should be decontaminated (140 )
(AII).
• HSCT recipients should be given sponge baths with
water that is not contami-nated with Legionella  species
(e.g., not with the HSCT center’s Legionella  species-
contaminated potable water system) (BIII).
• Patients should not take showers in LD-contaminated
water (DIII).
• Water from faucets containing LD-contaminated water
should not be used in patient rooms or the HSCT
center and outpatient clinic to avoid creating infectious
aerosols (CIII).
• HSCT recipients should be given sterile water instead
of tap water for drinking, brushing teeth, or flushing
nasogastric tubes during Legionellosis outbreaks (BIII).
HSCT center personnel should use only sterile water (i.e., not
distilled unsterile water) for rinsing nebulization devices and
other semicritical respiratory-care equipment after cleaning or
disinfecting and for filling reservoirs of nebulization devices
(140 ) (BII). HSCT centers should not use large-volume room air
humidifiers that create aerosols (e.g., by Venturi principle,
ultrasound, or spinning disk) and, thus, are actually nebulizers
(140 ) (DI) unless these humidifier or nebulizers are sterilized or
subjected to daily high-level disinfection and filled with sterile
water only (140 ) (CIII).
When a new hospital with an HSCT center is constructed,
the cooling towers should be placed so that the tower drift is di-
rected away from the hospital’s air-intake system, and the cooling
towers should be designed so that the volume of aerosol drift is
minimized (140 ) (BII). For operational hospital cooling towers,
hospitals should
• install drift eliminators,
• regularly use an effective biocide,
• maintain cooling towers according to the manufacturer’s
recommendations, and
• keep adequate maintenance records (140 ) (BII).
HSCT physicians are encouraged to consult published
recommendations regarding preventing nosocomial Legionellosis
(140,277 ) (BIII). No data were found to determine whether
drinking tap water poses a risk for Legionella  exposure among
HSCT recipients in the absence of an outbreak.
Recommendations Regarding Methicillin-Resistant
Sta. aureus
HSCT center HCWs should follow basic infection control
practices (e.g., hand washing between patients and use of barrier
precautions, including wearing gloves whenever entering the
methicillin-resistant Sta. aureus  [MRSA] infected or colonized
patient’s room); these practices are essential for MRSA control
(62 ) (AII). If MRSA is a substantial problem in the HSCT center
and evidence exists of ongoing MRSA transmission, MRSA in-
fected or colonized patients should be treated as a cohort (e.g.,
cared for exclusively by a limited number of HCWs) (BIII).
HSCT transplant recipients with recurrent Sta. aureus  infections
should undergo extensive evaluation for persistent colonization,
including cultures of nares, groin, axilla, and ostomy sites (e.g.,
tracheostomy or gastrointestinal tube) (BIII). For patients with
recurrent MRSA infection, elimination of the carrier state should
be attempted by applying a 2% mupirocin calcium ointment to
the nares (BIII), although this strategy has been only marginally
effective in certain institutions (278 ) (Appendix). High-level
mupirocin-resistant MRSA has been reported in Europe, the
Middle East, and South America (279–283 ) but is uncommon in
the United States. As with any antibiotic, incorrect or overuse of
mupirocin can result in mupirocin-resistant Staphylococci ; there-
fore, mupirocin use should be reserved for infection control strate-
28
gies only (279,280 ). For patients who fail mupirocin, physicians
have used bacitracin, TMP-SMZ, or rifampin administered with
another antibiotic, but no standardized protocol using these drugs
for this indication has been evaluated and no recommendations
can be made because of lack of data. Selection of a systemic anti-
biotic should be guided by susceptibility patterns.
Intravascular cannulas or other implantable devices that are
infected or colonized with MRSA should be removed (AIII).
Patients with MRSA should be placed under contact precautions
until all antibiotics are discontinued and until three consecutive
cultures, taken ≈1 weeks apart, are negative (62 ) (BIII). Screen-
ing cultures for MRSA include the anterior nares, any body site
previously positive for MRSA, and any wounds or surgical sites.
Recommendations Regarding Staphylococcus
Species with Reduced Susceptibility to Vancomycin
All HSCT centers should have sufficient laboratory capability
to identify all Staphylococci  isolates and their susceptibility pat-
terns to antibiotics, including vancomycin (284,285 ) (AIII).
Additionally, all HSCT center personnel should conduct routine
surveillance for the emergence of Staphylococcus  species strains
with reduced susceptibility to vancomycin (285,286 ) (AIII).
Reduced susceptibility should be considered for all Sta. aureus
strains that have a vancomycin MIC of ≈4 µg/mL and all coagu-
lase-negative Staphylococci  that have a vancomycin MIC of ≈8 µg/
mL. If repeat testing of the organism in pure culture confirms the
genus, species, and elevated vancomycin MICs, the following steps
should be taken (287 ):
• The laboratory should immediately contact hospital
infection control personnel, the patient’s clinical center,
and the patient’s attending physician, as well as the local or
state health department, and CDC’s Hospital Infections
Program Help Desk ([404] 639-6106 or [800] 893-0485)
(284,285,287,288 ) (AIII).
• The HSCT center’s infection control personnel, in
collaboration with appropriate authorities (i.e., state and
local health departments and CDC) should promptly
initiate an epidemiologic and laboratory investigation
(287,288 ) (AIII) and follow published guidelines for the
control of such species (285,287,288 ) (BIII).
• Medical and nursing staff should
— institute contact precautions (e.g., wearing of gown
and gloves, using antibacterial soap for hand
washing, and wearing masks when contamination
of the HCW with secretions is likely) as
recommended for multidrug-resistant organisms
(62,284,287 );
— minimize the number of persons with access to
colonized or infected patients (287 ); and
— treat as a cohort colonized or infected patients (e.g.,
care for them exclusively with a limited number of
HCWs) (286,287 ) (AIII).
• If a patient in an HSCT center is colonized or infected with
Staphylococci  that have reduced susceptibility to vancomy-
cin, the infection control personnel should follow
published guidelines for the control of such species
(285,287,288 ) (BIII).
Avoiding overuse and misuse of antibiotics will decrease the
emergence of Staphylococcus  species with reduced susceptibility to
vancomycin (286,287 ). There-fore, medical and ancillary staff
members who are responsible for monitoring antimicrobial use
patterns in the facility should routinely review vancomycin-use
patterns (284,285,287 ) (AIII). Additionally, HSCT center
personnel should institute prudent use of all antibiotics,
particularly vancomycin, to prevent the emergence of
Staphylococcus  with reduced susceptibility to vancomycin
(284,285,287–289 ) (AII). Intravascular cannulas or other
implantable devices that are infected or colonized with
Staphylococcus  species strains with reduced susceptibility to
vancomycin should be removed (AIII).
Recommendations Regarding VRE
Use of intravenous vancomycin is associated with VRE emer-
gence. Vancomycin and all other antibiotics, particularly
antianaerobic agents (e.g., metronidazole and third-generation
cephalosporins) must be used judiciously (284,290–292 ) (AII).
Oral van-comycin use can be limited by treating recurrences of
Cl. difficile  diarrhea with oral metronidazole instead of vancomy-
cin (BIII). Physicians have placed patients with a
history of VRE or VRE colonization into continuous isolation
during clinic visits and hospitalizations; however, this practice is
controversial because certain non-HSCT recipients might clear
VRE from their stools. No recommendation regarding use of
continuous isolation among HSCT recipients can be made
because of lack of data. To control VRE exposure, strict adher-
ence to the following standard infection control measures is nec-
essary (292 ) (AI):
• Wash hands with antibacterial soap before entering and
after leaving HSCT recipients’ rooms, particularly those
who have VRE colonization or infection; alternatively,
wash hands with a waterless antiseptic agent (e.g., an
alcohol-based rinse or gel) (250 ).
• Whenever possible, treat as a cohort patients who are
known to be colonized or infected with VRE (290 ).
• Disinfect patient rooms and equipment (291,293 ),
including surfaces of the hospital ward environment (e.g.,
floors, walls, bed frames, doors, bathroom surfaces) with
an FDA- or EPA-registered disinfectant (246,247 ). A
nontoxic disinfectant should be used for pediatric areas
(BIII).
• Place patients with VRE under contact precautions until
all antibiotics are discontinued (CIII) and repeated
cultures are negative (62 ) (BIII). HCWs should always
wear gloves when in the VRE patient or carrier’s room and
discard gloves in the patient’s room before exiting.
No evidence exists that treating VRE carriers is beneficial;
therefore, chronic antibiotic treatment of carriers is not
recommended (DIII). HSCT recipients and candidates
should be screened for VRE colonization at the time of
interfacility transfer to allow for immediate institution of
appropriate infection control practices and to minimize
transmission of VRE between and within facilities (294 ) (BII).
However, the role of outpatient surveillance in VRE control is
unknown; such surveillance is costly and should not be
undertaken in nonoutbreak settings (DIII). A history of
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having resolved VRE bacteremia or being a VRE carrier are not
contraindications to HSCT (BIII).
Recommendations Regarding Cl. difficile
HSCT physicians should follow published recommendations
for preventing and controlling Cl. difficile  disease, including
minimizing the duration of antibiotic therapy and number of
antibiotics used for any indication (295,296 ) (AIII). All pa-
tients with Cl. difficile  disease should be placed under contact
precautions for the duration of illness (62 ) (AII). All HCWs
who anticipate contact with a Cl. difficile -infected patient or
the patient’s environment or possessions should put on gloves
before entering the patient’s room (62,295–298 ) and before
handling the patient’s secretions and excretions (AI). During
Cl. difficile  outbreaks, HSCT center personnel should restrict
use of antibiotics (e.g., clindamycin) (299 ) (BII). To prevent
transmission of Cl. difficile  to patients during nosocomial Cl.
difficile  outbreaks, HSCT center HCWs should a) use dispos-
able rectal thermometers or tympanic thermometers; b) disin-
fect gastrointestinal endoscopes with 2% glutaraldehyde im-
mersion for 10 minutes or use an equivalent disinfectant strat-
egy (255,256 ); and c) perform surface sterilization of the hos-
pital ward environment (e.g., floors, walls, bed frames, doors,
bathroom surfaces) with an FDA- or EPA-registered sterilant
(e.g., phosphate-buffered sodium hypochlorite solution [1,660
ppm available chloride]; unbuffered hypochlorite solution [500
ppm available chloride]; 0.04% formaldehyde and 0.03% glu-
taraldehyde [255,295,300 ]; or ethylene oxide [247,296 ]) (BII).
Additionally, physicians should treat patients with Cl. difficile
disease with antibiotics as recommended in published reports
(62,295 ) (BII).
Certain researchers also recommend antibiotic treatment
of Cl. difficile  carriers (301 ). However, other researchers have
reported that treatment of asymptomatic Cl. difficile  carriers
with metronidazole is not effective and that treatment with
vancomycin is only effective temporarily (i.e., <2 months after
treatment) (302 ). Consequently, no recommendation regard-
ing treatment of asymptomatic Cl. difficile  carriers can be
made. Similarly, although symptomatic Cl. difficile  disease re-
currence or relapse occurs among 7%–20% of patients (295 ),
data are insufficient to make a recommendation for prevent-
ing multiple Cl. difficile  relapses.
The following practices are not recommended for Cl.
difficile  control:
• routine stool surveillance cultures for Cl. difficile  for
asymptomatic patients or HCWs, even during
outbreaks (DIII);
• culturing HCWs’ hands for Cl. difficile  (DIII); or
• treating patients presumptively for Cl. difficile  disease
pending toxin results (DIII), unless the patient is very
sick with a compatible syndrome or the hospital has a
high prevalence of Cl. difficile  (CIII).
Prophylactic use of lyophilized Saccharomyces boulardii  to
reduce diarrhea among antibiotic recipients is not
recommended because this therapy is not associated with a
substantial reduction in diarrhea associated with Cl. difficile
disease (303 ) and has been associated with Saccharomyces
boulardii  fungemia (304 ) (DII).
Recommendations Regarding CRV Infections
Physicians should institute appropriate precautions and in-
fection control measures for preventing nosocomial pneumo-
nia among hospitalized HSCT recipients and candidates un-
dergoing conditioning therapy, particularly during community
or nosocomial CRV outbreaks (140 ) (AIII). Patients with URI
or LRI symptoms should be placed under a) contact precau-
tions for most viral respiratory infections including varicella;
b) droplet precautions for influenza or adenovirus; or c) air-
borne precautions for measles or varicella to avoid transmit-
ting infection to other HSCT candidates and recipients as well
as to HCWs and visitors (BIII). Identifying HSCT recipients
with RSV infection and placing them under contact precau-
tions immediately (AIII) to prevent nosocomial transmission
is critical. When suctioning the respiratory tract of patients
with URI or LRI symptoms, HCWs should wear gowns, sur-
gical masks, and eye protection to avoid contamination from
the patient’s respiratory secretions. All protective clothing (e.g.,
gown, gloves, surgical mask, and eye protection) should be put
on when entering a patient’s room and discarded in the same
room before exiting; protective clothing should always be
changed between patient rooms (140 ) (AIII). When caring for
an HSCT recipient or candidate undergoing conditioning
therapy with URI or LRI, HCWs and visitors should change
gloves and wash hands a) after contact with a patient; b) after
handling respiratory secretions or objects contaminated with
secretions from one patient and before contact with another
patient, object, or environmental surface; and c) between con-
tacts with a contaminated body site and the respiratory tract of
or respiratory device used on the same patient (140 ) (AII). This
practice is critical because most respiratory infections are usu-
ally transmitted by contact, particularly by hand to nose and
eye. Therefore just wearing a mask, without appropriate hand
washing, glove-wearing, or use of eye protection is insufficient
to prevent transmission of CRV infections.
Researchers have proposed that HSCT recipients or can-
didates undergoing conditioning therapy be placed under con-
tact precautions during nosocomial outbreaks (131 ) (CIII).
Even when no nosocomial or community outbreak of CRV
infections exists, all persons who enter the HSCT center
should be screened daily for URI symptoms, including visitors
and HCWs (BIII). Researchers also describe systems where
HCWs provide daily verification (e.g., using sign-in sheets)
that they are free of URI symptoms before being allowed to
provide HSCT patient care. HCWs and visitors with URI
symptoms should be restricted from contact with HSCT re-
cipients and candidates undergoing conditioning therapy to
minimize the risk for CRV transmission (131 ) (AIII). All
HCWs with URI symptoms should be restricted from patient
contact and reassigned to nonpatient care duties until the
HCW’s symptoms resolve (BIII). Visitors with URI symptoms
should be asked to defer their visit to the HSCT center (131 )
until their URI symptoms resolve (BIII).
Respiratory secretions of any hospitalized HSCT candi-
date or recipient with signs or symptoms of CRV infection
should be tested promptly by viral culture and rapid diagnos-
tic tests for CRV (BIII). Appropriate samples include nasopha-
ryngeal washes, swabs, aspirates, throat swabs, and BAL fluid.
This practice is critical because preemptive treatment of cer-
tain CRVs (e.g., influenza and RSV) (133 ) might prevent
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severe disease and death among HSCT recipients. Viral shed-
ding among HSCT recipients with CRV infection has been
reported to last £4 months for influenza (143 ), £2 years for
adenovirus (305,306 ), and £22 days for RSV (136 ); however,
RSV viral shedding has been reported to last 112 days in a
child with severe combined immunodeficiency (307 ). There-
fore, to prevent nosocomial transmission of CRV (136 ), HSCT
center HCWs should recognize that prolonged CRV shedding
can occur when determining the duration of appropriate pre-
cautions for CRV-infected HSCT recipients or candidates
undergoing conditioning therapy (CIII). HSCT centers should
use serial testing by using cultures from nasopharyngeal swabs,
throat swabs or aspirates, or rapid antigen tests to help deter-
mine whether patients have stopped shedding influenza virus
(BIII). Researchers have proposed that HSCT physicians con-
duct routine CRV surveillance among HSCT recipients to
detect outbreaks and implement infection control measures as
early as possible (CIII). During RSV season, HSCT recipients
and candidates with signs or symptoms should be tested for RSV
infection (i.e., the presence of RSV antigen in respiratory
secretions tested by enzyme-linked immunosorbent assay and
viral culture) starting with admission to the HSCT center. All
patients who are RSV-antigen positive should be treated as a
cohort during nosocomial RSV outbreaks because this practice
reduces nosocomial RSV transmission (130,131 ) (BII).
Symptomatic HCWs should be excluded from patient contact
until symptoms resolve. HCWs and visitors with infectious con-
junctivitis should be restricted from direct patient contact until
the drainage resolves (i.e., usually, 5–7 days for adenovirus) and
the ophthalmology consultant concurs that the infection and
inflammation have resolved (268 ) (AII) to avoid possible trans-
mission of adenovirus to HSCT recipients.
Preventing CRV exposure among HSCT recipients after hos-
pital discharge is more challenging because of high CRV preva-
lence. Preventive measures should be individualized in accordance
with the immunologic status and tolerance of the patient. In out-
patient waiting rooms, patients with CRV infections should be
separated to the extent possible from other patients (BIII).
Recommendations Regarding TB
HSCT candidates should be screened for TB by careful
medical history and chart review to ascertain any history of
prior TB exposure (AIII) because immunocompromised per-
sons have higher risk for progression from latent TB infection
to active disease (244 ). Also, physicians can administer a tu-
berculin skin test (TST) using the Mantoux method with five
tuberculin units of purified protein derivative (CIII); but be-
cause of a patient’s immunocompromise, this test might not be
reliable. If a TST is administered, either the Tubersol® or
Aplisol® formulation of purified protein derivative can be used
(244,308 ). Persons with a recently positive TST or a history
of a positive TST and no prior preventive therapy should be
administered a chest radiograph and evaluated for active TB
(309 ) (AI). For immunocompromised persons, a positive TST
is defined as ≈5 mm of induration (309,310 ) because of their
decreased ability to mount a delayed hypersensitivity response
(CIII). Because immunosuppressive therapy decreases the sen-
sitivity of the TST, HSCT physicians should not rely solely on
the TST to determine whether latent TB infection is present
and whether preventive therapy should be administered to
HSCT recipients or candidates (DIII). Instead, a full 9-month
course of isonicotinic acid hydrazide preventive therapy should
be administered to immunocompromised HSCT recipients or
candidates who have been substantially exposed to someone with
active, infectious (i.e., sputum-smear positive) pulmonary or la-
ryngeal TB, regardless of the HSCT recipient’s or candidate’s
TST status (309 ) (BIII). A full 9-month course of isonicotinic
acid hydrazide preventive therapy should also be administered
to HSCT recipients or candidates with a positive TST who were
not previously treated and have no evidence of active TB disease
(309 ) (AIII) (Appendix). Routine anergy screening might not be
reliable among HSCT recipients and candidates undergoing con-
ditioning therapy and, therefore, is not recommended (DIII). An
HSCT should not be canceled or delayed because of a positive
TST (DIII).
Use of a 2-month course of a daily pyrazinamide/rifampin
(PZA/RIF) regimen has been recommended as an alternate pre-
ventive therapy for persons with TB (309 ). However, limited data
were found regarding safety and efficacy of this regimen among
non-HIV–infected persons. Furthermore, rifampin has substan-
tial drug interactions with certain medications, including
cyclosporine, tacrolimus (FK506), corticosteroids, fluconazole,
and pain medications. Therefore, routine use of the 2-month
PZA/RIF prophylactic regimen among HSCT recipients is not
recommended (DIII). However, this regimen can be used for
HSCT candidates who are not at risk for serious rifampin drug
interactions and whose HSCT is not scheduled until ≈2 weeks
after completion of the 2-month PZA/RIF course (CIII). This
delay will diminish the possibility of adverse effects of rifampin
on drugs used for routine HSCT OI prophylaxis (e.g.,
fluconazole) (311 ). An HSCT candidate or recipient who has
been exposed to an active case of extrapulmonary, and therefore,
noninfectious TB does not require preventive therapy (DIII).
HSCT center personnel should follow guidelines regarding the
control of TB in health-care facilities (244,245 ), including instituting
airborne precautions and negative pressure rooms for patients with
suspected or confirmed pulmonary or laryngeal TB (62,244 ) (AII).
HCWs should wear N95 respirators, even in isolation rooms, to pro-
tect themselves from possible TB transmission from patients with
active pulmonary or laryngeal TB, particularly during cough-induc-
ing procedures (62,244,245,312 ) (AIII). To be maximally effective,
respirators (e.g., N95) must be fit-tested, and all respirator users must
be trained to use them correctly (243 ) (AIII). Unless they become
soiled or damaged, changing N95 respirators between patient rooms
is not necessary (DIII). Bacillus of Calmette and Guérin vaccination is
contraindicated among HSCT candidates and recipients because it
might cause disseminated or fatal disease among
immunocompromised persons (313,314 ) (EII). No role has been
identified for chronic suppressive therapy or follow-up surveillance
cultures among HSCT recipients who have a history of successfully
treated TB (DIII).
Infection Control Surveillance
HSCT center personnel are advised to follow standard
guidelines for surveillance of antimicrobial use and nosoco-
mial pathogens and their susceptibility patterns (315 ) (BIII).
HSCT center personnel should not perform routine fungal or
bacterial cultures of asymptomatic HSCT recipients (166,167 )
(DII). In the absence of epidemiologic clusters of infections,
HSCT center personnel should not perform routine periodic
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bacterial surveillance cultures of the HSCT center environ-
ment or of equipment or devices used for respiratory therapy,
pulmonary-function testing, or delivery of inhalation anesthe-
sia (140 ) (DIII). Researchers recommend that hospitals per-
form routine sampling of air, ceiling tiles, ventilation ducts,
and filters to test for molds, particularly when construction or
renovation occurs near or around the rooms of
immunocompromised patients (167,174 ) or when clinical sur-
veillance demonstrates a possible increase in mold (i.e., as-
pergillosis) cases (CIII). Strategies that might decrease fungal
spores in the ventilation system include eliminating access of
birds (i.e., primarily pigeons) to air-intake systems, removing
bird droppings from the air-intake ducts, and eliminating moss
from the hospital roof (174 ). Furthermore, in the absence of a
nosocomial fungal outbreak, HSCT centers need not perform
routine fungal cultures of devices and dust in the rooms of
HSCT recipients and candidates undergoing conditioning
therapy (DIII). HSCT center personnel should routinely per-
form surveillance for the number of aspergillosis cases occur-
ring among HSCT recipients, particularly during hospital con-
struction or renovation (BIII). A two-fold or greater increase
in the attack rate of aspergillosis during any 6-month period
indicates that the HSCT center environment should be evalu-
ated for breaks in infection control techniques and procedures
and that the ventilation system should be investigated care-
fully (174 ) (BIII).
STRATEGIES FOR SAFE LIVING AFTER HSCT —
PREVENTING EXPOSURE AND DISEASE
Avoiding Environmental Exposures
HSCT recipients and candidates undergoing conditioning
therapy, particularly allogeneic recipients, and parents of
pediatric HSCT recipients and candidates should be edu-
cated regarding strategies to avoid environmental exposures
to opportunistic pathogens (AIII).
Preventing Infections Transmitted by Direct Contact
HSCT recipients and candidates should wash their hands
thoroughly (i.e., with soap and water) and often. For example,
hands should be washed
• before eating or preparing food;
• after changing diapers;
• after gardening or touching plants or dirt;
• after touching pets or animals;
• after touching secretions or excretions or items that
might have had contact with human or animal stool
(e.g., clothing, bedding, toilets, or bedpans);
• after going outdoors; and
• before and after touching wounds (249 ) (AIII).
Conscientious hand washing is critical during the first 6
months after HSCT and during other periods of substantial
immunosuppression (e.g., GVHD, systemic steroid use, or
relapse of the underlying disease for which the transplant was
performed) (AIII). Pediatric HSCT recipients and candidates
should be supervised by adults during hand washing to ensure
thorough cleaning (316 ) (BIII). Hand washing should be
performed with an antimicrobial soap and water (AIII);
alternatively, use of hygienic hand rubs is an acceptable means
of maintaining hand hygiene (250,251 ). HSCT recipients
who visit or live on farms should follow published
recommendations for preventing cryptosporidiosis (5,316,317–
319 ) (BIII).
Preventing Respiratory Infections
To prevent respiratory infections after hospital discharge,
HSCT recipients should observe the following precautions:
• Frequent and thorough hand washing is critical (BIII),
but HSCT recipients should also avoid touching their
mucus membranes, unless they have washed their hands
first, to avoid inoculating themselves with CRV.
• HSCT recipients should avoid close contact with
persons with respiratory illnesses (BIII). When close
contact is unavoidable, those persons with respiratory
illnesses should be encouraged to wash their hands
frequently and to wear surgical masks or, at a minimum,
smother their sneezes and coughs in disposable tissues.
Alternatively, the HSCT recipient can wear a surgical
mask (CIII).
• HSCT recipients should avoid crowded areas (e.g.,
shopping malls or public elevators) where close contact
with persons with respiratory illnesses is likely (BIII).
• HSCT candidates or recipients should be advised that
certain activities and occupations (e.g., work in health-
care settings, prisons, jails, or homeless shelters) can
increase their risk for TB exposure (BIII). In deciding
whether a patient should continue activities in these
settings, physicians should evaluate the patient’s specific
duties, the precautions used to prevent TB exposure in
the workplace, and the prevalence of TB in the
community. The decision to continue or terminate such
activities should be made jointly between patient and
physician (BIII). HSCT recipients should avoid
exposure to persons with active tuberculosis, particularly
during the first 6 months after HSCT and during other
periods of substantial immunosuppression (e.g., GVHD,
systemic steroid use, or relapse of the underlying disease
for which the transplant was performed) (BIII).
Researchers report that allogeneic recipients should avoid
construction or excavation sites or other dust-laden environ-
ments for the first 6 months after HSCT and during other
periods of substantial immunosuppression (e.g., GVHD, sys-
temic steroid use, or relapse of the underlying disease for
which the transplant was performed) to avoid exposures to
molds (CIII). Researchers also report that outpatient HSCT
recipients should be advised of travel routes to the HSCT cen-
ter that will avoid or minimize exposure to construction sites
(CIII).
Coccidioidomycosis is uncommon after allogeneic HSCT;
however, researchers report that HSCT recipients traveling to
or residing in coccidioidomycosis-endemic areas (e.g., the
American southwest, Mexico, and Central and South America)
should avoid or minimize exposure to disturbed soil, including
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construction or excavation sites, areas with recent earthquakes,
farms, or other rural areas (CIII). Histoplasmosis (Histoplasma
capsulatum ) after allogeneic HSCT is also rare; however, re-
searchers report that HSCT recipients in histoplasmosis-en-
demic areas should avoid exposure to chicken coops and other
bird-roosting sites and caves for the first 6 months after HSCT
and during periods of substantial immunosuppression (e.g.,
GVHD, systemic steroid use, or relapse of the underlying dis-
ease for which the transplant was performed) (CIII).
Smoking tobacco and exposure to environmental tobacco
smoke are risk factors for bacterial and CRV infections among
healthy adults and children (320–325 ); consequently, logic dic-
tates that physicians advise HSCT recipients not to smoke and
to avoid exposure to environmental tobacco smoke (CIII).
However, no data were found that specifically assess whether
smoking or environmental smoke exposure are risk factors for
OIs among HSCT recipients. Researchers have reported that
marijuana smoking might be associated with generation of
invasive pulmonary aspergillosis among immunocompromised
persons, including HSCT recipients (326–329 ). Therefore,
HSCT recipients should refrain from smoking marijuana to
avoid Aspergillus species exposure (326,330–334 ) (BIII).
Preventing Infections Transmitted Through Direct
Contact and Respiratory Transmission
Researchers have proposed that immunocompromised HSCT
recipients and candidates who are undergoing conditioning
therapy avoid gardening or direct contact with soil, plants, or their
aerosols to reduce exposure to potential pathogens (e.g., To. gondii,
Hi. capsulatum, Cryptococcus neoformans, Nocardia  species, and
Aspergillus  species) (CIII). HSCT recipients, particularly allo-
geneic recipients, could wear gloves while gardening or touching
plants or soil (335 ) (CIII), and they should avoid creating plant or
soil aerosols (BIII). Additionally, they should always wash their
hands afterwards (335 ) and care for skin abrasions or cuts sus-
tained during soil or plant contact (AIII).
Persons whose occupations involve animal contact (e.g.,
veterinarians, pet store employees, farmers, or slaughterhouse
workers) could be at increased risk for toxoplasmosis and other
zoonotic diseases. Although data are insufficient to justify a
general recommendation against HSCT recipients working in
such settings, these exposures should be avoided during the
first 6 months after HSCT and during other periods of sub-
stantial immunosuppression (e.g., GVHD, systemic steroid
use, or relapse of the underlying disease for which the trans-
plant was performed) (BIII).
Safe Sex
Sexually active HSCT recipients should avoid sexual prac-
tices that could result in oral exposure to feces (5,316 ) (AIII).
Sexually active patients who are not in long-term
monogamous relationships should always use latex condoms
during sexual contact to reduce their risk for exposure to CMV,
HSV, HIV, hepatitis B and C, and other sexually transmitted
pathogens (AII). However, even long-time monogamous part-
ners can be discordant for these infections. Therefore, during
periods of immunocompromise, sexually active HSCT recipi-
ents in such relationships should consider using latex condoms
during sexual contact to reduce the risk for exposure to these
sexually transmitted infections (CIII).
Pet Safety
Preventing Pet-Transmitted Zoonotic Infections
HSCT physicians should advise recipients and candidates
undergoing conditioning therapy of the potential infection risks
posed by pet ownership; however, they should not routinely
advise HSCT recipients to part with their pets, with limited
exceptions. Generally, immunocompromised HSCT recipients
and candidates undergoing conditioning therapy should mini-
mize direct contact with animals (336,337 ), particularly those
animals that are ill (e.g., with diarrhea) (335 ) (BIII).
Immunocompromised persons who choose to own pets should
be more vigilant regarding maintenance of their pet’s health
than immunocompetent pet owners (BIII). This recommenda-
tion means seeking veterinary care for their pet early in the
pet’s illness to minimize the possible transmission of the pet’s
illness to the owner (335 ) (BIII). Feeding pets only high-qual-
ity commercial pet foods reduces the possibility of illness caused
by spoiled or contaminated foods, thus reducing the possibility
of transmitting illness from the pet to the HSCT recipient. If
eggs, poultry, or meat products are given to the pet as supple-
ments, they should be well-cooked. Any dairy products given
to pets should be pasteurized (335 ) (BIII). Pets should be pre-
vented from drinking toilet bowl water and from having access
to garbage; pets should not scavenge, hunt, or eat other ani-
mals’ feces (335 ) (BIII).
If HSCT recipients have contact with pets or animals, they
should wash their hands after handling them (particularly be-
fore eating) and after cleaning cages; HSCT recipients should
avoid contact with animal feces to reduce the risk for toxoplas-
mosis, cryptosporidiosis, salmonellosis, and campylobacteriosis
(335 ) (BIII). Adults should supervise hand washing of pediatric
HSCT recipients (BIII). Immunocompromised HSCT recipi-
ents and candidates should not clean pet litter boxes or cages or
dispose of animal waste (DIII). If this cannot be avoided,
patients should wear disposable gloves during such activities
and wash their hands thoroughly afterwards (BIII).
Immunocompromised HSCT recipients and candidates should
avoid adopting ill or juvenile pets (e.g., aged <6 months for cats)
(335 ) and any stray animals (5,316 ) (BIII). Any pet that experi-
ences diarrhea should be checked by a veterinarian for infec-
tion with Cryptosporidium  (5,316 ), Giardia  species (335 ), Sal-
monella , and Campylobacter  (5,335,337 ) (BIII).
Immunocompromised HSCT recipients and candidates
should not have contact with reptiles (e.g., snakes, lizards,
turtles, or iguanas) (DII) to reduce their risk for acquiring sal-
monellosis (335,338–341 ). Additionally, patients should be
informed that salmonellosis can occur from fomite contact
alone (342 ). Therefore, HSCT recipients and candidates
should avoid contact with a reptile, its food, or anything that it
has touched, and if such contact occurs, recipients and candi-
dates should wash their hands thoroughly afterwards (AIII).
Immunocompromised HSCT recipients and candidates should
avoid contact with ducklings and chicks because of the risk for
acquiring Salmonella  or Campylobacter  species infections
(338,343 ) (BIII). Immunocompromised HSCT recipients and
candidates should avoid contact with exotic pets (e.g., nonhu-
man primates) (BIII). Bird cage linings should be cleaned regu-
larly (e.g., daily) (337 ). All persons, but particularly
immunocompromised HSCT candidates and recipients, should
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wear gloves whenever handling items contaminated with bird
droppings (337 ) (BIII) because droppings can be a source
of Cryptococcus neoformans, Mycobacterium avium, or Hi.
capsulatum. However, routine screening of healthy birds for
these diseases is not recommended (335 ) (DIII). To mini-
mize potential exposure to Mycobacterium marinum,
immunocompromised HSCT recipients and candidates
should not clean fish tanks (DIII). If this task cannot be
avoided, patients should wear disposable gloves during such
activities and wash their hands thoroughly afterwards
(335,337 ) (BIII).
Preventing Toxoplasmosis
The majority of toxoplasmosis cases in the United States
is acquired through eating undercooked meat (335,337 ).
However, all HSCT recipients and candidates, particularly
those who are To. gondii  seronegative, should be informed
of the risks for contracting toxoplasmosis from cat feces
(BIII), but need not be advised to give away their cats (DII).
For households with cats, litter boxes should not be placed
in kitchens, dining rooms, or other areas where food prepa-
ration and eating occur (335 ). Additionally, litter boxes
should be cleaned daily by someone other than the HSCT
recipient during the first 6 months after HSCT and during
periods of substantial immunosuppression (e.g., GVHD,
steroid use, or relapse of the underlying disease for which
the transplant was performed) to reduce the risk for trans-
mitting toxoplasmosis to the HSCT recipient (BIII). Daily
litter box changes will minimize the risk for fecal transmis-
sion of To. gondii  oocysts, because fecal oocysts require ≈2
days of incubation to become infectious. If HSCT recipi-
ents perform this task during the first 6 months after HSCT
and during subsequent periods of substantial
immunocompromise (e.g., during GVHD, systemic steroid
use, or relapse of the underlying neoplastic disease for which
the transplant was performed), they should wear disposable
gloves (335 ). Gloves should be discarded after a single use
(BIII). Soiled, dried litter should be disposed of carefully to
prevent aerosolizing the To. gondii  oocysts (BIII). Cat feces
(but not litter) can be flushed down the toilet (BIII). Also,
persons who clean cat litter, particularly HSCT recipients,
should wash their hands thoroughly with soap and water
afterwards to reduce their risk for acquiring toxoplasmosis
(BIII).
HSCT recipients and candidates with cats should keep
their cats inside (BIII) and should not adopt or handle stray
cats (DIII). Cats should be fed only canned or dried com-
mercial food or well-cooked table food, not raw or
undercooked meats, to eliminate the possibility of causing
an illness that could be transmitted from the cat to the
HSCT recipient (BIII). Pet cats of HSCT recipients do not
need to be tested for toxoplasmosis (EII). Playground sand-
boxes should be kept covered when not in use to prevent
cats from soiling them (BIII). HSCT recipients and candi-
dates undergoing conditioning therapy should avoid drink-
ing raw goat’s milk to decrease the risk for acquiring toxo-
plasmosis (BIII).
Water and Other Beverage Safety
Although limited data were found regarding the risks for
and epidemiology of Cryptosporidium  disease among HSCT
recipients, HSCT recipients are prudent to avoid possible
exposures to Cryptosporidium  (BIII) because it has been re-
ported to cause severe, chronic diarrhea, malnutrition, and
death among other immunocompromised persons
(5,318,319 ). HSCT recipients should avoid walking, wad-
ing, swimming, or playing in recreational water (e.g., ponds
or lakes) that is  l ikely to be contaminated with
Cryptosporidium, Es. coli  O157:H7 (344–346 ), sewage, or
animal or human waste (BII). HSCT recipients should also
avoid swallowing such water (e.g., while swimming)
(5,344,346 ) as well as any water taken directly from rivers
and lakes (5,316 ) (AIII).
HSCT recipients should not use well water from private
wells or from public wells in communities with limited popu-
lations (DIII) because tests for microbial contamination are
performed too infrequently (e.g., in certain locations, tests are
performed £1 times/month) to detect sporadic bacterial con-
tamination. However, drinking well water from municipal wells
serving highly populated areas is regarded as safe from bacte-
rial contamination because the water is tested ≈2 times/day for
bacterial contamination. If HSCT recipients consume tap wa-
ter, they should routinely monitor mass media (e.g., radio, tele-
vision, or newspapers) in their area to immediately implement
any boil-water advisories that might be issued for
immunocompromised persons by state or local governments
(BIII). A boil-water advisory means that all tap water should
be boiled for ≈1 minutes before it is consumed. Tap water
might not be completely free of Cryptosporidium. To eliminate
the risk for Cryptosporidium  exposure from tap water, HSCT
recipients can boil tap water for ≈1 minutes before consuming
it (e.g., drinking or brushing teeth) (5 ) (CIII). Alternately, they
can use certain types of water filters (316 ) or a home distiller
(317 ) to reduce their risk for Cryptosporidium  (5 ) and other
waterborne pathogens (CIII). If a home water filter* is used, it
should be capable of removing particles ≈1 µm in diameter, or
filter by reverse osmosis. However, the majority of these filters
are not capable of removing smaller microbes (e.g., bacteria or
viruses), and therefore, should only be used on properly treated
municipal water. Further, the majority of these devices would
not be appropriate for use on an unchlorinated private well to
control viral or bacterial pathogens. Bottled water can be con-
sumed if it has been processed to remove Cryptosporidium  by
one of three processes — reverse osmosis, distillation, or 1-µm
particulate absolute filtration. To confirm that a specific bottled
water has undergone one of these processes, HSCT recipients
should contact the bottler directly.†
Patients can take other precautions in the absence of boil-
water advisories to further reduce their risk for
cryptosporidiosis. These extra precautions include avoiding
*For a list of filters certified under NSF Standard 053 for cyst (i.e., Cryptosporidium ) removal, contact the NSF International consumer line
at (800) 673-8010 or <http://www.nsf.org/notice/crypto.html>.
† The International Bottled Water Association can be contacted at (703) 683-5213 from 9 a.m. to 5 p.m. EST or anytime at their Internet site
(<http://www.bottledwater.org>) to obtain contact information regarding water bottlers.
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fountain beverages and ice made from tap water at restau-
rants, bars, and theaters (5 ), fruit drinks made from frozen
concentrate mixed with tap water, and iced tea or coffee made
with tap water (317 ). Drinks that are likely to be
Cryptosporidium  safe for HSCT recipients include nationally
distributed brands of bottled or canned carbonated soft drinks
and beers (5 ); commercially packaged noncarbonated drinks
that contain fruit juice; fruit juices that do not require refrig-
eration until after opening (e.g., those that are stored
unrefrigerated on grocery shelves) (5 ); canned or bottled soda,
seltzer or fruit drinks; steaming hot (≈175 F) tea or coffee
(317 ); juices labeled as pasteurized; and nationally distributed
brands of frozen fruit juice concentrate that are reconstituted
with water from a safe source (5 ). HSCT recipients should
not drink unpasteurized milk or fruit or vegetable juices (e.g.,
apple cider or orange juice) to avoid infection with Brucella
species, Es. coli  O157:H7, Salmonella  species, Cryptosporidium,
and others (319,347–351 ) (DII).
Food Safety
HSCT candidates and household or family members who
prepare food for them after HSCT should review food safety
practices that are appropriate for all persons (352 ) (AIII), and
food preparers should be educated regarding additional food
safety practices appropriate for HSCT recipients. This review
and education should be done before the conditioning regi-
men (i.e., chemotherapy and radiation) begins (BIII). Adher-
ence to these guidelines will decrease the risk for foodborne
disease among HSCT recipients.
Food Safety Practices Appropriate for All Persons
Raw poultry, meats, fish, and seafood should be handled on
separate surfaces (e.g., cutting board or counter top) from other
food items. Food preparers should always use separate cutting
boards (i.e., one for poultry and other meats and one for veg-
etables and remaining cutting or carving tasks) (AIII), or the
board(s) should be washed with warm water and soap between
cutting different food items (AIII). To prevent foodborne ill-
nesses caused by Campylobacter jejuni  and Salmonella enteriti-
dis, which can cause severe and invasive infections among
immunocompromised persons (353,354 ), uncooked meats
should not come in contact with other foods (BIII).
After preparing raw poultry, meats, fish, and seafood and
before preparing other foods, food handlers should wash their
hands thoroughly in warm, soapy water. Any cutting boards,
counters, knives, and other utensils used should be washed
thoroughly in warm, soapy water also (AIII). Food preparers
should keep shelves, counter tops, refrigerators, freezers, uten-
sils, sponges, towels, and other kitchen items clean (AIII). All
fresh produce should be washed thoroughly under running
water before serving (355 ) (AIII). Persons preparing food
should follow published U.S. Department of Agriculture rec-
ommendations regarding safe food thawing (356 ) (BIII).
Persons cooking food for HSCT recipients should follow
established guidelines for monitoring internal cooking tem-
peratures for meats (357 ) (AII). The only method for deter-
mining whether the meat has been adequately cooked is to
measure its internal temperature with a thermometer because
the color of the meat after cooking does not reliably reflect
the internal temperature. Different kinds of meat should be
cooked to varying internal temperatures, all ≈150 F (AII).
Specifically, the U.S. Department of Agriculture recom-
mends that poultry be cooked to an internal temperature of
180 F; other meats and egg-containing casseroles and
souffles should be cooked to an internal temperature of ≈160
F. Cold foods should be stored at <40 F; hot foods should be
kept at >140 F (BIII). Food preparers should
• wash their hands before and after handling leftovers
(AIII);
• use clean utensils and food-preparation surfaces (AIII);
• divide leftovers into small units and store in shallow
containers for quick cooling (AII);
• refrigerate leftovers within 2 hours of cooking (AII).
• discard leftovers that were kept at room temperature for
>2 hours (AIII);
• reheat leftovers or heat partially cooked foods to ≈165 F
throughout before serving (AII);
• bring leftover soups, sauces, and gravies to a rolling boil
before serving (AIII); and
• follow published guidelines for cold storage of food
(352 ) (AII).
Additional Food Safety Practices Appropriate for
HSCT Recipients
HSCT recipients’ diets should be restricted to decrease
the risk for exposure to foodborne infections from bacteria,
yeasts, molds, viruses, and parasites (BIII). Currently, a low
microbial diet is recommended for HSCT recipients
(358,359 ) (BIII). This diet should be continued for 3
months after HSCT for autologous recipients. Allogeneic
recipients should remain on the diet until all immunosup-
pressive drugs (e.g., cyclosporine, steroids, and tacrolimus)
are discontinued. However, the HSCT physician should
have final responsibility for determining when the diet can
be discontinued safely. Only one study has reported that di-
etary changes (e.g., consuming yogurt) have decreased the
risk for mycotic infections (e.g., candidal vaginitis) (360 )
(Table 3). HSCT recipients should not eat any raw or
undercooked meat, including beef, poultry, pork, lamb,
venison or other wild game, or combination dishes contain-
ing raw or undercooked meats or sweetbreads from these
animals (e.g., sausages or casseroles) (AII). Also, HSCT re-
cipients should not consume raw or undercooked eggs or
foods that might contain them (e.g., certain preparations of
hollandaise sauce, Caesar and other salad dressings, home-
made mayonnaise, and homemade eggnog) because of the
risk for infection with Salmonella enteritidis  (354 ) (AII).
HSCT recipients should not consume raw or undercooked
seafood (e.g., oysters or clams) to prevent exposure to Vibrio
species, viral gastroenteritis, and Cryptosporidium parvum
(361–364 ) (AII).
HSCT recipients and candidates should only consume
meat that is well-done when they or their caretakers do not
have direct control over food preparation (e.g., when eating
in a restaurant) (AI). To date, no evidence exists in the
United States that eating food at a fast food restaurant is
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riskier than eating at a conventional sit-down restaurant. Gen-
erally, HSCT candidates undergoing conditioning therapy and
HSCT recipients with neutropenia (i.e., ANC < 1,000/ml3),
GVHD, or immunosuppression should avoid exposures to
naturopathic medicines that might contain molds (365 ) (DIII).
HSCT recipients wishing to take naturopathic medications are
advised to use them only as prescribed by a licensed naturo-
pathic physician working in consultation with the recipient’s
transplant and infectious disease physicians (CIII).
Travel Safety
Travel to developing countries can pose substantial risks
for exposure to opportunistic pathogens for HSCT recipients,
particularly allogeneic recipients chronically immunosup-
pressed. HSCT recipients should not plan travel to develop-
ing countries without consulting their physicians (AIII), and
travel should not occur until the period of severe immunosup-
pression has resolved. Generally, allogeneic recipients should
not plan travel to developing countries for 6–12 months after
HSCT, particularly if GVHD has occurred. Autologous re-
cipients can travel to developing countries 3–6 months after
HSCT if their physicians agree.
HSCT recipients should be informed regarding strategies
to minimize the risk for acquiring foodborne and waterborne
infections while traveling. They should obtain
updated, detailed health information for international travel-
ers from health organizations (366,367 ) (AIII). Generally,
while traveling in developing countries, HSCT recipients
should avoid consuming the following (BIII):
• raw fruits and vegetables,
• tap water or any potentially untreated or contaminated
water,
• ice made from tap water or any potentially
contaminated water,
• unpasteurized milk or any unpasteurized dairy
products,
• fresh fruit juices,
• food and drinks from street vendors, and
• raw or undercooked eggs.
Steaming hot foods, fruits peeled by oneself, bottled and
canned processed drinks, and hot coffee or tea are probably
safe (367,368 ). Travelers should plan for treating their
drinking water while in developing countries. If bottled water
is not available, boiling is the best method of making water
safe. However, if boiling water is not feasible, the traveler
should carry supplies for disinfecting water (e.g., commer-
cially available iodine disinfection tablets or a portable water
filter) (366,368 ).
Antimicrobial prophylaxis for traveler’s diarrhea is not rec-
ommended routinely for HSCT recipients traveling to devel-
oping countries (DIII) because traveler’s diarrhea is not known
to be more frequent or more severe among
immunocompromised hosts. However, HSCT physicians who
wish to provide prophylaxis to HSCT recipients who are
traveling can prescribe a fluoroquinolone (e.g., ciprofloxacin
hydrochloride) or TMP-SMZ (CIII), although resistance to
TMP-SMZ is now common and resistance to fluoroquinolones
is increasing in tropical areas (Appendix). Researchers recom-
mend using bismuth subsalicylate to prevent traveler’s diar-
rhea among adults (366 ). However, no data were found
regarding safety and efficacy among HSCT recipients, and
salicylates are not recommended for use among persons aged
<18 years because salicylates are associated with Reye’s syn-
drome (369 ).
HSCT recipients’ immunization status should be assessed
and their vaccinations updated as needed before travel (366 ).
Influenza chemoprophylaxis with rimantadine or amantadine
can be used for immunocompromised HSCT recipients who
are traveling outside the continental United States and who
could be exposed to influenza A (CIII).
HSCT RECIPIENT VACCINATIONS
Antibody titers to vaccine-preventable diseases (e.g., teta-
nus, polio, measles, mumps, rubella, and encapsulated organ-
isms) decline during the 1–4 years after allogeneic or autolo-
gous HSCT (66,370–373 ) if the recipient is not revaccinated.
Clinical relevance of decreased antibodies to vaccine-prevent-
able diseases among HSCT recipients is not immediately
apparent because a limited number of cases of vaccine pre-
ventable diseases are reported among U.S. recipients. How-
ever, vaccine-preventable diseases still pose risks to the U.S.
population. Additionally, evidence exists that certain vaccine-
preventable diseases (e.g., encapsulated organisms) can pose
increased risk for HSCT recipients (66 ); therefore, HSCT
recipients should be routinely revaccinated after HSCT so that
they can experience immunity to the same vaccine-prevent-
able diseases as others (Table 4).
HSCT center personnel have developed vaccination sched-
ules for HSCT recipients (374 ). One study determined that
HSCT center personnel used 3–11 different vaccination sched-
ules per vaccine (374 ); consequently, the study authors
requested national guidelines for doses and timing of vaccines
after HSCT to eliminate confusion among HSCT center per-
sonnel regarding how to vaccinate their patients. To address
this need, an interim vaccination schedule for HSCT recipi-
ents was drafted in collaboration with partner organizations,
including CDC’s Advisory Committee on Immunization Prac-
tices. The purpose of the vaccination schedule in these guide-
lines is to provide guidance for HSCT centers (Table 4). Al-
though limited data were found regarding safety and immuno-
genicity (e.g., serologic studies of antibody titers after vaccina-
tion) among HSCT recipients, no data were found regarding
vaccine efficacy among HSCT recipients (e.g., which deter-
mine whether vaccinated HSCT recipients have decreased
attack rates of disease compared with unvaccinated HSCT
recipients). Because certain HSCT recipients have faster
immune system recovery after HSCT than others, re-
searchers have proposed that different vaccination schedules
be recommended for recipients of different types of HSCT.
However, to date, data are too limited to do so. Therefore, the
same vaccination schedule is recommended for all HSCT
recipients (e.g., allogeneic, autologous, and bone marrow,
peripheral, or UCB grafts) until additional data are pub-
lished. In the tables, vaccines have only been recommended
for use among HSCT recipients if evidence exists of safety and
immunogenicity for those recipients. Vaccination of family
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members, household contacts, and HCWs are also recom-
mended to minimize exposure of vaccine-preventable diseases
among HSCT recipients (Tables 5–8).
HEMATOPOIETIC STEM CELL SAFETY
With allogeneic HSCT, the life of the recipient might depend
on the timely selection of an acceptable HLA-matched donor.
Only a limited number of HLA-matched donors might be identi-
fied; hence, the transplant physician often has to accept a higher
risk for transmission of an infectious agent through HSCT than
would be permitted for routine blood transfusion. This section
provides strategies for the HSCT physician to minimize trans-
mission of infectious diseases, whenever possible, from donors to
recipients.*† Whether to select a donor who is at risk for or who
has an infectious disease transmissible by HSCT, should be deter-
mined on a case-by-case basis (AIII) and is the final responsibility
of the HSCT physician (AIII). If the only possible donor is at risk
for or known to be infected with a bloodborne pathogen and the
patient is likely to succumb rapidly from his or her disease if an
HSCT is not received, the physician must carefully weigh the
risks and benefits of using potentially infected donor cells. No
person should be denied a potentially life-saving HSCT proce-
dure solely on the basis of the risk for an infectious disease. How-
ever, HSCT physicians should avoid transplanting any infected
or infectious donor hematopoietic stem cell product unless no
other stem cell product can be obtained and the risk for death
from not undergoing transplantation is deemed to be greater than
the risk for morbidity or death from the infection that could po-
tentially be transmitted (DII). If such a product is selected for use,
it should be done on a case-by-case basis (375 ) and the following
should be noted in the recipient’s chart:
• knowledge and authorization of the recipient’s HSCT
physician regarding the potential for transmission of an
infectious agent during HSCT, and
• advance informed consent from the recipient or recipient’s
legal guardian acknowledging the possible transmission of an
infectious agent during the transplantation (AIII).
Subsequently, the HSCT physician should include the
infectious agent in the differential diagnosis of any illness that
the HSCT recipient experiences so that the infection, if
transmitted, can be diagnosed early and treated preemptively,
if possible. Infectious products (except those in which CMV
seropositivity is the only evidence of infectiousness) should be
labeled as being a biohazard or as untested for biohazards, as
applicable. Tissue intended for autologous use should be
labeled “For Autologous Use Only — Use Only for (Patient’s
Name).”
Preventing Transmission of Infections
from HSCT Donors to Recipients
All prospective HSCT donors should be evaluated through a
physical history and examination to determine their general state
of health and whether they pose a risk for transmitting infectious
diseases to the recipient (376 ). To detect transmissible infections,
all HSCT donor collection site personnel should follow up-to-
date published guidelines and standards for donor screening (e.g.,
medical history), physical exam, and serologic testing (377–383 )
(AIII). Initial donor screening and physical exam should be per-
formed £8 weeks before the planned donation (BIII). Donor se-
rologic testing should be done £30 days before donation to detect
potentially transmissible infections (BII); additionally, research-
ers recommend that donors be retested £7 days before collection.
If testing is done >7 days before donation, donor screening should
be repeated to ensure that no new risk behaviors have occurred
during the interval between the original screening and the time of
donation (BIII). This practice is critical because if new behavioral
risk factors have occurred, the potential donor might need to be
deferred. Screening and testing should be done on all allogeneic
or syngeneic donors (AIII). Screening and testing of autologous
donors is recommended to ensure the safety of laboratory per-
sonnel and to prevent cross contamination (BIII). If autologous
donors are not tested, their autologous units should be specially
labeled and handled as if potentially infected (BIII). For donors
screened in the United States, FDA-licensed or -approved tests
should be used in accordance with the manufacturers’ instruc-
tions (AIII), and the donor samples should be tested in laborato-
ries certified by the Clinical Laboratory Improvement Amend-
ments of 1988 (AIII).
All HSCT donors should be in good general health (376 )
(BIII). Acute or chronic illness in the prospective donor should be
investigated to determine the etiology. Generally, persons who
are ill should not be HSCT donors (DIII). A flu-like illness in a
prospective donor at the time of evaluation or between the time
of evaluation and donation should prompt evaluation of and sero-
logic testing for infections that might pose a risk to the recipient
(e.g., EBV, CMV, To. gondii ) (BIII). Persons with a positive serum
EBV-viral capsid antigen IgM but negative serum EBV-viral
capsid antigen IgG should not serve as donors for allogeneic T-
cell–depleted HSCT, particularly for unrelated or mismatched
transplants, until their serum EBV-viral capsid antigen IgG be-
comes positive (DIII). Persons with acute toxoplasmosis should
not donate until the acute illness has resolved (DII); however,
physicians should be aware that persons who are asymptomatically
seropositive for To. gondii  might transmit this infection through
HSCT (218 ).
Prospective donors with symptoms of active TB should be
evaluated for that disease (383 ) (BIII). Prospective donors with
active TB should not donate (EIII) until the TB is well-controlled
(e.g., no longer contagious as determined by the donor’s primary
physician) after appropriate medical therapy. However, no known
risk exists from transplanting marrow from an untreated, tuber-
culin-positive donor who has no evidence of active disease.
Screening potential donors for TB with Mantoux skin tests (DIII)
is not necessary. Prospective HSCT donors who reside in or have
traveled to areas endemic for rickettsia or other tickborne patho-
gens and who are suspected of having an acute tickborne infec-
tion should be temporarily deferred as donors until infection with
these pathogens is excluded (DIII). Relevant pathogens include
Rickettsia rickettsii, Babesia microti  and other Babesia  species, Cox-
iella burnetii, and the Colorado tick fever virus, which are the etio-
logic agents of Rocky Mountain spotted fever, babesiosis, Q fe-
ver, and Colorado tick fever, respectively; these pathogens have
been reported to be transmitted by blood transfusion (384–388 ).
Researchers recommend deferral for a past history of Q fever or
babesiosis because these infections can be chronic and the babe-
siosis parasite might persist despite appropriate therapy (389 )
(CIII). Additionally, researchers have recommended deferring
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persons with acute human ehrlichiosis (e.g., human active human
granulocytic ehrlichiosis [390 ], human monocytic ehrlichiosis, as
well as any infections from Ehrlichia ewingii ) from HSCT dona-
tion (CIII).
The medical history of the prospective HSCT donor should
include the following:
• History of vaccinations (377 ) during the 4 weeks before
donation (AII). If the potential donor is unsure of
vaccinations received, his or her records should be
reviewed. HSCT donation should be deferred for 4 weeks
after the donor receives any live-attenuated vaccine (e.g.,
rubeola [measles], mumps, rubella [German measles], oral
polio, varicella, yellow fever, and oral typhoid vaccines)
(EIII). This deferral will avoid the possibility of infusing a
live infectious agent into an HSCT recipient. HSCT
donation need not be deferred for persons who have
recently received toxoid or killed (i.e., inactivated),
recombinant viral, bacterial, or rickettsial vaccines as long
as the donor is asymptomatic and afebrile (389 ) (BIII).
Such vaccines include tetanus toxoid, diphtheria toxoid,
hepatitis A and B, cholera, influenza (i.e., killed
intramuscular vaccine), meningococcal, paratyphoid,
pertussis, plague, polio (i.e., inactivated polio vaccine),
rabies, typhoid (i.e., inactivated intramuscular vaccine), or
typhus vaccines (389 ).
• Travel history (BIII) to determine whether the donor has
ever resided in or traveled to countries with endemic
diseases that might be transmitted through HSCT (e.g.,
malaria). Permanent residents of nonendemic countries
who have traveled to an area that CDC regards as endemic
for malaria can be accepted as HSCT donors if 1 year has
elapsed since the donor’s departure from the endemic area
and if the donor has been free of malaria symptoms,
regardless of whether he or she received antimalarial
chemoprophylaxis. Because cases ofHSCT-transmitted
malaria have been reported (391,392 ), persons who have
had malaria and received appropriate treatment should be
deferred from HSCT donation for 3 years after becoming
asymptomatic. Immigrants, refugees, citizens, or residents
for ≈5 years of endemic countries can be accepted as
HSCT donors if 3 years have elapsed since they departed
the malarious area and if they have been free of malaria
symptoms.
• History of Chagas’ disease and leishmaniasis. Persons with
active Chagas’ disease or leishmaniasis should not serve as
HSCT donors (DIII) because these diseases can be
transmitted by transfusion (227,229,231,393–395 ). Re-
searchers also recommend deferral of HSCT donation if a
past history exists of either of these diseases because the
parasite can persist despite therapy (227–229,231,
389,393–395 ) (CIII).
• History of any deferral from plasma or blood donation.
The reason for such a deferral (376 ) and whether it was
based on a reported infectious disease or behavioral or
other risk factor should be investigated (BIII).
• History of viral hepatitis. A person with a history of viral
hepatitis after his or her eleventh birthday should be
excluded from HSCT donation (BIII).
• History of blood product transfusion, solid organ
transplantation, or transplantation of tissue within the last
12 months (BIII). Such persons should be excluded from
HSCT donation (DIII). Xenotransplant product recipi-
ents and their close contacts should be indefinitely
deferred from donating any blood products, including
hematopoietic stem cells, whole blood, or other blood
components including plasma, leukocytes, and tissues
(396 ) (AIII). Close contacts to be deferred from donations
include persons who have engaged repeatedly in activities
that could result in an intimate exchange of body fluids
with a xenotransplantation product recipient. Such close
contacts could include sexual partners, household
members who share razors or toothbrushes, and HCWs or
laboratory personnel with repeated percutaneous,
mucosal, or other direct exposures.
• History of risk factors for classic Creutzfeldt-Jakob disease
(CJD), including any blood relative with Creutzfeldt-
Jakob disease, receipt of a human pituitary-derived growth
hormone or receipt of a corneal or dura mater graft
(383,397–399 ) (BIII). Potential HSCT donors should
also be screened for new variant Creutzfeldt-Jakob
Disease (nvCJD) risk factors, including a history of
cumulative travel or residence in the United Kingdom for
≈6 months during 1980–1996 or receipt of injectable
bovine insulin since 1980, unless the product was not
manufactured since 1980 from cattle in the United
Kingdom (398 ) (BIII). The clinical latency period for
iatrogenic, classic CJD can be >30 years (398 ), and
transmission of classic CJD by blood products is highly
unlikely (398 ). Although no classic or nvCJD has ever
been reported among HSCT recipients, persons with a
history of classic or nvCJD risk factors should be excluded
from donation for unrelated HSCT (DIII) if a choice exists
between two otherwise equally suitable donors. The risk
for transmitting classic or nvCJD from an HSCT donor to
a recipient is unknown, but researchers believe that
persons with nvCJD risk factors could be at higher risk for
transmitting nvCJD to HSCT recipients than persons
with classic CJD risk factors.
• Past medical history that indicates the donor has clinical
evidence of or is at high risk for acquiring a bloodborne
infection (e.g., HIV-1 or -2, human T-lymphotropic virus
[HTLV]-I or -II, hepatitis C, or hepatitis B) (381,383 ),
including
— men who have had sex with another man during the
preceding 5 years (381,383 ) (BIII);
— persons who report nonmedical intravenous,
intramuscular, or subcutaneous injection of drugs
during the preceding 5 years (381 ) (BIII);
— persons with hemophilia or related clotting
disorders who have received human-derived
*Th U S P bli H l h S i i i i h d d f l d i
38
clotting factor concentrates (381 ) (BIII);
— persons who have engaged in sex in exchange for
money or drugs during the preceding 5 years (381 )
(BIII);
— persons who have had sex during the preceding 12
months with any person described previously (381 )
or with a person known or suspected to have HIV
(381 ) or hepatitis B infections (BIII);
— persons who have been exposed during the
preceding 12 months to known or suspected HIV,
hepatitis B- or C-infected blood through
percutaneous inoculation or through contact with
an open wound, nonintact skin, or mucous
membrane (381 ) (BIII);
— inmates of correctional systems (379–381 ) and
persons who have been incarcerated for >72
consecutive hours during the previous 12 months
(BIII);
— persons who have had or have been treated for
syphilis or gonorrhea during the preceding 12
months (376,379,380 ) (BIII); and
— persons who within 12 months have undergone
tattooing, acupuncture, ear or body piercing
(380,400,401 ) in which shared instruments are
known to have been used (BIII) or other nonsterile
conditions existed.
Persons reporting any of these past medical histories should be
excluded from donation (DIII).
The following serologic tests should be performed for each
prospective donor:
• HIV-1 antigen, anti-HIV-1 and -2, anti-HTLV-I and -II,
hepatitis B surface antigen, total antihepatitis B core
antigen, antihepatitis C, anti-CMV, and a serologic test
for syphilis (376,379,380,383 ) (AIII). Potential donors
who have repeatedly reactive screening tests for HIV-1
antigen, anti-HIV-1 or -2, anti-HTLV-I or -II,
antihepatitis C, hepatitis B surface antigen, or antihepatitis
B core antigen should be excluded as HSCT donors (381 )
(EII). Persons who refuse infectious disease testing should
also be excluded as HSCT donors (381 ) (EIII).
• Investigational nucleic acid tests to detect hepatitis C virus
RNA and HIV RNA are currently being used in the
United States to screen blood donors and could be used for
screening HSCT donors. If nucleic acid tests are approved
by FDA, these tests should be incorporated into routine
screening regimens for HSCT donors. When nucleic acid
testing is done for HIV and hepatitis C investigationally, a
positive result should exclude the potential donor.
All infectious disease testing and results should be reported to the
HSCT physician before the candidate’s conditioning regimen
begins (381 ) (AIII). Bone marrow should be collected using
sterile technique in a medically acceptable setting and according
to standard operating procedures (AIII).
HSCT transplant center personnel should keep accurate
records of all HSCT received and the disposition of each sample
obtained (381 ). These tracking records must be separate from
patients’ medical records (e.g., in a log book) so that this informa-
tion is easily obtainable. Recorded information should include
the donor identification number, name of procurement of distri-
bution center supplying the HSCT, recipient-identifying infor-
mation, name of recipient’s physician, and dates of a) receipt by
the HSCT center and b) either transplantation to the recipient or
further distribution (381 ) (AIII). All centers for donation, trans-
plantation, or collection of hematopoietic stem cells should keep
records of donor screening and testing, and HSCT harvesting,
processing, testing, cryopreservation, storage, and infusion or dis-
posal of each aliquot of donated hematopoietic progenitor cells
for ≈10 years after the date of implantation, transplantation, infu-
sion, or transfer of the product (378 ) (AIII). However, if that date
is not known, records should be retained ≈10 years after the
product’s distribution, disposition, or expiration, whichever is lat-
est.
Pediatric Donors
Children aged >18 months who are born to mothers with or
at risk for HIV infection, who have not been breast-fed during
the past 12 months, and whose HIV antibody tests, physical ex-
amination, and medical records do not indicate evidence of HIV
infection can be accepted as donors (381 ) (BIII). Children aged
<18 months who are born to mothers with or at risk for HIV
infection and who have not been breast-fed by an HIV-infected
woman during the past 12 months can be accepted as donors only
if HIV infection has been excluded according to established crite-
ria (402 ) (BIII). Children who have been breast-fed by an HIV-
infected woman during the past 12 months should be excluded as
stem cell donors regardless of HIV infection status (AIII). The
mother and, if possible, the father of all pediatric stem-cell do-
nors who are at risk for perinatal transmission of HIV and other
bloodborne infections, should be interviewed by a health-care
professional competent to elicit information regarding risk fac-
tors for possible bloodborne infection in the potential pediatric
donor (AIII). Children who meet any of the adult donor exclu-
sion criteria should not become HSCT donors (381 ) (EIII).
Preventing Infection from Extraneous
Contamination of Donated Units
Personnel of donation, collection, or transplantation cen-
ters, cell-processing laboratories, and courier services should
follow current standards for detecting and preventing extrinsic
bacterial and fungal contamination of collected stem cell units
at the collection site, during processing and transportation, and
at the transplant center (376 ) (AIII). Quality improvement pro-
grams and procedure manuals of collection centers, cell-pro-
cessing laboratories, and transplant programs should include
strategies for preventing transplant-associated infections. For
example, collection centers should use aseptic techniques when
collecting marrow, peripheral blood, and UCB hematopoietic
stem cells (376,378 ) (AIII). Whenever possible, closed systems
should be used for pooling hematopoietic stem cells during a
collection procedure (BIII) because higher rates of microbial
contamination seen in marrow harvests versus blood stem cell
collections can be caused by use of open collecting systems
(375,403,404 ). The highest risk for extraneous microbial con-
tamination of hematopoietic stem cells occurs during extensive
manipulation and processing in the laboratory (404,405 ). Po-
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tential sources include unprotected hands and laboratory equip-
ment and freezers (406 ), particularly the liquid phases of liquid
nitrogen freezers (407 ). Therefore, stem cell processing should
be performed according to current standards (378 ) using ap-
proved manufacturing practices (AIII). Hematopoietic stem cell
units thawed in a water bath should be enclosed in a second bag
(i.e., double-bagged technique) to prevent contamination of the
ports or caps from unsterile bath water (407 ) (BIII). Addition-
ally, water baths should be cleaned routinely (BIII) and certain
researchers have proposed that the bath contain sterile water
(407 ) (CIII). Researchers also report sterilizing liquid nitrogen
freezers before initial use for hematopoietic stem cell storage
(407 ) until fungal and bacterial cultures are negative (CIII).
Cell-processing laboratory personnel should implement
programs to detect extrinsic bacterial or fungal contamination
of collected stem cell units, ideally before transplantation (AIII).
Although repeated cultures are costly (408 ), donated hemato-
poietic stem cells should be cultured for aerobic bacteria and
fungi ≈1 times during initial processing and freezing (BIII).
Researchers also have proposed adding anaerobic bacterial cul-
tures and culturing twice, once at the end of processing, and
once after thawing just before use (407 ) (CIII). If bacterial cul-
ture results are positive, antibiotic-susceptibility tests should be
performed (BIII). Results of cultures and antibiotic-suscepti-
bility tests should be provided to the transplant physician be-
fore release of a cryopreserved marrow or blood stem cell unit,
and as soon as feasible for transplants infused before comple-
tion of culture incubation (BIII).
Collection center, cell-processing laboratory, and transplant
program personnel should maintain active surveillance of in-
fections among persons who have received hematopoietic stem
cells from those facilities to collect data regarding the number
of infections after HSCT that might have been caused by exog-
enous contamination of donor stem cells (BIII) because this type
of infection has been reported (405 ).
In Utero or Fetal HSCT
No national standards exist for in utero or fetal HSCT,
and the overall risks for transmitting infections to a fetus
through HSCT (409,410 ) have not been determined. How-
ever, in addition to precautions appropriate for adult recipi-
ents, physicians performing in utero or fetal HSCT are ad-
vised to evaluate potential donors for evidence of active in-
fectious diseases that could cause serious congenital infec-
tions (e.g., rubella, varicella, CMV, syphilis, or To. gondii )
in the fetus (CIII).
ACKNOWLEDGMENTS
The authors gratefully acknowledge the assistance of the following
persons in the preparation of this report: Jon S. Abramson, M.D.; Saundra
N. Aker, R.D.; George J. Alangaden, M.D.; Ann Arvin, M.D.; Carol Baker,
M.D.; Michael Boeckh, M.D.; Brian J. Bolwell, M.D.; John M. Boyce,
M.D.; C. Dean Buckner, M.D.; Pranatharthi H. Chandrasekar, M.D.;
D.W. Chen, M.D., M.P.H.; Joan Chesney, M.D.; Raymond Chinn, M.D.;
Christina Cicogna, M.D.; Dennis Confer, M.D.; Stella M. Davies, M.D.,
Ph.D.; Alfred DeMaria, Jr., M.D.; David W. Denning, M.B.B.S.; Joseph Fay,
M.D.; Stephen Forman, M.D.; Michael Gerber, M.D.; Anne A. Gershon,
M.D.; Stuart L. Goldberg, M.D.; Marie Gourdeau, M.D.; Christine J. Hager,
Ph.D.; Rebecca Haley, M.D.; Liana Harvath, Ph.D.; Kelly Henning, M.D.;
Steve Heyse; Elizabeth Higgs; Kevin High, M.D.; Mary M. Horowitz, M.D.;
Craig W.S. Howe, M.D., Ph.D.; David D. Hurd, M.D.; Hakan Kuyu, M.D.;
Amelia A. Langston, M.D.; Catherine Laughlin, Ph.D.; Hillard M. Lazarus,
M.D.; Joseph H. Laver, M.D.; Helen Leather, Phar.D.; Paul R. McCurdy,
M.D.; Carole Miller, M.D.; I. George Miller, M.D.; Per Ljungman, M.D.,
Ph.D.; Paul R. McCurdy, M.D.; Richard J. O’Reilly, M.D.; Gary Overturf,
M.D.; Jan E. Patterson, M.D.; Lauren Patton, D.D.S.; Doug Peterson,
D.D.S., Ph.D.; Donna Przepiorka, M.D., Ph.D.; Philip A. Pizzo, M.D.;
Charles G. Prober, M.D.; Issam Raad, M.D.; Elizabeth C. Reed, M.D.; Frank
Rhame, M.D.; Olle Ringdén, M.D.; Stephen M. Rose, Ph.D.; Scott D.
Rowley, M.D.; Pablo Rubinstein, M.D.; Martin Ruta; Joel Ruskin, M.D.;
Thomas N. Saari, M.D.; Stephen Schoenbaum, M.D.; Mark Schubert,
D.D.S., M.S.D.; Jane D. Siegel, M.D.; Jacqueline Sheridan; Alicia Siston,
M.D.; Trudy N. Small, M.D.; Frank O. Smith, M.D.; Ruth Solomon, M.D.;
Cladd Stevens, M.D.; Patrick J. Stiff, M.D.; Andrew J. Streifel, M.P.H.;
Donna A. Wall, M.D.; Thomas Walsh, M.D.; Phyllis Warkentin, M.D.; Rob-
ert A. Weinstein, M.D.; Estella Whimbey, M.D.; Richard Whitley, M.D.;
Catherine Wilfert, M.D.; Drew J. Winston, M.D.; Jeffrey Wolf, M.D.; An-
drew Yeager, M.D.; John A. Zaia, M.D.; and Carol Zukerman.
Contributions from the following CDC staff are also gratefully acknowl-
edged: Larry J. Anderson, M.D.; Fred Angulo, D.V.M.; Richard Besser, M.D.;
Jay C. Butler, M.D.; Donald Campbell; Mary E. Chamberland, M.D.; James
Childs, Sc.D.; Nancy J. Cox, Ph.D.; Robert B. Craven, M.D.; Jackie Curlew;
Vance J. Dietz, M.D., M.P.H.T.M.; Richard Facklam, Ph.D.; Cindy R. Fried-
man, M.D.; Keiji Fukuda, M.D., M.P.H.; Rana A. Hajjeh, M.D.; Barbara
Herwaldt, M.D., M.P.H.; AnnMarie Jenkins; Dennis D. Juranek, D.V.M.,
M.Sc.; Paul Kilgore, M.D.; William Kohn, D.D.S.; Jacobus Kool, M.D.,
D.T.M.H.; John R. Livengood, M.D., M.Phil.; Eric Mast, M.D., M.P.H.;
Michael McNeil, M.D., M.P.H.; Robin R. Moseley, M.A.T.; Thomas R.
Navin, M.D.; Adelisa Panlilio, M.D., M.P.H.; Monica Parise, M.D.; Michele
Pearson, M.D.; Bradford A. Perkins, M.D.; Renee Ridzon, M.D.; Martha
Rogers, M.D.; Nancy Rosenstein, M.D.; Charles Rupprecht, Ph.D., V.M.D.;
Peter Schantz, Ph.D.; Lawrence B. Schonberger, M.D., M.P.H.; Jane Seward,
M.B.B.S., M.P.H.; John A. Stewart, M.D.; Raymond Strikas, M.D.; Robert
V. Tauxe, M.D., M.P.H.; Theodore Tsai, M.D.; Rodrigo Villar, M.D.; David
Wallace; and Sherilyn Wainwright, D.V.M., M.D.
The contributions of staff from other federal and nongovernmental agen-
cies are also gratefully acknowledged: Agency for Healthcare Research and
Quality; Food and Drug Administration; Health Resources and Services
Administration; National Institutes of Health; National Cancer Institute;
National Heart, Lung, and Blood Institute; National Institute for Allergy
and Infectious Diseases; CDC’s Advisory Committee on Immunization Prac-
tices; American Academy of Pediatrics’ Committee on Infectious Diseases;
American Association of Blood Banks; Hospital Infection Control Advisory
Committee; International Society of Hematotherapy and Graft Engineer-
ing; National Marrow Donor Program; Southwest Oncology Group; Foun-
dation for the Accreditation of Hematopoietic Cell Therapy; and Society for
Healthcare Epidemiology of America.
40
REFERENCES
Introduction
1. Institute of Medicine/Committee on Emerging Microbial Threats
to Health. Emerging infections: microbial threats to health in the
United States. Lederberg J, Shope RE, and Oaks SC Jr., eds.
Washington, DC: National Academy Press, 1992. Available at
<http://books.nap.edu/books/0309047412/html/index.html>.
Accessed June 28, 2000.
2. CDC. Addressing emerging infectious disease threats: a prevention
strategy for the United States. Atlanta, GA: US Department of
Health and Human Services, Public Health Service, CDC, 1994.
Available at <http://www.cdc.gov/ncidod/publications/eid_plan>.
Accessed May 17, 2000.
3. CDC. USPHS/IDSA guidelines for the prevention of opportunistic
infections in persons infected with human immunodeficiency virus:
a summary. MMWR 1995;44(No. RR-8):1–34.
4. CDC. 1997 USPHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human
immunodeficiency virus. MMWR 1997;46(No. RR-12):1–46.
5. CDC. 1999 USPHS/IDSA guidelines for the prevention of
opportunistic infections in persons infected with human
immunodeficiency virus. MMWR 1999;48(No. RR-10):1–66.
6. Gross PA, Barrett TL, Dellinger EP, et al. Purpose of quality
standards for infectious diseases. Clin Infect Dis 1994;18(3):421.
BACKGROUND
7. Appelbaum FR. Use of bone marrow and peripheral blood stem
cell transplantation in the treatment of cancer. CA Cancer J Clin
1996;46(3):142–64.
8. Kessinger A, Armitage JO. Use of peripheral stem cell support of
high-dose chemotherapy. In: DeVita VT Jr., Hellman S, Rosenberg
SA, eds. Important advances in oncology 1993. Philadelphia, PA:
J.B.Lippincott Co. 1993.
9. Bortin MM, Horowitz MM, Gale RP, et al. Changing trends in
allogeneic bone marrow transplantation for leukemia in the 1980s.
JAMA 1992;268(5):607–12.
10. Sobocinski KA, Horowitz MM, Rowlings PA, et al. Bone marrow
transplantation—1994: a report from the International Bone
Marrow Transplant Registry and the North American Autologous
Bone Marrow Transplant Registry. J Hematother 1994;3:95–102.
11. Zittoun RA, Mandelli F, Willemze R, et al. Autologous or allogeneic
bone marrow transplantation compared with intensive
chemotherapy in acute myelogenous leukemia. New Engl J Med
1995;332(4):217–23.
12. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for
the treatment of chronic myelogenous leukemia. Ann Intern Med
1986;104(2):155–63.
13. Storb R, Longton G, Anasetti C, et al. Changing trends in marrow
transplantation for aplastic anemia [Review]. Bone Marrow
Transplant 1992;10(suppl 1):45–52.
14. Mackinnon S, Hows JM, Goldman JM, et al. Bone marrow
transplantation for chronic myeloid leukemia: the use of
histocompatible unrelated volunteer donors. Exp Hematol
1990;18(5):421–5.
15. Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462
transplantations from unrelated donors facilitated by the National
Marrow Donor Program. N Engl J Med 1993;328(9):593–602.
16. Nademanee AP, Schmidt GM, Parker P, et al. Outcome of matched
unrelated donor bone marrow transplantation in patients with
hematologic malignancies using molecular typing for donor selection
and graft-versus-host disease prophylaxis regimen of cyclosporine,
methotrexate, and prednisone. Blood 1995;86:1228–34.
17. Clift RA, Hansen JA, Thomas ED, et al. Marrow transplantation
from donors other than HLA-identical siblings. Transplant
1979;28(3):235–42.
18. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation
from related donors other than HLA-identical siblings. N Engl J
Med 1985;313(13):765–71.
19. Ferrara JL, Deeg HJ. Graft-versus-host disease [Review]. N Engl J
Med 1991;324(10):667–74.
20. Marmont AM, Horowitz MM, Gale RP, et al. T-cell depletion of
HLA-identical transplants in leukemia. Blood 1991;78(8):2120–30.
21. Rowlings PA. 1996 summary slides show current use and outcome
of blood and marrow transplantation. Autologous Blood & Marrow
Transplant Registry—North America: ABMTR Newsletter
1996;3(1):6–12.
22. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored
placental blood for unrelated bone marrow reconstitution [Review].
Blood 1993;81(7):1679–90.
23. Kurtzberg J, Laughlin M, Graham ML, et al. Placental blood as a
source of hematopoietic stem cells for transplantation into unrelated
recipients. N Engl J Med 1996;335(3):157–66.
24. Wagner JE, Rosenthal J, Sweetman R, et al. Successful
transplantation of HLA-matched and HLA-mismatched umbilical
cord blood from unrelated donors: analysis of engraftment and acute
graft-versus-host disease. Blood 1996;88(3):795–802.
25. Meropol NJ, Overmoyer BA, Stadtmauer EA. High-dose
chemotherapy with autologous stem cell support for breast cancer.
Oncology (Huntingt) 1992;6(12):53–60, 63; discussion, 63–4, 69;
published erratum, Oncology (Huntingt) 1993;7(3):105.
26. Sullivan KM, Storek J, Kopecky KJ, et al. Controlled trial of long-
term administration of intravenous immunoglobulin to prevent late
infection and chronic graft-vs.-host disease after marrow
transplantation: clinical outcome and effect on subsequent immune
recovery. Biol Blood Marrow Transplant 1996;2(1):44–53.
27. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment
of acute graft-versus- host disease: the old and the new; a report
from The Eastern Cooperative Oncology Group (ECOG) [Review].
Bone Marrow Transplant 1997;19(6):577–600.
28. Antman KH, Rowlings PA, Vaughn WP, et al. High-dose
chemotherapy with autologous hematopoietic stem cell support for
breast cancer in North America. J Clin Oncol 1997;15(5):1870–9.
29. Nevill TJ, Shepherd JD, Nantel SH, et al. Stem cell transplant-
related mortality (TRM) 1985–1996: the Vancouver experience
[Abstract 4426]. Blood 1997;90(10)(suppl 1 [part 2 of 2]):373b.
30. Duell T, van Lint MT, Ljungman P, et al. Health and functional
status of long-term survivors of bone marrow transplantation. Ann
Intern Med 1997;126(3):184–92.
31. Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of
life of 125 adults surviving 6–18 years after bone marrow
transplantation. Soc Sci Med 1995;40(4):479–90.
32. Ochs L, Shu XO, Miller J, et al. Late infections after allogeneic bone
marrow transplantation: comparison of incidence in related and
unrelated donor transplant recipients. Blood 1995;86(10):3979–86.
33. Pearson ML. Guideline for prevention of intravascular device-
related infections. Part I. Intravascular device-related infections:
an overview. Am J Infect Control 1996;24:262–93.
34. Paulin T, Ringdén O, Lönnqvist B. Faster immunological recovery
after bone marrow transplantation in patients without
cytomegalovirus infection. Transplant 1985;39(4):377–84.
35. Armitage JO. Bone marrow transplantation. N Engl J Med
1994;330(12):827–38.
     41B B & M T
36. Thomas ED, Storb R, Clift RA, et al. Bone marrow transplantation
(second of two parts) [Review]. N Engl J Med 1975;292(17):895–
902.
37. Yeager AM, Vogelsang GB, Jones RJ, et al. Induction of cutaneous
graft-versus-host disease by administration of cyclosporine to
patients undergoing autologous bone marrow transplantation for
acute myeloid leukemia. Blood 1992;79(11):3031–5.
38. Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF. Effects of
corticosteroids on human monocyte function. J Clin Invest
1974;54(6):1337–43.
39. Atkinson K, Horowitz MM, Gale RP, et al. Consensus among bone
marrow transplanters for diagnosis, grading and treatment of chronic
graft-versus-host disease. Bone Marrow Transplant 1989;4(3):247–54.
40. Sullivan KM, Agura E, Anasetti C, et al. Chronic graft-versus-host
disease and other late complications of bone marrow transplantation.
Semin Hematol 1991;28(3):250–9.
41. Witherspoon RP, Storb R, Ochs HD, et al. Recovery of antibody
production in human allogeneic marrow graft recipients: influence
of time posttransplantation, the presence or absence of chronic graft-
versus-host disease, and antithymocyte globulin treatment. Blood
1981;58(2):360–8.
42. Lum LG, Munn NA, Schanfield MS, Storb R. Detection of specific
antibody formation to recall antigens after human bone marrow
transplantation. Blood 1986;67(3):582–7.
43. Ambrosino DM, Molrine DC. Critical appraisal of immunization
strategies for the prevention of infection in the compromised host.
Hematol Oncol Clin North Am 1993;7(5):1027–50.
44. Lum LG. Kinetics of immune reconstitution after human marrow
transplantation. Blood 1987;69(2):369–80.
45. Shulman HM, Sullivan KM, Weiden PL, et al. Chronic graft-versus-
host syndrome in man: a long-term clinicopathologic study of 20
Seattle patients. Am J Med 1980;69(2):204–17.
46. Izutsu KT, Sullivan KM, Schubert MM, et al. Disordered salivary
immunoglobulin secretion and sodium transport in human chronic
graft-versus-host disease. Transplant 1983;35(5): 441–6.
47. Aucouturier P, Barra A, Intrator L, et al. Long lasting IgG subclass
and antibacterial polysaccharide antibody deficiency after allogeneic
bone marrow transplantation. Blood 1987;70(3):779–85.
48. Hughes WT, Armstrong D, Bodey GP, et al. 1997 guidelines for
the use of antimicrobial agents in neutropenic patients with
unexplained fever [Review]. Clin Infect Dis 1997;25(3): 551–73.
49. Pizzo PA, Hathorn JW, Hiemenz J, et al. Randomized trial
comparing ceftazidime alone with combination antibiotic therapy
in cancer patients with fever and neutropenia. N Engl J Med
1986;315(9):552–8.
50. Amgen, Inc. Filgrastim. In: Physician’s desk reference. 54th edition.
Montvale, NJ: Medical Economics Company, Inc., 2000:528–33.
BACTERIAL INFECTIONS
51. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with
fluoroquinolones for bacterial infections in neutropenic patients: a meta-
analysis. Clin Infect Dis 1996(4);23:795–805.
52. Murphy M, Brown AE, Sepkowitz KA, et al. Fluoroquinolone
prophylaxis for the prevention of bacterial infections in patients with
cancer—is it justified [Letter]? Clin Infect Dis 1997;25(2):346–8.
53. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli  resistant
to fluoroquinolones in patients with cancer and neutropenia. N Engl J
Med 1994;330(17):1240–1.
54. Kirkpatrick BD, Harrington SM, Smith D, et al. Outbreak of
vancomycin-dependent Enterococcus faecium  in a bone marrow
transplant unit. Clin Infect Dis 1999;29(5):1268–73.
55. Vose JM, Armitage JO. Clinical applications of hematopoietic
growth factors. J Clin Oncol 1995;13(4):1023–35.
56. Rand KJ, Houck H, Ganju A, Babington RG, Elfenbein GJ.
Pharmacokinetics of cytomegalovirus specific IgG antibody
following intravenous immunoglobulin in bone marrow transplant
patients. Bone Marrow Transplant 1989;4(6):679–83.
57. Bosi A, De Majo E, Guidi S, et al. Kinetics of anti-CMV antibodies
after administration of intravenous immunoglobulins to bone
marrow transplant recipients. Haematologica 1990;75(2):109–12.
58. Buckley RH, Schiff RI. Use of intravenous immune globulin in
immunodeficiency diseases. N Engl J Med 1991;325(2):110–7.
59. Bowden RA, Myers JD. Infection complicating bone marrow
transplantation. In: Rubin RH, Young LS, eds. Clinical approach
to infection in the compromised host. 3rd edition. New York, NY:
Plenum Medical Book Co., 1994:601–28.
60. Sullivan KM, Storek J, Kopecky KJ, et al. Controlled trial of long-
term administration of intravenous immunoglobulin to prevent late
infection and chronic graft-versus-host disease following marrow
transplantation: clinical outcome and effect on subsequent immune
recovery. Biol Blood Marrow Transplant 1996;2:44–53.
61. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous
immunoglobulin to prevent infections in patients undergoing
autologous bone marrow transplantation or severe myelosuppressive
therapy. Ann Intern Med 1993;118(12):937–42.
62. Garner JS. Guideline for isolation precautions in hospitals. Hospital
Infection Control Practices Advisory Committee. Infect Control
Hosp Epidemiol 1996;17(1):53–80; published erratum, Infect
Control Hosp Epidemiol 1996;17(4):214.
63. CDC. Prevention of pneumococcal disease: recommendations of
the Advisory Committee on Immunization Practices (ACIP).
MMWR 1997;46(No. RR-8):1–24.
64. Winston DJ, Schiffman G, Wang DC, et al. Pneumococcal
infections after human bone-marrow transplantation. Ann Intern
Med 1979;91(6):835–41.
65. Hammarström V, Pauksen K, Azinge J, et al. Pneumococcal
immunity and response to immunization with pneumococcal vaccine
in bone marrow transplant patients: the influence of graft versus
host reaction. Support Care Cancer 1993;1:195–9.
66. Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate
vaccine responses in bone marrow transplant patients. Transplant
1994;57(5):677–84.
67. Schubert MM, Peterson DE, Lloid ME. Oral complications. In:
Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell
transplantation. 2nd ed. Oxford, England: Blackwell Science, Inc.,
1999;751–63.
68. Alcaide F, Linares JA, Pallares R, et al. In vitro activities of 22 ß-
lactam antibiotics against penicillin-resistant and penicillin-
susceptible viridans group Streptococci  isolated from blood.
Antimicrob Agents Chemother 1995;39(10):2243–7.
69. Steiner M, Villablanca J, Kersey J, et al. Viridans streptococcal shock
in bone marrow transplant patients. Am J Hematol 1993;42(4):354–8.
70. American Academy of Pediatrics/Committee on Infectious Diseases.
Haemophilus influenzae  infections. In: Pickering LK, ed. 2000 red
book: report of the Committee on Infectious Diseases. 25th ed. Elk
Grove Village, IL: American Academy of Pediatrics; 2000:262–72.
71. CDC. Recommendations for use of Haemophilus  b conjugate
vaccines and a combined diphtheria, tetanus, pertussis, and
Haemophilus  b vaccine: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR
1993;42(No. RR-13):1–15.
72. Granoff DM, Basden M. Haemophilus influenzae  infections in Fresno
42
County, California: a prospective study of the effects of age, race,
and contact with a case on incidence of disease. J Infect Dis
1980;141(1):40–6.
73. Band JD, Fraser DW, Ajello G. Prevention of Haemophilus influenzae
type b disease. JAMA 1984;251(18):2381–6.
74. Band JD, Fraser DW, Hightower AW, Broome CV. Prophylaxis of
Haemophilus influenzae  type b disease [Letter]. JAMA
1984;252(23):3249–50.
75. Barra A, Cordonnier C, Prezilosi MP, et al. Immunogenicity of
Haemophilus influenzae  type b conjugate vaccine in allogeneic bone
marrow transplant recipients. J Infect Dis 1992;166(5):1021–8.
76. Sable CA, Donowitz GA. Infections in bone marrow transplant
recipients. Clin Infect Dis 1994;18(3):273–84; quiz 282–4.
77. Roy V, Ochs L, Weisdorf D. Late infections following allogeneic
bone marrow transplantation: suggested strategies for prophylaxis
[Review]. Leuk Lymphoma 1997;26(1–2):1–15.
VIRAL INFECTIONS
78. Bowden RA, Slichter SJ, Sayers M, et al. Comparison of filtered
leukocyte-reduced and cytomegalovirus (CMV) seronegative blood
products for the prevention of transfusion-associated CMV infection
after marrow transplantation. Blood 1995;86(9):3598–603.
79. Boeckh M, Gooley TA, Myerson D, Cunningham T, Schoch G,
Bowden RA. Cytomegalovirus pp65 antigenemia-guided early
treatment with ganciclovir versus ganciclovir at engraftment after
allogeneic marrow transplantation: a randomized double blind study.
Blood 1996;88(10):4063–71.
80. Boeckh M, Stevens-Ayers T, Bowden R. Cytomegalovirus pp65
antigenemia after autologous marrow and peripheral blood stem cell
transplantation. J Infect Dis 1996;174(5):907–12.
81. Boeckh M, Bowden R. Cytomegalovirus infection in marrow
transplantation. In: Buckner CD, Clift RA, ed. Technical and biological
components of marrow transplantation. Boston, MA: Kluwer Academic
Publishers, 1995:97–136.
82. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction
monitoring reduces the incidence of cytomegalovirus disease and the
duration and side effect of antiviral therapy after bone marrow
transplantation. Blood 1995;86(7):2815–20.
83. Mendez JC, Sia IG, Paya CV. Human cytomegalovirus. In: Lennette
EH, Smith TF, eds. Laboratory diagnosis of viral infections. 3rd ed., revised
and expanded. New York, NY: Marcel Decker, Inc., 1999: 361–72.
84. Goodrich JM, Mori M, Gleaves CA, et al. Early treatment with
ganciclovir to prevent cytomegalovirus disease after allogeneic bone
marrow transplant. N Engl J Med 1991;325(23):1601–7.
85. Schmidt GM, Horak DA, Niland JC, Duncan SR, Forman SJ, Zaia
JA. Randomized controlled trial of prophylactic ganciclovir for
cytomegalovirus pulmonary infection in recipients of allogeneic bone
marrow transplants. New Engl J Med 1991;324(15):1005–11.
86. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G. Meyers
JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after
allogeneic marrow transplant. Ann Intern Med 1993;118(3):173–8.
87. Mazzulli T, Drew LW, Yen-Lieberman B, et al. Multicenter
comparison of the Digene Hybrid Capture CMV DNA Assay
(Version 2.0), the pp65 antigenemia assay, and cell culture for the
detection of cytomegalovirus viremia. J Clin Microbiol
1999;37(4):958–63.
88. Gerna G, Baldanti F, Middeldorp JM, et al. Clinical significance of
expression of human cytomegalovirus pp67 late transcript in heart,
lung, and bone marrow transplant recipients as determined by
nucleic acid sequence-based amplification. J Clin Microbiol
1999;37(4):902–11.
89. Singhal S, Mehta J, Powles R, et al. Three weeks of ganciclovir for
cytomegalovirus after allogeneic bone marrow transplantation. Bone
Marrow Transplant 1995;15(5):777–81.
90. Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek
MR. Risk-adapted approach with a short course of ganciclovir to
prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive
recipients of allogeneic bone marrow transplants. Clin Infect Dis
1997;24(5): 901–7.
91. Zaia J, Gallez-Hawkins GM, Longmate J, et al. Late bacterial and
fungal sepsis and mortality after BMT are increased by duration of
early ganciclovir preemptive therapy for CMV infection [Abstract
2128]. Blood 1998;92(10)(suppl 1 [part 1 of 2]):518a.
92. Bacigalupo A, Bregante S, Tedone E, et al. Combined foscarnet-
ganciclovir treatment for cytomegalovirus infections after allogeneic
hematopoietic stem cell transplantation. Transplant 1996;62(3);376–80.
93. Moretti S, Zikos P, Van Lint MT, et al. Foscarnet vs ganciclovir for
cytomegalovirus (CMV) antigenemia after allogeneic hematopoietic
stem cell transplantation (HSCT): a randomized study. Bone
Marrow Transplant 1998;22(2):175–80.
94. Boeckh M, Hoy C, Torok-Storb B. Occult cytomegalovirus infection
of marrow stroma. Clin Infect Dis 1998;26(1):209–10.
95. Krause H, Hebart H, Jahn G, Muller CA, Einsele H. Screening for
CMV-specific T-cell proliferation to identify patients at risk of
developing late onset CMV disease. Bone Marrow Transplant
1997;19(11):1111–16.
96. Gor D, Sabin C, Prentice HG, et al. Longitudinal fluctuations in
cytomegalovirus load in bone marrow transplant patients:
relationship between peak virus load, donor/recipient serostatus,
acute GVHD and CMV disease. Bone Marrow Transplant
1998;21(6):597–605.
97. Zaia JA, Gallez-Hawkins GM, Teftmeier BR, et al. Late
cytomegalovirus disease in marrow transplantation is predicted by
virus load in plasma. J Infect Dis 1997;176(3):782–5.
98. Ljungman P, Aschan J, Azinge JN, et al. Cytomegalovirus viremia and
specific T-helper cell responses as predictors of disease after allogeneic
marrow transplantation. Br J Haematol 1993;83(1):118–24.
99. Lazzarotto T, Varani S, Spezzacatena P, et al. Delayed acquisition
of high-avidity anti-cytomegalovirus antibody is correlated with
prolonged antigenemia in solid organ transplant recipients. J Infect
Dis 1998;178(4):1145–9.
100. Boeckh M, Gallez-Hawkins GM, Myerson D, Zaia JA, Bowden RA.
Plasma polymerase chain reaction for cytomegalovirus DNA after
allogeneic marrow transplantation: comparison with polymerase
chain reaction using peripheral blood leukocytes, pp65 antigenemia,
and viral culture. Transplant 1997;64(1):108–13.
101. Prentice HG, Gluckman E, Powles RL, et al. Impact of long-term
acyclovir on cytomegalovirus infection and survival after allogeneic
bone marrow transplantation. Lancet 1994;343(8900):749–53.
102. Boeckh M, Gooley TA, Bowden RA. Effect of high-dose acyclovir
on survival in allogeneic marrow transplant recipients who received
ganciclovir at engraftment or for cytomegalovirus pp65 antigenemia.
J Infect Dis 1998;178(4):1153–7.
103. Boeckh M, Gooley TA, Reusser P, Buckner CD, Bowden RA.
Failure of high-dose acyclovir to prevent cytomegalovirus disease
after autologous marrow transplantation. J Infect Dis
1995;172(4):939–43.
104. American Public Health Association. Mononucleosis, infectious. In:
Chin J, ed. Control of communicable diseases manual. 17th ed.
Washington, DC: American Public Health Association, 2000:350–2.
105. Papadopoulos E, Ladanyi M, Emanuel D, et al. Infusions of donor
leukocytes to treat Epstein-Barr virus-associated lymphoproliferative
     43B B & M T
disorders after allogeneic bone marrow transplantation. New Engl J
Med 1994;330(17):1185–91.
106. Rooney CM, Smith CA, Ng CY, et al. Infusion of cytotoxic T cells for
the prevention and treatment of Epstein-Barr virus-induced lymphoma
in allogeneic transplant recipients. Blood 1998;92(5):1549–55.
107. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated
B cell lymphopro-liferative disorders following bone marrow
transplantation. Blood 1988;71(5): 1234–43.
108. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus
lymphoproliferation after bone marrow transplantation. Blood
1988;72(2):520–9.
109. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir
prophylaxis of herpes-simplex-virus infections. N Engl J Med
1981;305(2):63–7.
110. Gluckman E, Lotsberg J, Devergie A, et al. Prophylaxis of herpes
infections after bone marrow transplantation by oral acyclovir. Lancet
1983;2(8352):706–8.
111. Wade JC, Newton B, McLaren C, Flournoy N, Keeney RE, Meyers
JD. Intravenous acyclovir to treat mucocutaneous herpes simplex virus
infection after marrow transplantation: a double-blind trial. Ann Intern
Med 1982;96(3):265–9.
112. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for
prevention of herpes simplex reactivation after marrow transplantation.
Ann Intern Med 1984;100(6):823–8.
113. Johnson JR, Egaas S, Gleaves CA, Hackman R, Bowden RA. Hepatitis
due to herpes simplex virus in marrow-transplant recipients. Clin Infect
Dis 1992;14(1):38–45.
114. Crumpacker CS. Ganciclovir [Review]. New Engl J Med 1996;335(10):721–9.
115. Chulay JD, Bell AR, Miller GB, and the International Valaciclovir HSV
Study Group. Long-term safety of valaciclovir for suppression of herpes
simplex virus infections [Abstract 105]. In: Infectious Diseases Society
of America (IDSA) Program and Abstracts, 34th annual meeting,
September 18–20, 1996, New Orleans, Louisiana;55.
116. Han CS, Miller W, Haake R, Weisdorf D. Varicella zoster infection
after bone marrow transplantation: incidence, risk factors, and
complications. Bone Marrow Transplant 1994;13(3):277–83.
117. Lawrence R, Gershon AA, Holzman R, Steinberg SP. Risk of zoster
after varicella vaccination in children with leukemia. New Engl J Med
1988;318(9):543–8.
118. Locksley RM, Fluornoy N, Sullivan KM, Meyers JD. Infection with
varicella-zoster virus after marrow transplantation. J Infect Dis
1985;152(6):1172–81.
119. Schuchter LM, Wingard J, Piantadose S, Burns WH, Santos GW,
Saral R. Herpes zoster infection after autologous bone marrow
transplantation. Blood 1989;74(4):1424–27.
120. CDC. Prevention of varicella: recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR 1996;45(No.
RR-11):1–36.
121. CDC. Prevention of varicella: updated recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR
1999;48(No. RR-06):1–5.
122. Wacker P, Hartmann O, Benhamou E, Salloum E, Lamerle J. Varicella-
zoster virus infections after autologous bone marrow transplantation
in children. Bone Marrow Transplant 1989;4(2):191–4.
123. Josephson A, Gombert ME. Airborne transmission of nosocomial
varicella from localized zoster. J Infect Dis 1988;158(1):238–41.
124. Sempere A, Sanz GF, Senent L, et al. Long-term acyclovir prophylaxis
for prevention of varicella zoster virus infection Diseases. 25th ed. Elk
Grove Village, IL: American Academy of Pediatrics, 2000:351–9.
125. Selby PJ, Powles RL, Easton D, et al. Prophylactic role of intravenous
and long-term oral acyclovir after allogeneic bone marrow
transplantation. Br J Cancer 1989;59(3):434–8.
126. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir
prophylaxis in bone marrow transplant recipients and lymphocyte
proliferation to herpes antigens in vitro. Bone Marrow Transplant
1986;1(2):185–92.
127. Cirrelli R, Herne K, McCrary M, Lee P, Tyrine, SK. Famciclovir:
review of clinical efficacy and safety [Review]. Antiviral Res
1996;29(2–3):141–51.
128. Cat LK, Yamauchi NK. Varicella vaccine in immunocompromised
patients [Review]. Annuals of Pharmacology 1996;30(2):181–4.
129. Redman RL, Nader S, Zerboni L, et al. Early reconstitution of
immunity and decreased severity of herpes zoster in bone marrow
transplant recipients immunized with inactivated varicella vaccine. J
Infect Dis 1997;176(3):578–85.
130. Garcia R, Raad I, Abi-Said D, et al. Nosocomial respiratory syncytial
virus infections: prevention and control in bone marrow transplant
patients. Infect Control Hosp Epidemiol 1997;18(6):412–6.
131. Raad I, Abbas J, Whimbey E. Infection control of nosocomial
respiratory viral disease in the immunocompromised host. Am J Med
1997;102(3A):48–52.
132. Sable CA, Hayden FG. Orthomyxoviral and paramyxoviral infections
in transplant patients [Review]. Infect Dis Clin North Am
1995;9(4):987–1003.
133. Whimbey E, Champlin R, Couch RB, et al. Community respiratory
virus infections among hospitalized adult bone marrow transplant
recipients. Clin Infect Dis 1996;22(5):778–82.
134. Whimbey E, Englund JA, Couch RB. Community respiratory virus
infections in immunocompromised patients with cancer. Am J Med
1997;102(3A):10–8.
135. Bowden RA. Respiratory virus infections in bone marrow transplant:
the Fred Hutchinson Cancer Research Center experience. Am J Med
1997;102(3A):27–30.
136. Harrington RD, Hooton RD, Hackman RC, et al. Outbreak of
respiratory syncytial virus in a bone marrow transplant center. J Infect
Dis 1992;165(6):987–93.
137. Whimbey E, Champlin R, Englund JA, et al. Combination therapy
with aerosolized ribavirin and intravenous immunoglobulin for
respiratory syncytial virus disease in adult bone marrow transplant
recipients. Bone Marrow Transplant 1995;16(3):393–9.
138. Folz RJ, Elkordy MA. Coronavirus pneumonia following autologous
bone marrow transplantation for breast cancer. Chest
1999;115(3):901–5.
139. Whimbey E, Elting LS, Couch RB, et al. Influenza A virus infection
among hospitalized adult bone marrow transplant recipients. Bone
Marrow Transplant 1994;13(4):437–40.
140. CDC. Guideline for prevention of nosocomial pneumonia. Respiratory
Care 1994;39(12): 1191–236.
141. CDC. Prevention and control of influenza: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR
2000;49(No. RR-3):1–38.
142. Engelhard D, Nagler A, Hardan I, et al. Antibody response to a two-
dose regimen of influenza vaccine in allogeneic T cell-depleted and
autologous BMT recipients. Bone Marrow Transplant 1993;11(1):1–5.
143. Hayden FG. Prevention and treatment of influenza in
immunocompromised patients. Am J Med 1997;102(3A):55–60.
144. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ,
Crisp A. Zanamivir in the prevention of influenza among healthy adults:
a randomized controlled trial. JAMA 1999;282(1):31–5.
145. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral
neuraminidase inhibitor oseltamivir to prevent influenza. New Engl
J Med 1999;341(18):1336–43.
44
146. Hayden FG, Gubareva L, Klein T, et al. Inhaled zanamivir for
preventing transmission of influenza in families [Abstract LB-2]. In:
Final program, abstracts and exhibits addendum, 38th Interscience
Conference on Antimicrobial Agents and Chemotherapy. Washington,
DC: American Society for Microbiology, 1991:1.
147. CDC. Neuraminidase inhibitors for treatment of influenza A and B
infections. MMWR 1999;48(No. RR-14):1–10.
148. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of
amantadine- and rimantadine-resistant influenza A viruses in
symptomatic immunocompromised adults. Clin Infect Dis
1998;26(6):1418–24.
149. Klimov AI, Rocha E, Hayden FG, et al. Prolonged shedding of
amantadine-resistant influenzae A viruses by immunodeficient patients:
detection by polymerase chain reaction-restriction analysis. J Infect
Dis 1995;172(5):1352–55.
150. Knight V, Gilbert BE. Ribavirin aerosol treatment of influenza [Review].
Infect Dis Clin North Am 1987;1(2):441–57.
151. Hayden FG, Sabie CA, Connor JD, Lane J. Intravenous ribavirin by
constant infusion for serious influenza and parainfluenza virus infection.
Antiviral Therapy 1996;1:51–6.
152. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK.
Safety and efficacy of the neuraminidase inhibitor GG167 in
experimental human influenza. JAMA 1996;275(4): 295–9.
153. Hayden FG. Combination antiviral therapy for respiratory virus
infections. Antiviral Res 1996;29(1):45–8.
154. Martin MA, Bock MJ, Pfaller MA, Wenzel RP. Respiratory syncytial
virus infections in adult bone marrow transplant recipients [Letter].
Lancet 1988;1(8599):1396–7.
155. Hertz MI, Englund JA, Snover D, Bitterman PB, McGlave PB.
Respiratory syncytial virus-induced acute lung injury in adult patients
with bone marrow transplants: a clinical approach and review of the
literature [Review]. Medicine 1989;68(5):269–81.
156. Win N, Mitchell D, Pugh S, Russell NH. Successful therapy with
ribavirin of late onset respiratory syncytial virus pneumonitis
complicating allogeneic bone transplantation. Clin Lab Haematol
1992;14(1):29–32.
157. DeVincenzo JP, Leombuno D, Soiffer RJ, Siber GR. Immunotherapy
of respiratory syncytial virus pneumonia following bone marrow
transplantation. Bone Marrow Transplant 1996;17(6):1051–6.
158. Boeckh M, Bowden RA, Berrey MM, et al. Phase I evaluation of a
RSV-specific humanized monoclonal antibody (MEDI-493) after
hematopoietic stem cell transplantation (HSCT) [Abstract MN-20].
38th Interscience Conference on Antimicrobial Agents and Chemo-
therapy, September 24–27, 1998, San Diego, CA;593.
159. Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of
adenovirus disease in bone marrow transplant recipients. J Infect Dis
1994;169(4):775–81.
160. Englund JA, Piedra PA, Whimbey EA. Prevention and treatment of
respiratory syncytial virus and parainfluenza viruses in
immunocompromised patients. Am J Med 1997;102(3A):61–70.
161. American Academy of Pediatrics. Influenza. In: Pickering LK, ed. 2000
red book: report of the Committee on Infectious Diseases. 25th ed. Elk
Grove Village, IL: American Academy of Pediatrics, 2000:351–9.
162. American Academy of Pediatrics. Parainfluenza viral infections. In:
Pickering LK, ed. 2000 red book: report of the Committee on Infectious
Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics, 2000:419–20.
163. American Academy of Pediatrics. Adenovirus infections. In: Pickering
LK, ed. 2000 red book: report of the Committee on Infectious Diseases.
25th ed. Elk Grove Village, IL: American Academy of Pediatrics,
2000:162–3.
164. American Academy of Pediatrics. Respiratory syncytial virus. In:
Pickering LK, ed. 2000 red book: report of the Committee on Infectious
Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics, 2000:483–7.
FUNGAL INFECTIONS
165. Vose JM, Armitage JO. Clinical applications of hematopoietic growth
factors. J Clin Oncol 1995;13(4):1023–35.
166. Riley DK, Pavia AT, Beatty PG, Denton D, Carroll KC. Surveillance
cultures in bone marrow transplant recipients: worthwhile or wasteful?
Bone Marrow Transplant 1995;15(3):469–73.
167. Walsh TJ. Role of surveillance cultures in prevention and treatment of
fungal infections. National Cancer Institute Monograph No.
9;1990:43–5.
168. Crawford SW. Bone-marrow transplantation and related infections.
Semin Respir Infect 1993;8(3):183–90.
169. Goodman JL, Winston DJ, Greenfield RA, et al. Controlled trial of
fluconazole to prevent fungal infections in patients undergoing bone
marrow transplantation. N Engl J Med 1992;326(13):845–51.
170. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole
prophylaxis for fungal infections after marrow transplantation—a
prospective, randomized, double-blind study. J Infect Dis
1995;171(6):1545–52.
171. Reed EC. Infectious complications during autotransplantation
[Review]. Hematol Oncol Clin North Am 1993;7:717–35.
172. Donowitz G, Harman C. Low dose fluconazole prophylaxis in
neutropenia [Abstract 024]. 9th International Symposium on Infections
in the Immunocompromised Host, Assisi, Italy, June 23–26, 1996.
173. Bjerke JW, Meyers JD, Bowden RA. Hepatosplenic candidiasis—a
contraindication to marrow transplantation? Blood
1994;84(8):2811–4.
174. Walsh TJ, Dixon DM. Nosocomial aspergillosis: environmental
microbiology, hospital epidemiology, diagnosis and treatment. Eur J
Epidemiol 1989;5(2):131–42.
175. Weems JJ Jr, Davis BJ, Tablan OC, Kaufman L, Martone WJ.
Construction activity: an independent risk factor for invasive
aspergillosis and zygomycosis in patients with hematologic malignancy.
Infect Control 1987;8(2):71–5.
176. Krasinski K, Holzman RS, Hanna B, Greco MA, Graff M, Bhogal M.
Nosocomial fungal infection during hospital renovation. Infection
Control 1985;6(7):278–82.
177. Thio CL, Smith D, Merz WG, et al. Refinements of environmental
assessment during an outbreak investigation of invasive aspergillosis in
a leukemia and bone marrow transplant unit. Infect Control Hosp
Epidemiol 2000;21(1):18–23.
178. Rhame FS, Streifel AJ, Kersey JH Jr, McGlave PB. Extrinsic risk factors
for pneumonia in the patient at high risk of infection [Review]. Am J
Med 1984;76(5A):42–52.
179. Opal SM, Asp AA, Cannady, PB Jr, Morse PL, Burton LJ, Hammer
PG 2nd. Efficacy of infection control measures during a nosocomial
outbreak of disseminated aspergillosis associated with hospital
construction. J Infect Dis 1986;153(3):634–7.
180. American Institute of Architects Academy of Architecture for Health,
with assistance from the US Department of Health and Human
Services. Guidelines for design and construction of hospital and medical
facilities. Washington, DC: American Institute of Architects Press,
1996–67:58.
181. Bowden RA, Cays M, Gooley T, Mamelok RD, van Burik JA. Phase I
study of amphotericin B colloidal dispersion for the treatment of invasive
fungal infections after marrow transplant. J Infect Dis
1996;173(5):1208–15.
     45B B & M T
182. Kruger W, Stockschlader M, Russman B, et al. Experience with
liposomal amphotericin-B in 60 patients undergoing high-dose therapy
and bone marrow or peripheral blood stem cell transplantation. Br J
Haematol 1995;91(3):684–90.
183. Ringdén O, Tollemar J, Dahllof G, Tyden G. High cure rate of invasive
fungal infections in immunocompromised children using AmBisome.
Transplant Proc 1994;26(1):175–7.
184. Andstrom EE, Ringdén O, Remberger M, Svahn BM, Tollemar J. Safety
and efficacy of liposomal amphotericin B in allogeneic bone marrow
transplant recipients. Mycoses 1996;39(5–6):185–93.
185. O’Donnell MR, Schmidt GM, Tegtmeier BR, et al. Prediction of
systemic fungal infection in allogeneic marrow recipients: impact of
amphotericin prophylaxis in high-risk patients. J Clin Oncol
1994;12(4):827–34.
186. Rousey SR, Russler S, Gottlieb M, Ash RC. Low-dose amphotericin B
prophylaxis against invasive Aspergillus  infections in allogeneic marrow
transplantation. Am J Med 1991;91(5):484–92.
187. Perfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous
amphotericin B in neutropenic autologous bone marrow transplant
recipients. J Infect Dis 1992;165(5):891–7.
188. Wade JC. Chapter 5: epidemiology of Candida  infections. In: Bodey
GP, ed. Candidiasis: pathogenesis, diagnosis and treatment. New York,
NY: Raven Press, Ltd., 1993:85–107.
189. Tollemar J, Ringdén O, Andersson S, et al. Prophylactic use of liposomal
amphotericin B (AmBisome) against fungal infections: a randomized
trial in bone marrow transplant recipients. Transplant Proc 1993;25(1
part 2):1495–7.
190. Conneally E, Cafferkey MT, Daly PA, Keane CT, McCann SR. Nebulized
amphotericin B as prophylaxis against invasive aspergillosis in
granulocytopenic patients. Bone Marrow Transplant 1990;5(6):403–6.
191. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy.
Ann of Pharmacother 1992;26(4):502–9.
192. Jennings TS, Hardin TC. Treatment of aspergillosis with itraconazole
[Review]. Annals of Pharmacother 1993;27(10):1206–11.
193. Poirier JM, Berlioz F, Isnard F, Chrymol G. Marked intra- and inter-
patient variability of itraconazole steady state plasma concentrations.
Thérapie 1996;51(2):163–7.
194. Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA.
Multiple dose pharmacokinetics of an oral solution of itraconazole in
autologous bone marrow transplant recipients. J Antimicrob
Chemother 1994;34(2):247–52.
195. Tam JY, Hamed KA, Blume K, Prober CG. Use of itraconazole in
treatment of prevention of invasive aspergillosis in bone marrow
transplant recipients [Abstract 813]. 33rd Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC), New
Orleans, LA, 1993;268.
196. Ortho Biotech, Inc. Itraconazole. In: Physician’s desk reference (PDR),
Montvale, NJ: Medical Economics Company, 2000:2131–4.
197. Denning DW. Invasive aspergillosis [Review]. Clin Infect Dis
1998;26(4):781–803; quiz 804–5.
198. McWhinney PHM, Kibbler CC, Hamon MD, et al. Progress in
the diagnosis and management of aspergillosis in bone marrow
transplantation: 13 years’ experience. Clin Infect Dis
1993;17(3):397–404.
199. Lupinetti FM, Behrendt DM, Giller RH, Trigg ME, de Alarcon
P. Pulmonary resection for fungal infection in children undergoing
bone marrow transplantation. J Thorac Cardiovasc Surg
1992;104(3):684–7.
200. Richard C, Romon I, Baro J, et al. Invasive pulmonary aspergillosis
prior to BMT in acute leukemia patients does not predict a poor
outcome. Bone Marrow Transplant 1993;12(3):237–41.
PROTOZOAL AND HELMINTHIC INFECTIONS
201. Brazinsky JH, Phillips JE. Pneumocystis pneumonia transmission
between patients with lymphoma. JAMA 1969;209(10):1527.
202. Chave JP, David S, Wauters JP, Van Meller G, Francioli P. Transmission
of Pneumocystic carinii  from AIDS patients to other immunosuppressed
patients: a cluster of Pneumo-cystis carinii  pneumonia in renal transplant
patients. AIDS 1991;5(8):927–32.
203. Goesch TR, Götz G, Stellbrinck KH, Albrecht H. Weh HJ, Hossfeld
DK. Possible transfer of Pneumocystis carinii  between immunodeficient
patients [Letter]. Lancet 1990;336(8715): 627.
204. Bensousan T, Garo B, Islam S, Bourbigot B, Cledes J, Garre M. Possible
transfer of Pneumocystic carinii  between kidney transplant recipients
[Letter]. Lancet 1990;336(8722):1066–7.
205. Ruskin J, Remington JS. Compromised host and infection. I:
Pneumocystic carinii  pneumonia. JAMA 1967;202(12):1070–4.
206. Watanabe JM, Chinchinian H, Weitz C, McIlvanie SK. Pneumocystis
carinii  pneumonia in a family. JAMA 1965;193(8):685–6.
207. Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii  pneumonitis
following bone marrow transplantation. Bone Marrow Transplant
1992;10(3):267–72.
208. Maltezou HC, Petropoulos D, Choroszy M, et al. Dapsone for Pneumocystic
carinii  prophylaxis in children undergoing bone marrow transplantation
[Review]. Bone Marrow Transplant 1997;20(10):879–81.
209. Link H, Vöhringer H-F, Wingen F, Bragas B, Schwardt A, Ehninger
G. Pentamidine aerosol prophylaxis of Pneumocystis carinii  pneumonia
after BMT. Bone Marrow Transplant 1993;11(5):403–6.
210. Chan C, Montaner J, Lefebvre EA, et al. Atovaquone suspension
compared with aerosolized pentamidine for prevention of Pneumocystis
carinii  pneumonia in human immuno-deficiency virus-infected subjects
intolerant of trimethoprim or sulfonamides. J Infect Dis
1999;180(2):369–76.
211. Nunn PP, Allistone JC. Resistance to trimethoprim-sulfamethoxazole
in the treatment of Pneumocystis carinii  pneumonia: implication of folinic
acid. Chest 1984;86(1):149–50.
212. Safrin S, Lee BL, Sande MA. Adjunctive folinic acid with trimethoprim-
sulfamethoxazole for Pneumocystic carinii  pneumonia in AIDS patients
is associated with an increased risk of therapeutic failure and death. J
Infect Dis 1994;170(4):912–7.
213. Martino R, Martínez, Brunet S, Sureda A. Successful bone marrow
transplantation in patients with recent Pneumocystis carinii
pneumonia: report of two cases [Letter]. Bone Marrow Transplant
1995;16(3):491.
214. Castagnola E, Dini G, Lanino E, et al. Low CD4 lymphocyte count
in a patient with P. carinii  pneumonia after autologous bone marrow
transplantation. Bone Marrow Transplant 1995;15(16):977–8.
215. Derouin F, Devergie A, Auber P, et al. Toxoplasmosis in bone
marrow transplant recipients: report of seven cases and review
[Review]. Clin Infect Dis 1992;15(2):267–70.
216. Koneru B, Anaissie E, Tricot G, et al. High incidence of and
mortality from Toxoplasma gondii  infections in T-cell depleted
allogeneic bone marrow transplant recipients [Abstract 987]. 39th
Annual American Society of Hematology Meeting, San Diego, CA,
December 5–9, 1997;224A.
217. Siegel SE, Lunde MN, Gelderman AH, et al. Transmission of
toxoplasmosis by leukocyte transfusion. Blood 1971;37(4):388–94.
218. Slavin MA, Meyers JD, Remington JS, Hackman RC. Toxoplasma
gondii  infection in marrow transplant recipients: a 20 year
experience. Bone Marrow Transplant 1994;13(5): 549–57.
219. Jurges E, Young Y, Eltumi M, et al. Transmission of toxoplasmosis
by bone marrow transplant associated with Campath-1G. Bone
Marrow Transplant 1992;9(1):65–6.
46
220. Chandrasekar PH, Momin F, Bone Marrow Transplant Team.
Disseminated toxoplasmosis in marrow recipients: a report of three
cases and a review of the literature. Bone Marrow Transplant
1997;19(7):685–9.
221. Foot ABM, Garin YJF, Ribaud P, Devergie A, Derouin F, Gluckman
E. Prophylaxis of toxoplasmosis with pyrimethamine/sulfadoxine
(Fansidar) in bone marrow transplant recipients. Bone Marrow
Transplant 1994;14(2):241–5.
222. Peacock JE Jr, Greven CM, Cruz JM, Hurd DD. Fansidar:
reactivation toxoplasmic retinochoroiditis in patients undergoing
bone marrow transplantation: is there a role for chemoprophylaxis
[Review]? Bone Marrow Transplant 1995;15(6):983–7.
223. Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode
infections [Review]. Infect Dis Clin North Am 1993;7(3):655–82.
224. Conway DJ, Atkins NS, Lillywhite JE, et al. Immunodiagnosis of
Strongyloides stercoralis  infection: a method for increasing the
specificity of the indirect ELISA. Trans R Soc Trop Med Hyg
1993;87(2):173–6.
225. Fishman JA. Pneumocystis carinii  and parasitic infections in the
immunocompromised host. In: Rubin RH, Young LS, eds. Clinical
approach to infection in the compromised host 3rd edition. New
York, NY: Plenum Medical Book Company, 1994;275–334.
226. Fishman JA. Pneumocystis carinii  and parasitic infections in
transplantation. Infect Dis Clin North Am 1995;9(4):1005–44.
227. Leiby DA, Fucci MH, Stumpf RJ. Trypanosoma cruzi  in a low- to
moderate-risk blood donor population: seroprevalence and possible
congenital transmission. Transfusion 1999;39(3):310–5.
228. Dictar M, Sinagra A, Verón MT, et al. Recipients and donors of
bone marrow transplants suffering from Chagas’ disease:
management and preemptive therapy of parasitemia. Bone Marrow
Transplant 1998;21(4):391–3.
229. Moraes-Souza H, Bordin JO. Strategies for prevention of
transfusion-associated Chagas’ disease. Transfus Med Rev
1996;10(3):161–70.
230. Altclas J, Sinagra A, Jaimovich G, et al. Reactivation of chronic
Chagas’ disease following allogeneic bone marrow transplantation
and successful pre-emptive therapy with benznidazole. Transplant
Infectious Disease 1999;1:135–7.
231. Altclas J, Jaimovich G, Milovic V, Klein F, Feldman L. Chagas’
disease after bone marrow transplantation. Bone Marrow Transplant
1996;18(2):447–8.
HOSPITAL INFECTION CONTROL
232. Streifel AJ. Chapter 80: design and maintenance of hospital
ventilation systems and the prevention of airborne nosocomial
infections. In: Mayhall CG, ed. Hospital epidemiology and infection
control. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins
1999;1211–21.
233. Streifel AJ, Marshall JW. Parameters for ventilation controlled
environments in hospitals. In: Moschandreas DJ, ed. Design,
construction, and operation of healthy buildings; solutions to global
and regional concerns. Atlanta, GA: American Society of Heating,
Refrigerating and Air-Conditioning Engineers Press, 1998;305–9.
234. Barnes RA, Rogers TR. Control of an outbreak of nosocomial
aspergillosis by laminar airflow isolation. J Hosp Infect
1989;14(2):89–94.
235. Sheretz FJ, Belani A, Kramer BS, et al. Impact of air filtration on
nosocomial Aspergillus  infections: unique risk to bone marrow
transplant recipients. Am J Med 1987;83(4):709–18.
236. Walter EA, Bowden RA. Infection in the bone marrow transplant
recipient [Review]. Infect Dis Clin North Am 1995;9(4):823–47.
237. Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease
and survival in patients with aplastic anemia treated by marrow grafts
from HLA-identical siblings. N Engl J Med 1983;308(6):302–7.
238. Streifel AJ. Maintenance and engineering; biomedical engineering;
support services and facilities management. In: Association for
Professionals in Infection Control and Epidemiology, Inc. Principles
and practice. 2nd ed. St. Louis, MO: Mosby, 2000 (in press).
239. Vesley D, Streifel AJ. Chapter 69: environmental services. In:
Mayhall CG, ed. Hospital epidemiology and infection control.
2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins,
1999;1047–53.
240. Carter CD, Barr BA. Infection control issues in construction and
renovation. Infect Control Hosp Epidemiol 1997;18(8):587–96.
241. Loo VG, Bertrand C, Dixon C, et al. Control of construction-
associated nosocomial aspergillosis in an antiquated hematology
unit. Infect Control Hospital Epidemiol 1996;17(6):360–4.
242. Rask DR, Dziekan B, Swincicki WC, et al. Air quality control
during renovation in health care facilities. In: Moschandreas DJ,
ed. Design, construction, and operation of healthy buildings;
solutions to global and regional concerns. Atlanta, GA: American
Society of Heating, Refrigerating, and Air-Conditioning Engineers
Press, 1998:291–304.
243. CDC. Laboratory performance evaluation of N95 filtering facepiece
respirators, 1996. MMWR 1998;47(48):1045–9.
244. CDC. Guidelines for preventing the transmission Mycobacterium
tuberculosis  in health- care facilities, 1994. MMWR 1994;43(No.
RR-13):1–132.
245. CDC/National Institute of Occupational Safety and Health. Protect
yourself against tuberculosis—a respiratory protection guide for
health care workers. Cincinnati, OH: US Department of Health
and Human Services, US Public Health Service, CDC, National
Institute for Occupational Health and Safety, 1995; DHHS
publication no. (NIOSH) 96-102:1–132. Available at <http://
www.cdc.gov/niosh>. Accessed May 15, 2000.
246. Rutala WA. APIC guideline for selection and use of disinfectants.
Am J Infect Control 1996;24(4):313–42.
247. National Antimicrobial Information Network. List of EPA
registered products. Available at <http://ace.orst.edu/info/nain/
lists.htm>. Accessed May 15, 2000.
248. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR,
Hospital Infection Control Practices Advisory Committee.
Guideline for prevention of surgical site infection, 1999. Infect
Control Hosp Epidemiol 1999;20(4):247–80 or Am J Infect
Control 1999;27(2):97–134.
249. Garner JS, Favero MS. Guideline for handwashing and
hospital environmental control, 1985; supersedes guideline for
hospital environmental control published in 1981. Available at
<http://www.cdc.gov/ncidod/hip/Guide/handwash.htm>.
Accessed May 15, 2000.
250. Rotter ML. Chapter 87: hand washing and hand disinfection. In:
Mayhall CG, ed. Hospital epidemiology and infection control. 2nd ed.
Baltimore, MD: Lippincott Williams and Wilkins, 1999:1339–55.
251. Larson EL. APIC guideline for handwashing and hand antisepsis
in health care settings. Am J Infect Control 1995;23(4):251–69.
252. McNeil SA, Foster CL, Kauffman CA. Effect of hand cleansing
with antimicrobial soap gel on microbial colonization of artificial
nails (AN) [Abstract 1696]. 39th Interscience Conference on
Antimicrobial Agents and Chemotherapy Abstracts, San Francisco,
CA, 1999;635.
253. CDC/National Center for Infectious Diseases/Hospital Infections
Program. Sterilization or disinfection of medical devices: general
     47B B & M T
principles. Atlanta, GA: US Department of Health and Human
Services, CDC, 2000. Available at <http://www.cdc.gov/ncidod/hip/
sterile/sterilgp.htm>. Accessed May 15, 2000.
254. Favero MS, Bond WW. Chapter 24: sterilization, disinfection, and
antisepsis in the hospital. In: Hauser WJ Jr, Herrmann KL, Isenberg
HD, Shadomy HJ, eds. Manual of clinical microbiology. Washington
DC: American Society for Microbiology, 1991:183–200.
255. Johnson S, Gerding DN. Chapter 29: Clostridium difficile. In: Mayhall
CG, ed. Hospital epidemiology and infection control. 2nd ed.,
Philadelphia, PA: Lippincott Williams & Wilkins, 1999:467–76.
256. Rutala WA, Weber DJ. Disinfection of endoscopes: review of new
chemical sterilants used for high-level disinfection. Infect Control
and Hospital Epidemiol 1999;20(1):69–75; published erratum, Infect
Control Hosp Epidemiol 1999;20(5):302.
257. CDC. Nosocomial outbreak of Rhizopus  infections associated with
Elastoplast® wound dressings—Minnesota. MMWR 1978;27(5):33–4.
258. CDC. Follow-up on Rhizopus  infections associated with Elastoplast®
bandages—United States. MMWR 1978;27(28):243–4.
259. Bryce EA, Walker M, Scharf S, et al. Outbreak of cutaneous
aspergillosis in a tertiary-care hospital. Infect Control Hosp
Epidemiol 1996;17(3):170–2.
260. McCarty JM, Flam MS, Pullen G, Jones R, Kassel SH. Outbreak of
primary cutaneous aspergillosis related to intravenous arm boards.
J Pediatr 1986;108(5 Pt 1):721–4.
261. Mitchell SJ, Gray J, Morgan MEI, Hocking MC, Durbin GM.
Nosocomial infection with Rhizopus microsporus  in preterm infants:
association with wooden tongue depressors. Lancet
1996;348(9025):441–3.
262. Gerson SL, Parker P, Jacobs MR, Creger R, Lazarus HM.
Aspergillosis due to carpet contamination [Letter]. Infect Control
Hosp Epidemiol 1994;15(4 Pt 1):221–3.
263. Richet H, McNeil M, Pewters W, et al. Aspergillus flavus  in a bone
marrow transplant unit (BMTU): pseudofungemia traced to hallway
carpeting [Abstract F-23]. 89th Annual Meeting of the American
Society for Microbiology, New Orleans, Louisiana, May 14–18,
1989:462.
264. Staib F. Ecological and epidemiological aspects of Aspergilli
pathogenic for man and animal in Berlin (West). Zentrablatt fur
Bakteriologie, Mikrobiologie, und Hygiene—Series A
1984;257(2):240–5.
265. CDC. ABCs of safe and healthy child care: an on-line handbook
for child care providers. Atlanta, GA: US Department of Health
and Human Services, CDC, 2000. Available at <http://www.cdc.gov/
ncidod/hip/ABC/abc.htm>. Accessed May 15, 2000.
266. Buttery JP, Alabaster SJ, Heine RG, et al. Multiresistant Pseudomonas
aeruginosa  outbreak in a pediatric oncology ward related to bath
toys. Pediatr Infect Dis J 1998;17(6):509–13.
267. CDC. Immunization of health care workers: recommendations of
the Advisory Committee on Immunization Practices (ACIP) and
the Hospital Infection Control Practices Advisory Committee.
MMWR 1997;46(No. RR-18):1–42.
268. Bolyard EA, Tablan OC, Williams WW, et al. Guideline for
infection control in health care personnel. Infect Control Hospital
Epidemiol 1998;19(6):407–63.
269. Stover BH, Bratcher DF. Varicella-zoster virus: infection, control,
and prevention [Review]. Am J Infect Control 1998;26(3):369–83;
quiz 382–4.
270. Schubert MM, Peterson DE, Lloid ME. Oral complications. In:
Thomas ED, Blume KG, Forman SJ, eds. Hematopoietic cell
transplantation. 2nd ed. Oxford, England: Blackwell Science, Inc.,
1999;751–63.
271. Wilkes JD. Prevention and treatment of oral mucositis following
cancer chemotherapy [Review]. Semin Oncol 1998;25(5):538–51.
272. Toscano CM, Bell M, Zukerman C, et al. Bloodstream infections
(BSI) associated with needleless device use, bathing practices and
home infusion [Poster abstract P3]. 48th Annual Epidemic
Intelligence Service Conference, April 19–23, 1999, Atlanta, GA;47.
273. Do AN, Ray BJ, Banerjee SN, et al. Bloodstream infection associated
with needleless device use and the importance of infection-control
practices in the home health care setting. J Infect Dis
1999;179(2):442–8.
274. Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of
unrecognized nosocomial transmission of Legionnaires’ disease
among transplant patients. Infect Control Hosp Epidemiol
1998;19(12):898–904.
275. CDC. Sustained transmission of nosocomial Legionnaires’ disease—
Arizona and Ohio. MMWR 1997;46(19):416–21.
276. Lepine LA, Jernigan DB, Butler JC, et al. Recurrent outbreak of
nosocomial Legionnaires’ disease detected by urinary antigen
testing: evidence for long-term colonization of a hospital plumbing
system. Infect Control Hosp Epidemiol 1998;19(12):905–10.
277. Muraca PW, Yu VL, Goetz A. Disinfection of water distribution
systems for Legionella : a review of application procedures and
methodologies [Review]. Infect Control Hosp Epidemiol
1990;11(2):79–88.
278. Harbarth S, Dharan S, Liassine N, Herrault P, Auckenthaler R,
Pittet D. Randomized, placebo-controlled, double-blind trial to
evaluate the efficacy of mupirocin for eradicating carriage of
methicillin-resistant Staphylococcus aureus . Antimicrob Agents
Chemother 1999;43(6):1412–6.
279. Leski TA, Gniadkowski M, Skoczynska A, Stefaniuk E, Trzcinski
K, Hryniewicz W. Outbreak of mupirocin-resistant Staphylococci  in
a hospital in Warsaw, Poland, due to plasmid transmission and clonal
spread of several strains. J Clin Microbiol 1999;37(9):2781–8.
280. Schmitz FJ, Lindenlauf E, Hofmann B, et al. Prevalence of low-
and high-level mupirocin resistance in Staphylococci  from 19
European hospitals. J Antimicrob Chemother 1998;42(4):489–95.
281. Irish D, Eltringham I, Teall A, et al. Control of an outbreak of an
epidemic methicillin-resistant Staphylococcus aureus  also resistant to
mupirocin. J Hosp Infect 1998;39(1):19–26.
282. Udo EE, Farook VS, Mokadas EM, Jacob LE, Sanyal SC. Molecular
fingerprinting of mupirocin-resistant methicillin-resistant
Staphylococcus aureus  from a burn unit. Int J Infect Dis 1998–
99;3(2):82–7.
283. Bastos MC, Mondino PJ, Azevedo ML, Santos KR, Giambiagi-
deMarval M. Molecular characterization and transfer among
Staphylococcus  strains of a plasmid conferring high-level resistance
to mupirocin. Eur J Clin Microbiol Infect Dis 1999;18(6):393–8.
284. CDC. Recommendations for preventing the spread of vancomycin
resistance: recommendations of the Hospital Infection Control
Practices Advisory Committee (HICPAC). MMWR 1995;44(No.
RR-12):1–13.
285. CDC. Update: Staphylococcus aureus  with reduced susceptibility to
vancomycin—United States, 1997. MMWR 1997;46(35):813–5.
286. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of
vancomycin resistance in Staphylococcus aureus. N Engl J Med
1999;340(7):493–501.
287. CDC. Interim guidelines for prevention and control of
staphylococcal infection associated with reduced susceptibility to
vancomycin. MMWR 1997;46(27):626–35.
288. CDC. Reduced susceptibility of Staphylococcus aureus  to
vancomycin—Japan, 1996. MMWR 1997;46(27):624–35.
48
289. Waldvogel FA. New resistance in Staphylococcus aureus. N Engl J
Med 1999;340(7):556–7.
290. Montecalvo MA, Shay DK, Patel P, et al. Bloodstream infections
with vancomycin-resistant Enterococci . Arch Intern Med
1996;156:1458–62.
291. Hospital Infection Control Practices Advisory Committee
(HICPAC). Recommendations for preventing the spread of
vancomycin resistance. Infect Control Hosp Epidemiol
1995;16:105–13.
292. Kirkpatrick BD, Harrington SM, Smith D, et al. Outbreak of
vancomycin-dependent Enterococcus faecium  in a bone marrow
transplant unit. Clin Infect Dis 1999;29(5):1268–73.
293. Byers KE, Durbin LJ, Simonton BM, Anglim AM, Adel KA, Farr
BM. Disinfection of hospital rooms contaminated with vancomycin-
resistant Enterococcus faecium. Infect Control Hosp Epidemiol
1998;19(4):261–4.
294. Trick WE, Kuehnert MJ, Quirk SB, et al. Regional dissemination
of vancomycin-resistant Enterococci  resulting from interfacility
transfer of colonized patients. J Infect Dis 1999;180(2):391–6.
295. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr.
Clostridium difficile-associated diarrhea and colitis [Review]. Infect
Control Hosp Epidemiol 1995;16(8):459–77.
296. Johnson S, Gerding DN. Clostridium difficile-associated diarrhea.
Clin Infect Dis 1998;26:1027–36; quiz 1035–6.
297. McFarland LV, Mulligan M, Kwok RY, Stamm WE. Nosocomial
acquisition of Clostridium difficile  infection. N Engl J Med
1989;321(3):204–10.
298. Johnson S, Gerding DN, Olson MM, et al. Prospective, controlled
study of vinyl glove use to interrupt Clostridium difficile  nosocomial
transmission. Am J Med 1990;88(2):137–40.
299. Pear SM, Williamson T, Bettin K, Gerding DN, Galgiami JN.
Decrease in nosocomial Clostridium difficile-associated diarrhea by
restricting clindamycin use. Ann Intern Med 1994;120(4):272–7.
300. Kaatz GW, Gitlin SD, Schaberg DR et al. Acquisition of Clostridium
difficile  from the hospital environment. Am J Epidemiol
1988;127(6):1289–94.
301. Delmee M, Vandercam B, Avesani V, Michaux JL. Epidemiology
and prevention of Clostridium difficile  infections in a leukemia unit.
Eur J Clin Microbiol 1987;6(6):623–7.
302. Johnson S, Homann SR, Bettin KM, et al. Treatment of asymptomatic
Clostridium difficile  carriers (fecal excretors) with vancomycin or
metronidazole. Ann Intern Med 1992;117(4):297–302.
303. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J,
Van Belle G. Prevention of antibiotic associated diarrhea by
Saccharomyces boulardii: a prospective study. Gastroenterology
1989;96(4):981–8.
304. Niault M, Thomas F, Prost J, Ansai FH, Kalfon P. Fungemia due to
Saccharomyces  species in a patient treated with enteral Saccharomyces
boulardii. Clin Infect Dis 1999;28:930.
305. Fox JP, Brandt CD, Wasserman FE, et al. Virus watch program: a
continuing surveillance of viral infections in metropolitan New
York families. VI: observations of adenovirus infections: virus
excretion patterns, antibody response, efficacy of surveillance,
patterns of infections, and relation to illness. Am J Epidemiol
1969;89(1):25–50.
306. Hillis WO, Cooper MR, Bang FB. Adenovirus infection in West
Bengal. I: persistence of viruses in infants and young children. Indian
J Med Res 1973;61(7):980–8.
307. Hall CB, Powell KR, MacDonald DE, et al. Respiratory syncytial
virus infection in children with compromised immune function. New
Engl J Med 1986;315(2):77–81.
308. Villarino ME, Burman W, Wang YC, et al. Comparable specificity
of 2 commercial tuberculin reagents in persons at low risk for
tuberculous infection. JAMA 1999;281(2):169–71.
309. American Thoracic Society/CDC. Targeted tuberculin testing and
treatment of latent tuberculosis infection. Am J Respir Crit Care
Med 2000;161(4, part 2):S221–47.
310. American Academy of Pediatrics. Tuberculosis. In: Pickering LK,
ed. 2000 red book: report of the Committee on Infectious Diseases.
25th ed. Elk Grove Village, IL: American Academy of
Pediatrics;2000:593–613.
311. CDC. Notice to readers: use of short-course tuberculosis preventive
therapy regimens in HIV-seronegative persons. MMWR
1998;47(42):911–2.
312. Fennelly KP. Transmission of tuberculosis during medical
procedures [Letter]. Clin Infect Dis 1997;25:1273–5.
313. Talbot EA, Perkins MD, Silva SFM, Frothingham R. Disseminated
Bacille Calmette-Guérin disease after vaccination: case report and
review. Clin Infect Dis 1997;24(6):1139–46.
314. CDC. Role of BCG vaccine in the prevention and control of
tuberculosis in the United States: a joint statement by the
Advisory Council for the Elimination of Tuberculosis and the
Advisory Committee on Immunization Practices. MMWR
1996;45(No. RR-4):13.
315. Gaynes RP, Horan TC. Chapter 85: surveillance of nosocomial
infections. In: Mayhall CG, ed. Hospital epidemiology and infection
control. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins,
1999:1285–317.
STRATEGIES FOR SAFE LIVING AFTER HSCT —
PREVENTION OF EXPOSURE AND DISEASE
316. CDC/National Center for Infectious Diseases/Working Group
on Waterborne Cryptosporidiosis. Cryptosporidium and water:
a public health handbook. Atlanta, GA: US Department of
Health and Human Services, CDC, 1997. Available at <http://
www.cdc.gov/ncidod/diseases/crypto/crypto.pdf>. Accessed
May 15, 2000.
317. CDC/National  Center  for  Infect ious  Diseases .
Cryptosporidiosis [Fact sheet]. Atlanta, GA: US Department
of Health and Human Services, CDC, 1999. Available at <http:/
/www.cdc.gov/ncidod/dpd/paras i tes/cryptosporidios is/
factsht_cryptosporidiosis.htm>. Accessed May 15, 2000.
318. American Academy of Pediatrics. Cryptosporidiosis. In: Pickering
LK, ed. 2000 red book: report of the Committee on Infectious
Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics 2000:223–4.
319. American Public Health Association. Cryptosporidiosis. In: Chin J,
ed. Control of communicable diseases manual. 17th ed. Washington,
DC: American Public Health Association, 2000:134–7.
320. DiFranza JR, Lew RA. Morbidity and mortality in children
associated with the use of tobacco products by other people.
Pediatrics 1996;97(4):560–8.
321. Cohen S, Tyrrell DA, Russell MA, Jarvis MJ, Smith AP. Smoking,
alcohol consumption, and susceptibility to the common cold. Am J
Pub Health 1993;83(9):1277–83.
322. Fischer M, Hedberg K, Cardosi P, et al. Tobacco smoke as a risk
factor for meningococcal  disease.  Pediatr Infect Dis J
1997;16:979–83.
323. Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for
acquiring pneumococcal infections. Arch Intern Med
1986;146:2179–85.
     49B B & M T
324. Hall CB, Hall WJ, Gala CL, MaGill FB, Leddy JP. Long-term
prospective study in children after respiratory syncytial virus
infection. J Pediatr 1984;105(3):358–64.
325. Nuorti JP, Butler JC, Farley MM, et al. Cigarette smoking and
invasive pneumococcal disease. New Engl J Med
2000;342(10):681–9.
326. Levitz SM, Diamond RD. Aspergillosis and marijuana [Letter]. Ann
Intern Med 1991;115(7):578–9.
327. Marks WH, Florence L, Lieberman J, et al. Successfully treated
invasive pulmonary aspergillosis associated with smoking marijuana
in a renal transplant recipient [Review]. Transplant
1996;61(12):1771–4.
328. Chusid MJ, Gelfand JA, Nutter C, Fauci AS. Letter: pulmonary
aspergillosis, inhalation of contaminated marijuana smoke, chronic
granulomatous disease. Ann Intern Med 1975;82(5):682–3.
329. Hamadeh R, Ardehali A, Locksley RM, York MK. Fatal aspergillosis
associated with smoking contaminated marijuana in a marrow
transplant recipient. Chest 1988;94(2):432–3.
330. Kurup VP, Resnick A, Kagen SL, Cohen SH, Fink JN. Allergenic
fungi and actinomycetes in smoking materials and their health
implications. Mycopathologia 1983;82(1):61–4.
331. Kagen SL. Aspergillus : an inhalable contaminant of marihuana. N
Engl J Med 1981;304(8):483–4.
332. Schwartz IS. Marijuana and fungal infection [Letter]. Am J Clin
Pathol 1985;84(2):256.
333. Schwartz IS. Non-Aspergillus  sinusitis and marijuana use [Letter].
Am J Clin Pathol 1992;97(4):601–2.
334. Llamas R, Hart R, Schneider NS. Allergic bronchopulmonary
aspergillosis associated with smoking moldy marihuana. Chest
1978;73(6):871–2.
335. Angulo FJ, Glaser CA, Juranek DD, Lappin MR, Regnery RL.
Caring for pets of immunocompromised persons. J Am Vet Med
Assoc 1994;205(12):1711–8.
336. Elliott DL, Tolle SW, Goldberg L, Miller JB. Pet-associated illness.
New Engl J Med 1985;313(16):985–94.
337. Glaser CA, Angulo FJ, Rooney JA. Animal-associated opportunistic
infections among persons infected with the human
immunodeficiency virus. Clin Infect Dis 1994;18:14–24.
338. Adams RM. Animals in schools: a zoonosis threat? Pediatr Infect
Dis J 1998;17(2):174–6.
339. Dalton C, Hoffman R, Pape J. Iguana-associated salmonellosis in
children. Pediatr Infect Dis J 1995;14(4):319–20.
340. CDC. Reptile-associated salmonellosis—selected states, 1996–1998.
MMWR 1999;48(44):1009–13.
341. CDC. Errata: Reptile-associated salmonellosis—selected states,
1996–1998. MMWR 1999;48(45):1051.
342. Mermin J, Hoar B, Angulo FJ. Iguanas and Salmonella marina
infection in children: a reflection of the increasing incidence of
reptile-associated salmonellosis in the United States. Pediatr
1997;99(3):399–402.
343. CDC. Salmonellosis associated with chicks and ducklings—
Michigan and Missouri, Spring 1999. MMWR 2000;49(14):297–9.
344. CDC. Lake-associated outbreak of Escherichia coli  O157:H7—
Illinois, 1995. MMWR 1996;45(21):437–9.
345. CDC. Outbreak of cryptosporidiosis associated with a water
sprinkler foundation—Minnesota, 1997. MMWR
1998;47(40):856–60.
346. Kramer MH, Sorhage FE, Goldstein ST, Dalley E, Wahlquist SP,
Herwaldt BL. First reported outbreak in the United States of
cryptosporidiosis associated with a recreational lake. Clin Infect Dis
1998;26(1):27–33.
347. al-Eissa YA, Kambal AM, al-Nasser MN, al-Habib SA, al-Fawaz
IM, al-Zamil FA. Childhood brucellosis: a study of 102 cases. Pediatr
Infect Dis J 1990;9(2):74–9.
348. Keene WE, Hedberg K, Herriott DE, et al. Prolonged outbreak of
Escherichia coli  O157:H7 infections caused by commercially
distributed raw milk. J Infect Dis 1997;176(3):815–8.
349. CDC. Outbreak of Escherichia coli  O157:H7 infections associated
with drinking unpasteurized commercial apple juice—British
Columbia, California, Colorado, and Washington, October 1996.
MMWR 1996;45(44):975.
350. CDC. Outbreaks of Escherichia coli  O157:H7 infection and
cryptosporidiosis associated with drinking unpasteurized apple
cider—Connecticut and New York, October 1996. MMWR
1997;46(1):4–8.
351. CDC. Outbreak of Salmonella  serotype Muenchen infections
associated with unpasteurized orange juice—United States and
Canada, June 1999. MMWR 1999;48(27): 582–5.
352. CDC/National Center for Infectious Diseases. Handle and prepare
food safely. Atlanta, GA: US Department of Health and Human
Services, CDC, 2000. Available at <http://www.cdc.gov/ncidod/op/
food.htm>. Accessed May 15, 2000.
353. CDC. Outbreak of Campylobacter  enteritis associated with cross-
contamination of food—Oklahoma, 1996. MMWR 1998;47(7):129–31.
354. CDC. Outbreaks of Salmonella  serotype enteritidis infection
associated with consumption of raw shell eggs—United States, 1994–
1995. MMWR 1996;45(34):737–42.
355. CDC. Foodborne outbreak of cryptosporidiosis—Spokane,
Washington, 1997. MMWR 1998;47(27):565–7.
356. US Department of Agriculture/Food Safety and Inspection
Service. Big thaw—safe defrosting methods. Washington, DC: US
Department of Agriculture, Food Safety and Inspection Service,
Consumer Education and Information, 1996;1–2. Available at
<http://www.fsis.usda.gov/OA/news/bigthaw.htm>. Accessed May
15, 2000.
357. US Department of Agriculture/Food Safety and Inspection Service.
Kitchen thermometers. Washington, DC: US Department of
Agriculture Consumer, Food Safety and Inspection Service,
Education and Information, 2000 (in press).
358. Moe GL. Chapter 12: low-microbial diets for patients with
granulocytopenia. In: Bloch AS, ed. Nutrition management of
the cancer patient. Rockville, MD: Aspen Publishing, Inc.,
1990:125–34.
359. Aker SN, Lenssen P. Chapter 80: nutritional support of patients
with hematologic malignancies. In: Benz EJ Jr, Cohen HJ, Burie B,
et al., eds. Hematology: basic principles and practice, 3rd ed. New
York, NY: Churchill Livingstone, 2000:1501–14.
360. Hilton E, Isenberg HD, Alperstein P, France K, Borenstein MT.
Ingestion of yogurt containing Lactobacillus acidophilus  as prophylaxis
for candidal vaginitis. Ann Intern Med 1992;116(5):353–7.
361. CDC. Vibrio vulnificus  infections associated with eating raw
oysters—Los Angeles, 1996. MMWR 1996;45(29):621–4.
362. CDC. Outbreak of Vibrio parahaemolyticus  infection associated with
eating raw oysters and clams harvested from Long Island Sound—
Connecticut, New Jersey, and New York, 1998. MMWR
1999;48(03):48–51.
363. CDC. Viral gastroenteritis associated with eating oysters—
Louisiana, December 1996–January 1997. MMWR
1997;46(47):1109–12.
364. Fayer R, Lewis EJ, Trout JM, et al. Cryptosporidium parvum  in
oysters from commercial harvesting sites in Chesapeake Bay. Emerg
Infect Dis 1999;5(5):706–10.
50
365. Oliver MR, van Voorhis WC, Boeckh M, Mattson D, Bowden RA.
Hepatic mucormycosis in a bone marrow transplant recipient who
ingested naturopathic medicine. Clin Infect Dis 1996;22:521–4.
366. CDC. Health Information for international travel 1999–2000.
Atlanta, GA: US Department of Health and Human Services, CDC,
1999. Available at <http://www.cdc.gov/travel/yellowbk99.pdf>.
Accessed May 16, 2000.
367. World Health Organization. Guide on safe food for travelers.
Geneva, Switzerland: World Health Organization, 1997:1–4.
Available at <http://www.who.int/dsa/cat98/trav8.htm>. Accessed
May 15, 2000.
368. CDC/National Center for Infectious Diseases. Food and water
precautions and traveler’s diarrhea prevention. Atlanta, GA: US
Department of Health and Human Services, CDC, 2000;1–2.
Available at <http://www.cdc.gov/travel/foodwatr.htm>. Accessed
May 15, 2000.
369. Belay E, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger
LB. Reye’s syndrome in the United States from 1981 through 1997.
New Engl J Med 1999;340(18):1377–82.
HSCT RECIPIENT VACCINATIONS
370. Pauksen K, Hammarström V, Ljungman P, et al. Immunity to
poliovirus and immunization with inactivated poliovirus vaccine after
autologous bone marrow transplantation. Clin Infect Dis
1994;18(4):547–52.
371. Pauksen K, Duraj V, Ljungman P, et al. Immunity to and
immunization against measles, rubella and mumps in patients after
autologous bone marrow transplantation. Bone Marrow Transplant
1992;9(6):427–32.
372. Ljungman P, Wiklund-Hammarsten M, Duraj V, et al. Responses
to tetanus toxoid immunization after allogeneic bone marrow
transplantation. J Infect Dis 1990;162(2):496–500.
373. Ljungman P, Fridell E, Lonnqvist B, et al. Efficacy and safety of
vaccination of marrow transplant recipients with a live attenuated
measles,  mumps, and rubella vaccine.  J  Infect Dis
1989;159(4):610–5.
374. Henning KJ, White MH, Sepkowitz KA, Armstrong D. National
survey of immunization practices following allogeneic bone marrow
transplantation. JAMA 1997;277(14):1148–51.
HEMATOPOIETIC STEM CELL SAFETY
375. Padley D, Koontz F, Trigg ME, Gingrich R, Strauss RG. Bacterial
contamination rates following processing of bone marrow and
peripheral blood progenitor cell preparations. Transfusion
1996;36(1):53–6.
376. National Marrow Donor Program.® Standards: effective September
1, 1999. 17th ed. Minneapolis, MN: National Marrow Donor
Program, 1999:1–35.
377. Progenitor Cell Standards Task Force. Standards for hematopoietic
progenitor cells. Bethesda, MD: American Association of Blood
Banks, 1996:1–36.
378. Foundation for the Accreditation of Hematopoietic Cell Therapy.
Standards for hematopoietic progenitor cell collection, processing
and transplantation. 1st ed.-North America. Omaha, NE: FAHCT
Accreditation Office, 1996:1–58.
379. Food and Drug Administration. Memorandum, June 8, 1995:
recommendations for the deferral of current and recent inmates of
correctional institutions as donors of whole blood, blood
components, source leukocytes, and source plasma. Rockville, MD:
US Department of Health and Human Services, Food and Drug
Administration, 1995. Available at <http://www.fda.gov/cber/
bldmem/6_8_95.txt>. Accessed May 16, 2000.
380. American Association of Blood Banks. New uniform donor history
questionnaire issued [Association bulletin 99-10]. American
Association of Blood Banks News 1999;(Nov/Dec):13–21.
381. CDC. Guidelines for preventing transmission of human
immunodeficiency virus through transplantation of human tissue
and organs. MMWR 1994;43(No. RR-8):1–17.
382. CDC. Public health service inter-agency guidelines for screening
donors of blood, plasma, organs, tissues, and semen for evidence of
hepatitis B and hepatitis C. MMWR 1991;40(No. RR-4):1–17.
383. Food and Drug Administration. Suitability determination for donors
of human cellular and tissue-based products [Proposed rule]. Federal
Register 1999;64:52696–723. Available at <http://www.fda.gov/cber/
rules/suitdonor.pdf>. Accessed May 16, 2000.
384. Wells GM, Woodward TE, Fiset P, Hornick RB. Rocky Mountain spotted
fever caused by blood transfusion. JAMA 1978;239(26):2763–65.
385. Herwaldt BL, Kjemtrup AM, Conrad PA, et al. Transfusion-
transmitted babesiosis in Washington State: first reported case
caused by a WA1-type parasite. J Infect Dis 1997;175(5):1259–62.
386. Dobroszycki J, Herwaldt BL, Boctor F, et al. Cluster of transfusion-
associated babesiosis cases traced to a single asymptomatic donor.
JAMA 1999;281(10):927–30.
387. CDC. Q fever—California. MMWR 1977;26(10):86, 91.
388. CDC. Transmission of Colorado tick fever virus by blood
transfusion—Montana. MMWR 1975;24:422–7.
389. American Association of Blood Banks. Standards for blood banks
and transfusion services. 19th ed. Bethesda, MD: American
Association of Blood Banks, 1999:1–98.
390. Klein MB, Miller JS, Nelson CM, Goodman JL. Primary bone
marrow progenitors of both granulocytic and monocytic lineages
are susceptible to infection with the agent of human granulocytic
ehrlichiosis. J Infect Dis 1997;176(5):1405–9.
391. Dharmasena F, Gordon-Smith EC. Transmission of malaria by bone
marrow transplantation [Letter]. Transplant 1986;42(2):228.
392. Villeneuve L, Cassaing S, Magnaval JF, et al. Plasmodium falciparum
infection following allogeneic bone-marrow transplantation. Ann
Trop Med Parasitol 1999;93(5):533–5.
393. Leiby DA, Lenes BA, Tibbals MA, Tames-Olmedo MT. Prospective
evaluation of a patient with Trypanosoma cruzi  infection transmitted
by transfusion. New Engl J Med 1999; 341(16):1237–9.
394. Leiby DA, Read EJ, Lenes BA, et al. Seroepidemiology of
Trypanosoma cruzi , etiologic agent of Chagas’ disease, in US blood
donors. J Infect Dis 1997;176:1047–52.
395. Dodd RY. Transmission of parasites by blood transfusion [Review].
Vox Sang 1998;74(suppl 2):161–3.
396. Food and Drug Administration. Guidance for industry:
precautionary measures to reduce the possible risk of transmission
of zoonoses by blood and blood products from xenotransplantation
products recipients and their contacts—12/23/99 [Draft guidance].
Rockville, MD: US Department of Health and Human Services,
Food and Drug Administration, 1999;1–11. Available at <http://
www.fda.gov/cber/guidelines.htm>. Accessed May 16, 2000.
397. CDC. Creutzfeldt-Jakob disease associated with cadaveric dura
mater grafts—Japan, January 1979–May 1996. MMWR
1997;46(45):1066–9.
398. Food and Drug Administration. Guidance for industry: revised
precautionary measures to reduce the possible risk of transmission
of Creutzfeldt-Jakob Disease (CJD) and new variant Creutzfeldt-
Jakob disease (nvCJD) by blood and blood products—11/23/99.
Rockville, MD: US Department of Health and Human Services,
     51B B & M T
Food and Drug Administration, 1999;1–16. Available at <http://
www.fda.gov/cber/guidelines.htm>. Accessed May 16, 2000.
399. Will RG, Alpers MP, Dormont D, Schonberger LB, Tateishi J.
Infectious and sporadic prion diseases. In: Prusiner SB, ed. Prion
biology and diseases. Cold Spring Harbor, NY: Cold Spring
Harbor Laboratory Press, 1999:465–507.
400. Food and Drug Administration. Memorandum, April 23, 1992:
revised recommendations for the prevention of Human
Immunodeficiency Virus (HIV) transmission by blood and blood
products. Rockville, MD: US Department of Health and Human
Services, Food and Drug Administration, 1992:1–24. Available
at <http://www.fda.gov/cber/memo.htm>. Accessed May 16,
2000.
401. Pugatch D, Mileno M, Rich JD. Possible transmission of human
immunodeficiency virus type 1 from body piercing. Clin Infect
Dis 1998;26(3):767–8.
402. CDC. 1995 revised guidelines for prophylaxis against Pneumocystic
carinii  pneumonia for children infected with or perinatally
exposed to human immunodeficiency virus. MMWR 1995;44(No.
RR-4):1–11.
403. Attarian H, Bensinger WI, Buckner CD, McDonald DL, Rowley
SD. Microbial contamination of peripheral blood stem cell
collections. Bone Marrow Transplant 1996;17(5):699–702.
404. Rowley SD, Davis J, Dick J, et al. Bacterial contamination of bone
marrow grafts intended for autologous and allogeneic bone marrow
transplantation: incidence and clinical significance. Transfusion
1988;28(2):109–12.
405. Webb IJ, Coral FS, Andersen JW, et al. Sources and sequelae of
bacterial contamination of hematopoietic cell components:
implications for the safety of hematotherapy and graft engineering.
Transfusion 1996;36(9):782–8.
406. Meyers JD, Huff JC, Holmes KK, Thomas ED, Bryan JA.
Parenterally transmitted hepatitis A associated with platelet
transfusions: epidemiologic study of an outbreak in a marrow
transplantation center. Ann Intern Med 1974;81(2):145–51.
407. Fountain D, Ralston M, Higgins N, et al. Liquid nitrogen freezers:
a potential source of microbial contamination of hematopoietic stem
cell components. Transfusion 1997;37(6):585–91.
408. Nasser RM, Hajjar I, Sandhaus LM, et al. Routine cultures of bone
marrow and peripheral stem cell harvests: clinical impact, cost
analysis, and review. Clin Infect Dis 1998;27(4):886–8.
409. Flake AW, Roncarolo MG, Puck JM, et al. Treatment of x-linked
severe combined immunodeficiency by in utero transplantation of
paternal bone marrow. N Engl J Med 1996;335(24):1806–10.
410. Flake AW, Zanjani ED. In utero hematopoietic stem cell
transplantation: a status report. JAMA 1997;278(11):932–7.
52
TABLE 1. Evidence-based rating system used to determine strength of recommendations
Category Definition Recommendation
A Strong evidence for efficacy and substantial clinical benefit Strongly recommended
B Strong or moderate evidence for efficacy, but only limited clinical Generally recommended
benefit
C Insufficient evidence for efficacy; or efficacy does not outweigh Optional
possible adverse consequences (e.g., drug toxicity or interactions)
or cost of chemoprophylaxis or alternative approaches
D Moderate evidence against efficacy or for adverse outcome Generally not recom-
mended
E Strong evidence against efficacy or of adverse outcome Never recommended
Source: Adapted from CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in per-
sons infected with human immunodeficiency virus. MMWR 1999;48(RR-10):1–66.
TABLE 2. Evidence-based rating system used to determine quality of evidence supporting
recommendation
Category Definition
I Evidence from at least one well-executed randomized, controlled trial
II Evidence from at least one well-designed clinical trial without randomization; cohort or case-
controlled analytic studies (preferably from more than one center); multiple time-series studies;
or dramatic results from uncontrolled experiments
III Evidence from opinions of respected authorities based on clinical experience, descriptive studies,
or reports of expert committees
Source: Adapted from CDC. 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in per-
sons infected with human immunodeficiency virus. MMWR 1999;48(RR-10):1–66.
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TABLE 3. Foods that pose a high risk for hematopoietic stem cell transplant (HSCT) recipients
and safer substitutions
Foods That Pose a High Risk Safer Substitutions
Raw and undercooked eggs* and foods containing them Pasteurized or hard boiled eggs
(e.g., french toast, omelettes, salad dressings, egg nog,
and puddings)
Unpasteurized dairy products (e.g., milk, cheese, Pasteurized dairy products
cream, butter, and yogurt)
Fresh-squeezed, unpasteurized fruit and vegetable juices Pasteurized juices
Unpasteurized cheeses or cheeses containing molds Pasteurized cheeses
Undercooked or raw poultry, meats, fish, and seafood Cooked poultry, well-done meats,
cooked fish, and seafood
Vegetable sprouts (e.g., alfalfa, bean, and other seed Should be avoided
sprouts)†
Raw fruits with a rough texture (e.g., raspberries)§ Should be avoided
Smooth raw fruits Should be washed under running
water, peeled, or cooked
Unwashed raw vegetables¶ Should be washed under running
water, peeled, or cooked
Undercooked or raw tofu Cooked tofu (i.e., cut into ≤1-inch cubes
and boiled for ⊕5 minutes in water or broth before eating or using in recipes)
Raw or unpasteurized honey Should be avoided
Deli meats, hot dogs, and processed meats** Should be avoided unless further cooked
Raw, uncooked grain products Cooked grain products including bread,
cooked, and ready-to-eat cold  cereal, pretzels, popcorn, potato chips, corn
chips, tortilla chips, cooked pasta, and rice
Maté tea†† Should be avoided
All moldy and outdated food products Should be avoided
Unpasteurized beer (e.g., home-brewed and certain Pasteurized beer (i.e., retail microbrewery beer)
bottled or canned, or draft beer that has been pasteurized
after fermentation)
Raw, uncooked brewers yeast Should be avoided; HSCT recipients
should avoid any  contact with raw yeast (e.g., they should not make bread
products themselves)
Unroasted raw nuts Cooked nuts
Roasted nuts in the shell Canned or bottled roasted nuts or
nuts in baked products
* Source: CDC. Outbreaks of Salmonella  serotype enteritidis infection associated with consumption of raw shell eggs—
United States, 1994–1995. MMWR 1996; 45(34):737–42.
† Source: Taormina PJ, Beuchat LR, Slutsker L. Infections associated with eating seed sprouts: an international con-
cern. Emerg Infect Dis 1999;5(5):626–34.
§ Source: Herwaldt BL, Ackers ML. Outbreak in 1996 of cyclosporiasis associated with imported raspberries. New Engl
J Med 1997;336(22):1548–56.
¶ Source: CDC. Foodborne outbreak of cryptosporidiosis—Spokane, Washington, 1997. MMWR 1998;47(27):565–7.
** Source: CDC. Update: multistate outbreak of listeriosis—United States, 1998–1999. MMWR 1999;47(51):1117–8.
†† Source: Kusminsky G, Dictar M, Arduino S, Zylberman M, Sanchez Avalos JC. Do not drink Maté: an additional source
of infection in South American neutropenic patients. Bone Marrow Transplant 1996;17(1):127.
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* Studies report that an HSCT recipient can be primed if the donor has had primary vaccination series. Studies also report that a recipient’s antibody titer
before HSCT might affect the titer 1 year after HSCT (Source: Lum LG. Kinetics of immune reconstitution after human marrow transplantation. Blood
1987;69[2]:369–80). No data were found regarding safety and immunogenicity of pertussis vaccination among HSCT recipients.
† DT should be used whenever a contraindication exists to pertussis vaccination.
§ HSCT recipients should be revaccinated with tetanus-diphtheria toxoids every 10 years, as routinely recommended for all adolescents and adults (Sources:
CDC. Diphtheria, tetanus, and pertussis: recommendations of vaccine use and other prevention measures; recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 1991;40[No. RR-10]:1–28; and CDC. Use of vaccines and immunoglobulin in persons with altered immunocompe-
tence: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1993;42[No. RR-4]:1–18).
¶ Hib conjugate vaccine is recommended for HSCT recipients of any age (Sources: CDC. Recommendations for use of Haemophilus  b conjugate vaccines and
a combined diphtheria, tetanus, pertussis, and Haemophilus  b vaccine: recommendations of the Advisory Committee on Immunization Practices [ACIP].
MMWR 1993;42[No. RR-13]:1–15; and CDC. Use of vaccines and immunoglobulin in persons with altered immunocompetence: recommendations of the
Advisory Committee on Immunization Practices [ACIP]. MMWR 1993;42[No. RR-4]:1–18).
** Hepatitis B vaccination is recommended for all susceptible persons aged ≤18 years and for adults who have risk factors for hepatitis B virus infection
(Sources: CDC. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination;
recommendations of the Immunization Practices Advisory Committee [ACIP]. MMWR 1991;40[No. RR-13]:1–25; and CDC. Notice to readers: update; recom-
mendations to prevent hepatitis B virus transmission—United States. MMWR 1995;44[30]:574–5). ACIP hepatitis B vaccination recommendations indicate
that high doses (40 µg/dose) are recommended for adult dialysis patients and other immunocompromised adults (Source: CDC. Notice to readers: update;
recommendations to prevent hepatitis B virus transmission—United States. MMWR 1995;44[30]:574–5). No data were found regarding immunocompromised
children and their response to higher doses of vaccine. Postvaccination testing for antibody to hepatitis B surface antigen is recommended 1–2 months after
the third vaccine dose to ensure protection among immunocompromised persons (Source: CDC. Notice to readers: update; recommendations to prevent
hepatitis B virus transmission—United States. MMWR 1995;44[30]:574–5). Persons who do not respond to the primary vaccine series should complete a
second 3-dose series.
†† The 23-valent pneumococcal polysaccharide vaccine might not be protective against pneumococcal infection among HSCT recipients. The second dose of
vaccine is not a booster dose, but provides a second chance for immunologic response among persons who failed to respond to the first dose (Source:
Guinan EC, Molrine DC, Antin JH, et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplant 1994;57[5]:677–84).
Adjunctive antibiotic prophylaxis against encapsulated organisms, including pneumococcal disease, is recommended for allogeneic recipients with chronic
GVHD (Source: Bortin MM, Horowitz MM, Gale RP, et al. Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. JAMA 1992;
268[5]:607–12). No data were found regarding safety and immunogenicity of the 7-valent conjugate pneumococcal vaccine among HSCT recipients; there-
fore, no recommendation regarding use of this vaccine can be made.
§§ No data were found regarding immunogenicity, safety, and efficacy of hepatitis A vaccine among HSCT recipients. Researchers report that hepatitis A
vaccination can be used for investigational use among HSCT recipients aged ⊕24 months at ⊕12 months after HSCT and who are at increased risk for
hepatitis A or its adverse consequences (e.g., persons with chronic liver disease, including chronic GVHD, and children living in areas with consistently
elevated hepatitis A incidence) (Source: CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Commit-
tee on Immunization Practices [ACIP]. MMWR 1999;48[No. RR-12]:1–37).
¶¶ Children aged <9 years receiving influenza vaccination for the first time require two doses. Children aged ≤12 years should receive only split-virus influenza
vaccine. Persons aged >12 years can receive whole- or split-virus vaccine. ACIP’s and the American Academy of Pediatrics’ dosing schedule should be used
(Sources: American Academy of Pediatrics. Influenza. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove
Village, IL: American Academy of Pediatrics, 2000:351–9; and CDC. Prevention and control of influenza: recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 2000;49[No. RR-3]:1–38). For optimal influenza prevention, both vaccination and influenza chemoprophylaxis should
be used among HSCT recipients.
*** Administration of meningococcal vaccine should be evaluated for HSCT recipients who live in endemic areas or areas experiencing outbreaks (Source: CDC.
Control and prevention of meningococcal disease and control and prevention of serogroup C meningococcal disease: evaluation and management of
suspected outbreaks. MMWR 1997;46[No. RR-5]:1–21). However, meningococcal vaccine immunogenicity and efficacy among HSCT recipients have not
been studied.
TABLE 4. Recommended vaccinations for hematopoietic stem cell transplant* (HSCT) recipients, including both allogeneic and
autologous recipients
For these guidelines, HSCT recipients are presumed immunocompetent at ⊕24 months after HSCT if they are not on immuno-
suppressive therapy and do not have graft-versus-host disease (GVHD).
Time after HSCT
Vaccine or toxoid 12 months 14 months 24 months Rating
Inactivated vaccine or toxoid
Diphtheria, tetanus, pertussis
Children aged <7 years* Diphtheria toxoid-tetanus DTP or DT DTP or DT BIII
toxoid-pertussis vaccine (DTP) or
diphtheria toxoid-tetanus toxoid (DT)†
Children aged ⊕7 years§ Tetanus-diphtheria toxoid (Td) Td Td BII
Haemophilus influenzae  type  Hib conjugate Hib conjugate Hib conjugate BII
b (Hib) conjugate¶
Hepatitis (HepB)** HepB HepB HepB BIII
23-valent pneumococcal PPV23 — PPV23 BIII
polysaccharide (PPV23)††
Hepatitis A§§ Routine administration not indicated Not rated
because of
limited data
Influenza¶¶ Lifelong, seasonal administration, beginning before HSCT and resuming at ⊕6 months after HSCT BII
Meningococcal*** Routine administration not indicated Not rated
because of
limited data
Inactivated polio (IPV)††† IPV IPV IPV BII
Rabies§§§ Routine administration not indicated Not rated
because of
limited data
Lyme disease Routine administration not indicated; limited data regarding safety, efficacy, Not rated
or immunogenicity among HSCT recipients because of
limited data
Live-attenuated vaccine
Measles-mumps-rubella
(MMR)¶¶¶ ****†††† — — MMR BIII
Varicella vaccine §§§§ Contraindicated for HSCT recipients EIII
Rotavirus vaccine Not recommended for any person in the United States¶¶¶¶ EII
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††† Inactivated polio virus vaccine is immunogenic among HSCT recipients, although no data were found regarding efficacy and more data are needed regarding
optimal methods and timing of immunization (Sources: Henning KJ, White MH, Sepkowitz KA, Armstrong D. National survey of immunization practices
following allogeneic bone marrow transplantation. JAMA 1997;277[14]:1148–51; and CDC. Poliomyelitis prevention in the United States: introduction of a
sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 1997;46[No. RR-3]:1–25).
§§§ Clinicians can administer preexposure rabies vaccine to HSCT recipients with potential occupational exposures to rabies (Source: CDC. Human rabies
prevention—United States, 1999: recommendations of the Advisory Committee on Immunization Practices [ACIP] MMWR 1999;48[No. RR-1]:1–21; and
published erratum, MMWR 1999;48[1]:16). However, the safety and immunogenicity of rabies vaccination among HSCT recipients has not been studied.
Preexposure rabies vaccination should probably be delayed until 12–24 months after HSCT. Administration of rabies vaccine with human rabies immunoglo-
bulin postexposure can be administered anytime after HSCT as indicated. Existing ACIP and American Academy of Pediatrics guidelines for postexposure
human rabies immunoglobulin and vaccine administration should be followed, which include administering 5 doses of rabies vaccine administered on days
0, 3, 7, 14, and 28 postexposure (Sources: American Academy of Pediatrics. Rabies. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious
Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:475–82; and CDC. Human rabies prevention—United States, 1999: recommen-
dations of the Advisory Committee on Immunization Practices [ACIP] MMWR 1999;48[No. RR-1]:1–21; published erratum, MMWR 1999;48[1]:16).
¶¶¶ The first dose of measles-mumps-rubella vaccine should be administered ⊕24 months after HSCT if the HSCT recipient is presumed immunocompetent. The
second measles-mumps-rubella dose is recommended 6–12 months later (BIII); however, the benefit of a second dose among HSCT recipients has not been
evaluated. During outbreaks, the second dose can be administered 4 weeks after the first dose (Source: CDC. Use of vaccines and immunoglobulin in persons
with altered immunocompetence: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1993;42[No. RR-4]:1–18).
**** The half-life of intravenous immunoglobulin is decreased among HSCT recipients, but its effect on vaccine immunogenicity has not been evaluated. ACIP’s
and the American Academy of Pediatrics’ recommendations regarding intervals between administration of immunoglobulin preparations for various indica-
tions and vaccines containing live measles virus should be used (Sources: American Academy of Pediatrics. Measles. In: Pickering LK, ed. 2000 red book:
report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:385–96; CDC. Measles, mumps, and
rubella—vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the
Advisory Committee on Immunization Practices [ACIP]. MMWR 1998;47[No. RR-8]:1–48; and CDC. General recommendations on immunization: recommen-
dations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1994;43[No. RR-1]:1–38).
†††† Use of live vaccines (e.g., measles-mumps-rubella) is indicated only among immunocompetent persons and is contraindicated for recipients after HSCT who
are not presumed immunocompetent (Sources: CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices
[ACIP]. MMWR 1996;45[No. RR-11]:1–36; and CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immuniza-
tion Practices [ACIP]. MMWR 1994;43[No. RR-1]:1–38). Further research is needed to determine the safety, immunogenicity, and efficacy of varicella vaccine
among HSCT recipients.
§§§§ To protect HSCT recipients from varicella exposure, all varicella-susceptible health-care workers, family members, and close contacts of the recipient should
be vaccinated against varicella (Source: American Academy of Pediatrics. Varicella-zoster infections. In: Pickering LK, ed. 2000 red book: report of the
committee on Infectious diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:624–38).
¶¶¶¶ Source: CDC. Withdrawal of rotavirus vaccine recommendation. MMWR 1999;48[43]:1007.
Additional Notes: All indicated nonlive vaccines should be administered to HSCT recipients regardless of HSCT type or presence of GVHD. Live-attenuated
vaccines, (e.g., measles-mumps-rubella, varicella, Bacillus Calmette-Guérin, yellow fever, and oral typhoid vaccines) should not be administered to any HSCT
recipient with active GVHD or immunosuppression (Source: CDC. Role of BCG [Bacillus of Calmette and Guérin] vaccine in the prevention and control of
tuberculosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization
Practices. MMWR 1996;45[No. RR-4]:1–18). To date, no adverse events have been reported (e.g., exacerbation of GVHD) among vaccinated HSCT recipients.
However, data regarding immunization among HSCT recipients are limited and further studies are needed to evaluate safety, efficacy, and immunogenicity of
the proposed HSCT immunization schedule. Use of combination vaccines is encouraged (Source: CDC. Combination vaccines for childhood immunization:
recommendations of the Advisory Committee on Immunization Practices [ACIP], the American Academy of Pediatrics [AAP], and the American Academy of
Family Physicians [AAFP]. MMWR 1999;48[No. RR-5]:1–15). No contraindications to simultaneous administration of any vaccines exist, except cholera and
yellow fever. Adverse events after vaccination should be reported promptly to the Vaccine Adverse Event Reporting System (VAERS), P.O. Box 1100,
Rockville, MD 20849-1100. Forms and information can be obtained from VAERS ([800] 822-7967). If the HSCT recipient has lapsed immunizations after HSCT
(i.e., has missed one or more vaccine doses), the immunization schedule does not have to be restarted. Instead, the missing vaccine dose should be
administered as soon as possible or during the next scheduled clinic appointment.
TABLE 4. (Continued ) Recommended vaccinations for hematopoietic stem cell transplant* (HSCT) recipients, including both
allogeneic and autologous recipients
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Hepatitis A†
Influenza§ ¶
Polio**
Measles-mumps-
rubella††
Rotavirus§§
Varicella¶¶
BII
AI
AI
AI
AI
EII
AIII
Routine vaccination is recommended for persons at increased
risk for hepatitis A or its adverse consequences (e.g., persons
with chronic liver disease or persons traveling to hepatitis A-
endemic countries) and for children aged ⊕24 months living in
areas with consistently elevated hepatitis A incidence.†
Household contacts — Vaccination is strongly recommended
during each influenza season (i.e., October–May) beginning in the
season before the transplant and continuing to ⊕24 months after
HSCT. All household contacts of immunocompromised HSCT
recipients should be vaccinated annually as long as these
conditions persist.
HCWs and home caregivers — Annual vaccination is strongly
recommended during each influenza season.
Vaccination is not routinely recommended for adults but should
be administered when polio vaccination is indicated according to
published Advisory Committee on Immunization Practices
guidelines; when polio vaccine is administered, inactivated polio
vaccine should be used.
Vaccination is recommended for all persons who are aged ⊕12
months and who are not pregnant or immunocompromised.
Contraindicated because intussusception has been reported
among infants during the first 1–2 weeks after rotavirus
vaccination with substantially increased frequency.
Vaccination should be administered to all susceptible HCWs,
household contacts, and family members who are aged ⊕12
months and who are not pregnant or immunocompromised.
When varicella vaccination is administered to persons aged ⊕13
years, 2 doses are required, administered 4–8 weeks apart.
TABLE 5. Vaccinations for family, close contacts, and health-care workers (HCWs) of
hematopoietic stem cell transplantation (HSCT) recipients*
Vaccine Recommendations for use Rating
* This vaccination schedule refers only to vaccine-preventable diseases that are spread person-to-person.
† Source: CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1–37.
§ Children aged <9 years receiving influenza vaccination for the first time require 2 doses. Children aged ≤12
years should receive only split-virus influenza vaccine. Persons aged >12 years can receive whole- or split-
virus vaccine (Sources: CDC. Prevention and control of influenza: recommendations of the Advisory Commit-
tee on Immunization Practices [ACIP]. MMWR 2000;49[No. RR-3]:1–38; and CDC. Immunization of health care
workers: recommendations of the Advisory Committee on Immunization Practices [ACIP] and the Hospital
Infection Control Practices Advisory Committee. MMWR 1997;46[No. RR-18]:1–42).
¶ If HCWs, family members, or other close contacts of HSCT recipients receive influenza vaccination during an
influenza A outbreak, they should also receive amantadine or rimantadine chemoprophylaxis for 2 weeks
after the influenza vaccination (BI) while the vaccinee develops an immunologic response to the vaccine.
However, if a nosocomial outbreak occurs with an influenza A strain that is not contained in the available
influenza vaccine, HCWs, family members, and other close contacts of HSCT recipients and candidates should
be administered influenza A chemoprophylaxis with amantadine or rimantadine until the end of the outbreak
(Source: CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immuni-
zation Practices [ACIP]. MMWR 2000;49[No. RR-3]:1–38) (BIII). HCWs, family members, or other close contacts
can be offered a neuroaminidase inhibitor (e.g., zanamivir or oseltamivir) using the same strategies outlined
previously, if one or more of the following exists: a) rimantadine or amantadine cannot be tolerated; b) the
outbreak strain of influenza A is amantadine- or rimantadine-resistant; or c) the outbreak strain is influenza B
(Sources: Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the preven-
tion of influenza among healthy adults: a randomized controlled trial. JAMA 1999;282[1]:31–5; Hayden FG,
Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influ-
enza. New Engl J Med 1999;341[18]:1336–43; Hayden FG, Gubareva L, Klein T, et al. Inhaled zanamivir for
preventing transmission of influenza in families [Abstract LB-2]. In: Final program, abstracts and exhibits
addendum, 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: Ameri-
can Society for Microbiology, 1991:1; and CDC. Neuraminidase inhibitors for treatment of influenza A and B
infections. MMWR 1999;48[No. RR-14]:1–10) (BI). Zanamivir can be administered to persons aged ⊕12 years,
and oseltamivir can be administered to persons aged ⊕18 years.
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** Caution: Vaccine-strain polio virus in oral polio vaccine can be transmitted person-to-person; therefore, oral
polio vaccine administration is contraindicated among household contacts of immunocompromised per-
sons. If oral polio vaccine is inadvertently administered to a household contact of an HSCT recipient, ACIP’s
and the American Academy of Pediatrics’ recommendations should be followed to minimize close contact
with the immunocompromised person for 4–6 weeks after vaccination (Sources: American Academy of Pedi-
atrics. Poliovirus infections. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Dis-
eases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics, 2000:465–70; CDC. Immunization of
health care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the
Hospital Infection Control Practices Advisory Committee. MMWR 1997;46[No. RR-18]:1–42; and CDC. Polio-
myelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated
poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory Committee on Im-
munization Practices [ACIP]. MMWR 1997;46[No. RR-3]:1–25). Although vaccine-associated paralytic polio-
myelitis has not been reported among HSCT recipients after exposure to household contacts inadvertently
vaccinated with oral polio vaccine, inactivated polio vaccine should be used among family members, close
contacts, and HCWs to avoid person-to-person transmission of vaccine-strain polio virus (Source: CDC. Polio-
myelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated
poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory Committee on Im-
munization Practices [ACIP]. MMWR 1997;46[No. RR-3]:1–25).
†† No evidence exists that live-attenuated vaccine-strain viruses in measles-mumps-rubella vaccine have ever
been transmitted from person-to-person, except rubella vaccine virus from a nursing mother to her infant
(Source: CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, rubella,
and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 1998;47[No. RR-8]:1–48).
** HCWs, family members, close contacts and visitors who do not have a documented history of varicella-zoster
infection or who are seronegative should receive this vaccination before being allowed to visit or have direct
contact with an HSCT recipient (AIII). Ideally, varicella-zoster–susceptible HCWs, family members, household
contacts, and potential visitors of immunocompromised HSCT recipients should be vaccinated as soon as the
decision to perform an HSCT is made. The vaccination dose or doses should be completed ⊕4 weeks before
the conditioning regimen begins or ⊕6 weeks (42 days) before contact with the HSCT recipient is planned
(BIII). If a varicella vaccinee develops a postvaccination rash within 42 days of vaccination, the vaccinee
should avoid contact with HSCT recipients until all rash lesions are crusted or the rash has resolved (Sources:
CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices [ACIP].
MMWR 1996;45[No. RR-11]:1–36; and CDC. Immunization of health care workers: recommendations of the
Advisory Committee on Immunization Practices [ACIP] and the Hospital Infection Control Practices Advisory
Committee. MMWR 1997;46[No. RR-18]:1–42).
TABLE 5. (Continued ) Vaccinations for family, close contacts, and health-care workers
(HCWs) of hematopoietic stem cell transplantation (HSCT) recipients*
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21.
†† Source: CDC. Prevention of plague: recommendations of the Advisory Committee on Immunization Prac-
tices (ACIP). MMWR 1996;45(No. RR-14):1–15.
§§ Source: CDC. Poliomyelitis prevention in the United States: introduction of a sequential vaccination sched-
ule of inactivated poliovirus vaccine followed by oral poliovirus vaccine; recommendations of the Advisory
Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-3):1–25.
¶¶ Source: CDC. Human rabies prevention—United States, 1999: recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP) MMWR 1999;48(No. RR-1):1–21; published erratum, MMWR
1999;48(1):16.
*** Source: CDC. Typhoid immunization: recommendations of the Advisory Committee on Immunization Prac-
tices (ACIP). MMWR 1994;43(No. RR-14):1–7.
††† Source: CDC. Yellow fever vaccine: recommendations of the Immunization Practices Advisory Committee
(ACIP). MMWR 90;39(No. RR-6):1–6.
Additional Note: Specific advice for international travelers, including information regarding endemic diseases
by country, is available through CDC’s automated travelers’ hotline at (404) 332-4559; by facsimile at (404) 335-
4565; on the Internet at <http://www.cdc.gov>; and by file transfer protocol at <ftp.cdc.gov>.
Bacillus of Calmette and
Guérin (live-attenuated
vaccine)
Cholera
Hepatitis A
Japanese B encephalitis
Lyme disease
Meningococcal vaccine
Plague
Polio (inactivated polio
vaccine only)
Rabies
Typhoid, oral (live-
attenuated vaccine)
Typhoid (intramuscular)
Yellow fever (live-
attenuated vaccine)
Use of live-attenuated vaccine is contraindicated among
HSCT recipients at <24 months after HSCT and among all
persons who are immunocompromised.* No data were
found regarding use among HSCT recipients.
Vaccination is not indicated. No data were found regarding
safety and immunogenicity among HSCT recipients.†
No data were found regarding immunogenicity, safety, or
efficacy of hepatitis A vaccine among HSCT recipients;
therefore, intramuscular immunoglobulin use is preferred
for hepatitis A prophylaxis among HSCT recipients.
However, administration of intramuscular immunoglobulin
does not replace avoidance behaviors (e.g., careful selection
of food and water).§ Researchers recommend that hepatitis
A vaccination be evaluated for investigational use among
HSCT recipients aged ⊕24 months; however, no recommen-
dation can be made because of limited data.
No data were found regarding safety, immunogenicity, or
efficacy among HSCT recipients.¶
No data were found regarding safety, immunogenicity, or
efficacy among HSCT recipients.
Vaccine should be administered to HSCT recipients traveling
to endemic areas or to areas experiencing outbreaks.**
However, meningococcal vaccine immunogenicity and
efficacy have not been studied among HSCT recipients.
No data were found regarding safety, immunogenicity, or
efficacy among HSCT recipients.††
Booster dose can be administered as indicated.§§
Researchers recommend that administration of a
preexposure series be evaluated for persons at ⊕12 months
after HSCT if they anticipate travel to endemic areas.¶¶
However, no data were found regarding safety, immunoge-
nicity, or efficacy among HSCT recipients.
Use of oral typhoid vaccine (live-attenuated strain) is
contraindicated among HSCT recipients at <24 months after
HSCT and among those who are immunocompromised.***
No data were found regarding safety, immunogenicity, or
efficacy among HSCT recipients.
No data were found regarding safety, immunogenicity, or
efficacy among HSCT recipients.
Use of live-attenuated vaccine is contraindicated among
HSCT recipients at <24 months after HSCT and among all
immunocompromised persons.††† No data were found
regarding safety, immunogenicity, or efficacy among HSCT
recipients.
EIII
DIII
Not rated because
of limited data
Not rated because
of limited data
Not rated because
of limited data
Not rated because
of limited data
Not rated because
of limited data
CIII
Not rated because
of limited data
EIII
Not rated because
of limited data
EIII
TABLE 6. Vaccinations for hematopoietic stem cell transplant (HSCT) recipients traveling
to areas endemic for selected vaccine-preventable diseases
Vaccine Recommendations for use Rating
* Source: CDC. Role of BCG [Bacillus of Calmette and Guérin] vaccine in the prevention and control of tuber-
culosis in the United States: a joint statement by the Advisory Council for the Elimination of Tuberculosis
and the Advisory Committee on Immunization Practices. MMWR 1996;45(No. RR-4):1–18.
† Source: CDC. Recommendations of the Immunization Practices Advisory Committee: cholera vaccine.
MMWR 1988;37(40):617–8; 623–4.
§ Source: CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1–37.
¶ Source: CDC. Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP). MMWR 1993;42(No. RR-1):1–15.
** Source: CDC. Control and prevention of meningococcal disease and control and prevention of serogroup C
meningococcal disease: evaluation and management of suspected outbreaks. MMWR 1997;46(No. RR-5):1–
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DI
CIII
CIII
CIII
Not rated because
of limited data
CIII
AII
BIII
CIII
Cytomegalovirus immunoglobulin
Hepatitis B immunoglobulin
Human rabies immunoglobulin
Respiratory syncytial virus
immunoglobulin¶
Respiratory syncytial virus
monoclonal antibody
Tetanus immunoglobulin
Varicella-zoster immunoglobulin¶¶
Intramuscular immunoglobulin
Intravenous immunoglobulin¶¶¶
Not recommended for prophylaxis among HSCT
recipients because of its lack of efficacy.*
Immunocompromised persons who have percutaneous or
permucosal exposure to hepatitis B virus should receive 2
doses administered 1 month apart. For immunocompe-
tent persons, the need for postexposure prophylaxis
depends on the vaccination history and antibody to
hepatitis B surface antigen response status of the exposed
person.†
Should be administered with rabies vaccine at anytime
after HSCT as indicated for postexposure rabies
prophylaxis. Existing Advisory Committee on Immuniza-
tion Practices guidelines for postexposure should be
followed, with 5 doses of rabies vaccine administered on
days 0, 3, 7, 14, and 28 postexposure.§
Because of high rates of case fatality from respiratory
syncytial virus pneumonia among HSCT recipients, HSCT
physicians can administer HSCT recipients with upper or
lower respiratory infection preemptive therapy with a
high titer of neutralizing antibodies to prevent severe
disease and death until controlled trials can be per-
formed.**
Physicians can use respiratory syncytial virus monoclonal
antibody†† investigationally as preemptive therapy
(Appendix).
Postexposure vaccination should be administered with or
without tetanus immunoglobulin as indicated for tetanus
exposure§§ that occurs anytime after HSCT.
Ideally, should be administered to HSCT recipients ≤96
hours after close contact with a person with varicella or
shingles if the HSCT recipient is at a) <24 months after
HSCT or b) ⊕24 months after HSCT and still
immunocompromised. Administration can extend the
varicella incubation period from 10–21 days to 10–28
days. If the HSCT recipient experiences a varicella-zoster
virus-like rash after contact with or exposure to a person
with varicella or herpes zoster, antiviral drug therapy
should be administered until ⊕2 days after all lesions
have crusted.***
Should be administered to hepatitis A-susceptible HSCT
recipients who anticipate hepatitis A exposure, (e.g.,
during travel to endemic areas) and for postexposure
prophylaxis as indicated.††† Should also be administered
after measles exposure among HSCT recipients who were
not vaccinated against measles after HSCT.§§§
Can be administered to HSCT recipients with severe
hypogammaglobulinemia (immunoglobulin G < 400 mg/
dl) ≤100 days after HSCT to prevent bacterial infec-
tions**** (Appendix).
TABLE 7. Use of passive immunization for hematopoietic stem cell transplant (HSCT)
recipients exposed to vaccine-preventable diseases
Preparation Recommendations for Use Rating
* Source: Boeckh M, Bowden R. Cytomegalovirus infection in marrow transplantation. In: Buckner CD, ed.
Technical and biological components of marrow transplantation. Boston, MA: Kluwer Academic Publish-
ers, 1995:97–136.
† Source: CDC. Immunization of health care workers: recommendations of the Advisory Committee on Im-
munization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee. MMWR
1997;46(No. RR-18):1–42.
§ Sources: American Academy of Pediatrics. Rabies. In: Pickering LK, ed. 2000 red book: report of the Com-
mittee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:475–82;
and CDC. Human rabies prevention—United States, 1999: recommendations of the Advisory Committee
on Immunization Practices (ACIP) MMWR 1999;48(No. RR-1):1–21; published erratum, MMWR 1999;48(1):16.
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¶ Researchers recommend substituting respiratory syncytial virus immunoglobulin for intravenous immu-
noglobulin for HSCT recipients on replacement intravenous immunoglobulin therapy during respiratory
syncytial virus season (i.e., November–April) (Source: American Academy of Pediatrics. Respiratory syn-
cytial virus. In: Pickering LK, ed. 2000 red book: report of the Committee on Infectious Diseases. 25th ed. Elk
Grove Village, IL: American Academy of Pediatrics;2000:483–7) (CIII). However, no data were found dem-
onstrating safety and efficacy of respiratory syncytial virus immunoglobulin use among HSCT recipients.
§§ Source: CDC. Diphtheria, tetanus, and pertussis: recommendations of vaccine use and other prevention
measures; recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR
1991;40(No. RR-10):1–28.
¶¶ If intravenous immunoglobulin replacement therapy (>250 mg/kg) has been administered <2 weeks before
varicella or zoster rash exposure, varicella-zoster immunoglobulin administration is probably not required.
Varicella-zoster immunoglobulin is distributed by the American Red Cross, except in Massachusetts, where
it is distributed by the Massachusetts Public Health Biologic Laboratories (now a unit of the University of
Massachusetts) (Source: CDC. Prevention of varicella: recommendations of the Advisory Committee on
Immunization Practices [ACIP]. MMWR 1996;45[No. RR-11]:1–36).
*** Source: CDC. Prevention of varicella: recommendations of the Advisory Committee on Immunization Prac-
tices (ACIP). MMWR 1996;45(No. RR-11):1–36.
††† Source: CDC. Prevention of hepatitis A through active or passive immunization: recommendations of the
Advisory Committee on Immunization Practices (ACIP). MMWR 1999;48(No. RR-12):1–37.
§§§ Sources: CDC. Measles, mumps, and rubella—vaccine use and strategies for elimination of measles, ru-
bella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Commit-
tee on Immunization Practices (ACIP). MMWR 1998;47(No. RR-8):1–48; and Eibl MM, Wedgwood RJ. Intra-
venous immunoglobulin: a review. Immunodeficiency Reviews 1989;1:1–42.
¶¶¶ When administered, serum immunoglobulin G levels should be monitored regularly (e.g., every 2 weeks).
**** Sources: Antman KH, Rowlings PA, Vaughn WP, et al. High-dose chemotherapy with autologous hemato-
poietic stem cell support for breast cancer in North America. J Clin Oncol 1997;15(5):1870–9; and Wolff SN,
Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients
undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. Ann Intern
Med 1993;118(12):937–42.
Additional Notes: Intravenous immunoglobulin can be obtained from the American Red Cross Blood Services,
although shortages occasionally occur. Physicians who have difficulty obtaining urgently needed intravenous
immunoglobulin and other immunoglobulin products are advised to contact any of the following:
• American Red Cross Customer Service Center, (800) 261-5772;
• Alpha Therapeutic Corporation, (800) 421-0008;
• Baxter Healthcare Corporation, (847) 940-5955;
• Bayer Pharmaceutical Division, (800) 288-8370;
• Aventis Behring Customer Support, (800) 683-1288;
• Novartis Pharmaceuticals Corporation, (973) 781-8300, or the Intravenous Immunoglobulin Emergency
         Hotline, (888) 234-2520; or
• Immune Deficiency Foundation, (800) 296-4433.
Physicians who are unable to obtain intravenous immunoglobulin for a licensed indication from one of these
sources should contact the Product Shortage Officer at the Food and Drug Administration’s Center for Biologics
Evaluation and Research, Office of Compliance, (301) 827-6220, for assistance. Patients with immunoglobulin E
anti-immunoglobulin A antibodies are at high risk for experiencing anaphylaxis from immunoglobulin adminis-
tration (Source: Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administra-
tion in patients with hypogammaglobulinemia. New Engl J Med 1986;314[9]:560–4). Therefore, persons with
immunoglobulin A deficiency should not be administered standard immunoglobulin preparations (DIII; BIII).
However, researchers report that use of immunoglobulin A-depleted immunoglobulin preparations can be used
with caution in these persons (Sources: Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma
globulin administration in patients with hypogammaglobulinemia. New Engl J Med 1986;314[9]:560–4; Siberry
GK, Iannone R, eds. Harriet Lane handbook: a manual for pediatric house officers. 15th ed.; St. Louis, MO: Mosby,
Inc., 2000:339;739; and Stiehm ER. Human intravenous immunoglobulin in primary and secondary antibody
deficiencies [Review]. Pediatr Infect Dis J 1997;16[7]:696–707).
TABLE 7. (Continued ) Use of passive immunization for hematopoietic stem cell transplant
(HSCT) recipients exposed to vaccine-preventable diseases
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Diphtheria toxoid-tetanus
toxoid-pertussis vaccine
Diphtheria toxoid-tetanus
toxoid-pertussis vaccine–
Haemophilus influenzae
type b
Tetanus-diphtheria toxoid
(adult) and
Diphtheria-tetanus toxoid
(pediatric)
Haemophilus influenzae
type b
Haemophilus influenzae
type b-Hepatitis B
Inactivated polio vaccine
Measles-mumps-rubella
Measles-rubella
Mumps-rubella
Measles
Mumps
Rubella
Varicella
Hepatitis A
Hepatitis B
Influenza
Japanese encephalitis
Tripedia®
Infanrix®
Acel-Imune®
Certiva®
Tetramune®
DTP/ACTHib®
TriHibit®
Generic
ACTHib®
HibTiter®
PedvaxHIB®
OmniHIB®
COMVAX®
IPOL®
M-M-R II®
M-R-Vax II®
Biavax II®
Attenuvax®
Mumpsvax®
Meruvax II®
Varivax®
Vaqta®
Havix®
Engerix-B®
Recombivax B®
Fluzone®
Fluvirin®
Flu-Shield®
Fluogen®
JE-VAX
Aventis Pasteur, Inc.
(800) Vaccine
SmithKline Beecham
(800) 877-1158
Wyeth-Lederle
(800) 572-8221
North American Vaccine
(888) 628-2829
Wyeth-Lederle
(800) 572-8221
Aventis Pasteur, Inc.
(800) Vaccine
Aventis Pasteur, Inc.
(800) Vaccine
Wyeth-Lederle
(800) 572-8221
Aventis Pasteur, Inc.
(800) Vaccine
Wyeth-Lederle
(800) 572-8221
Merck Human Health Division
(800) MerckRX (ordering)
(800) NSCmerc (questions)
SmithKline Beecham
(800) 877-1158
Merck Human Health Division
(800) MerckRX (ordering)
(800) NSCmerc (questions)
Aventis Pasteur, Inc.
(800) Vaccine
Merck Human Health Division
(800) MerckRX (ordering)
(800) NSCmerc (questions)
SmithKline Beecham
(800) 877-1158
Merck Human Health Division
(800) MerckRX (ordering)
(800) NSCmerc (questions)
Aventis Pasteur, Inc.
(800) Vaccine
Celltech Medeva Pharmaceutical
(800) 234-5535
Wyeth-Ayerst Laboratories
(800) 358-7443
Monarch Pharmaceuticals
(888) 358-6436
Research Foundation for
Microbial Diseases of Osaka
University, Japan; Distributed by
Aventis Pasteur, Inc.
(800) Vaccine
SmithKline Beecham
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); freezing is
permissible
Maintain in a
frozen state of –15
C (5 F) or colder
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
TABLE 8. Vaccine information
Manufacturer/ Storage
Vaccine or toxoid Trade name telephone number recommendation
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TABLE 8. (Continued ) Vaccine information
Manufacturer/ Storage
Vaccine or toxoid Trade name telephone number recommendation
LYMErix™
Pru-Immune-23®
Pneumovax 23®
Menomune-A/C/Y/W-
135®
Generic
Imovax Rabies® and
Imovax Rabies ID®
RabAvert™
Typhoid Vaccine
U.S. P.
Typhim Vi™
(800) 877-1158
Wyeth-Lederle
(800) 572-8221
Merck Human Health Division
(800) MerckRX (ordering)
(800) NSCmerc (questions)
Aventis Pasteur, Inc.
(800) Vaccine
BioPort Corporation
(517) 327-1500;
distributed by
SmithKline Beecham
(800) 877-1158
Aventis Pasteur, Inc.
(800) Vaccine
Chiron Corporation
(800) 244-7668
Wyeth-Lederle
(800) 572-8221
Aventis Pasteur, Inc.
(800) Vaccine
Lyme disease
Pneumococcal 23-valent
Meningococcal
Rabies
Typhoid
Typhoid Vi polysaccha-
ride
Notes: Persons needing additional vaccine information or CDC’s Advisory Committee on Immunization Prac-
tices guidelines can contact the CDC Immunization Hotline at (800) CDC-SHOT ([800] 232-7468) or at <http://
www.cdc.gov/nip>. Adverse events after vaccination should be reported promptly to the Vaccine Adverse Event
Reporting System (VAERS), P.O. Box 1100, Rockville, MD 20849-1100. Forms and information can be obtained
from VAERS at (800) 822-7967.
Store at 2–8 C 36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
Store at 2–8 C (36–
46 F); do not freeze
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Appendix
Dosing Charts for Preventing Opportunistic Infections
Among Hematopoietic Stem Cell Transplant Recipients
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Universal prophylaxis for
cytomegalovirus disease among
all allogeneic adult or adolescent
HSCT recipients at risk through-
out phase II (i.e., from engraft-
ment to day 100 after HSCT)
Or preemptive cytomegalovirus
treatment administered <100
days after HSCT to all allogeneic
adult or adolescent HSCT
recipients at risk: Start ganciclovir
when the patient experiences any
level of cytomegalovirus
antigenemia or viremia or has
⊕2 consecutively positive
cytomegalovirus-DNA poly-
merase chain reaction tests
Preemptive treatment for
cytomegalovirus seropositive
autologous adult or adolescent
HSCT recipients at <100 days
after HSCT: Start ganciclovir
when antigenemia is ⊕5 cells/
slide, but CD34+-selected patients
should be treated at any level of
antigenemia*
Preemptive treatment of
allogeneic adult or adolescent
HSCT recipients >100 days after
HSCT: Start ganciclovir when a)
antigenemia is ⊕5 cells/slide or b)
the patient has had ⊕2 consecu-
tively positive viremia or
polymerase chain reaction tests
(e.g., in a person receiving
steroids for graft-versus-host
disease or who received
ganciclovir or foscarnet at
<100 days after HSCT)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
5–7 days, followed by 5–6 mg/kg
intravenously daily for 5 days/
week from engraftment until day
100 after HSCT (AI)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7–14 days, followed by 5 mg/kg/
day for 5 days/week until day 100
after HSCT or for a minimum of
3 weeks, whichever is longer (AI);
or administer ganciclovir for a
total of 3–6 weeks; antigen or
polymerase chain reaction tests
should be negative when
ganciclovir is stopped; reinstitute
ganciclovir if subsequent weekly
cytomegalovirus antigenemia
screening tests become positive
(BI)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7 days, followed by 5 mg/kg/day
intravenously for 5 days/week for
2 weeks (BII)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7 days, followed by 5 mg/kg/day
intravenously for 5 days/week for
2 weeks (BIII)
Foscarnet, 60 mg/kg intrave-
nously every 12 hours for 7 days,
followed by 90–120 mg/kg
intravenously daily until day 100
after HSCT (CIII)
I. Preventive regimens for adult or adolescent hematopoietic stem cell transplant (HSCT)
recipients
Pathogen: Cytomegalovirus
Indication First choice Alternatives
* Source: Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after au-
tologous CD34-selected peripheral blood stem cell transplantation [Clinical observations, interventions, and
therapeutic trials]. Blood 1999;94(12):4029–35.
Notes: Patients who do not tolerate standard doses of ganciclovir should be administered foscarnet. Ganciclovir
and foscarnet doses should be modified for renal impairment. Prehydration is required for foscarnet administra-
tion.
Pathogen: Herpes simplex virus
Indication First choice Alternatives
Prevention of herpes simplex
virus reactivation among
seropositive adult or adolescent
HSCT recipients: Start acyclovir
at the beginning of conditioning
therapy and continue until
engraftment or until mucositis
resolves (i.e., approximately 30
days after HSCT for allogeneic
HSCT recipients)
Acyclovir, 200 mg by mouth
3 times/day or 250 mg/m2/dose
infused over 1 hour intravenously
every 12 hours (BIII)
Valacyclovir, 500 mg by mouth
daily (CIII)
Note: For patients requiring prophylaxis for cytomegalovirus and herpes simplex virus after engraftment,
ganciclovir alone provides effective prophylaxis for both pathogens.
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Prevention of varicella-zoster
virus disease after exposure
among adult or adolescent HSCT
recipients who are at <24 months
after HSCT or who are at
⊕24 months after HSCT and on
immunosuppressive therapy or
have chronic graft-versus-host
disease: Ideally, administer
prophylaxis within 96 hours
(preferably, within 48 hours) after
close contact with a person who
has chickenpox or shingles
Varicella-zoster immunoglobulin,
5 vials (1.25 ml each or 625 units
total) intramuscularly (AII)
None
Pathogen: Varicella-zoster virus
Indication First choice Alternatives
Pathogen: Influenza
Indication First choice Alternatives
Prevention of influenza A or B
among adult or adolescent HSCT
recipients
Prophylaxis and preemptive
treatment among all HSCT
recipients during community and
nosocomial outbreaks of
influenza A
Lifelong annual seasonal (i.e.,
October–May) influenza
vaccination starting before HSCT
and restarting 6 months after
HSCT (BIII); whole- or split-virus
influenza vaccine, 0.5 ml/dose
intramuscularly
Rimantadine, 100 mg by mouth
2 times/day (CIII)
None
Amantadine, 100 mg by mouth 2
times/day (CIII)
Notes: Rimantadine dose should be reduced for patients with impaired renal function or for severely impaired
hepatic function. Amantadine dose should be reduced for renal impairment.
Pathogen: Bacterial infections, general prophylaxis
Indication First choice Alternatives
Prevention of bacterial infections
among allogeneic adult or
adolescent HSCT recipients with
severe hypogammaglobulinemia
(i.e., serum immunoglobulin G
level < 400 mg/dl) at <100 days
after HSCT
Intravenous immunoglobulin,
500 mg/kg/week (CIII)
None
Notes: Patients with immunoglobulin E anti-immunoglobulin A antibodies are at high risk for experiencing
anaphylaxis from immunoglobulin administration (Source: Burks AW, Sampson HA, Buckley RH. Anaphylactic
reactions after gamma globulin administration in patients with hypogammaglobulinemia. New Engl J Med
1986;314[9]:560–4). Therefore, persons with immunoglobulin A deficiency should not receive standard immu-
noglobulin products (Source: Siberry GK, Iannone R, eds. Harriet Lane handbook: a manual for pediatric house
officers. 15th ed.; St. Louis, MO: Mosby, Inc., 2000:339;739) (DIII). However, researchers have reported that use of
immunoglobulin A-depleted immunoglobulin preparations can be used with caution among these persons
(Sources: Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in
patients with hypogammaglobulinemia. New Engl J Med 1986;314[9]:560–4; Stiehm ER. Human intravenous
immunoglobulin in primary and secondary antibody deficiencies [Review]. Pediatr Infect Dis J 1997;16[7]:696–
707; and American Academy of Pediatrics. Passive immunization. In: Pickering LK, ed. 2000 red book: report of
the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:41–
53). Researchers also propose checking serum immunoglobulin G levels every 2 weeks among patients receiv-
ing intravenous immunoglobulin replacement therapy.
Pathogen: Streptococcus pneumoniae
Indication First choice Alternatives
Prevention of pneumococcal
disease among adult or
adolescent HSCT recipients
23-valent pneumococcal
polysaccharide vaccine at 12 and
24 months after HSCT (BIII)
None
Note: Penicillin-resistant Streptococcus pneumoniae  is increasing in the United States.
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Pathogen: Methicillin-resistant Staphylococcus aureus
Indication First choice Alternatives
Elimination of methicillin-
resistant Staphylococcus aureus
carrier state among adults or
adolescents to prevent this
disease among chronic carriers
Mupirocin calcium ointment 2%;
use a cotton-tipped applicator or
equivalent to apply to nares
2 times/day for 5 days or to
wounds daily for 2 weeks
None
Pathogen: Haemophilus influenzae  type b
Indication First choice Alternatives
Prevention of invasive
Haemophilus influenzae type b
(Hib) disease among adult or
adolescent HSCT recipients
Generally, HSCT recipients
who are household contacts
of a person with Hib disease
should be administered rifampin
prophylaxis* (BIII); however,
prophylaxis is not needed for
adult or adolescent HSCT
recipients who are household
contacts of a person with Hib
disease if all household contacts
aged <4 years are fully vaccinated
Hib conjugate vaccine adminis-
tered at 12, 14, and 24 months
after HSCT (BII)
Rifampin 600 mg by mouth daily
for 4 days (BIII)
None
* Source: American Academy of Pediatrics. Haemophilus influenzae  infections. In: Pickering LK, ed. 2000 red
book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics;2000:262–72.
Pathogen: Candida  species
Indication First choice Alternatives
Prophylaxis for disease from
fluconazole-susceptible Candida
species among a) allogeneic
adult or adolescent HSCT
recipients or b) autologous adult
or adolescent HSCT recipients
with lymphoma or leukemia and
who have or will have prolonged
neutropenia and mucosal
damage from intense condition-
ing regimens or graft manipula-
tion or who have recently
received fludarabine or
2-chlorodeoxyadenosine:
Administer prophylaxis from the
day of transplantation (i.e., day 0)
until engraftment (i.e., approxi-
mately 30 days after HSCT) or
until 7 days after the absolute
neutrophil count > 1,000 cells/
mm3
Fluconazole, 400 mg by mouth or
intravenously daily (AI)
None
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Pathogen: Strongyloides  species
Indication First choice Alternatives
Prevention of strongyloidiasis
hyperinfection among adult or
adolescent HSCT candidates
whose HSCT screening tests are
positive for Strongyloides
species or who have an
unexplained eosinophilia and a
travel or residence history
suggestive of exposure to
Strongyloides stercoralis:
Administer prophylaxis before
HSCT
Ivermectin, 200 µg/kg by mouth
daily for 2 consecutive days* (BIII);
1 tablet = 6 mg; doses administered
as follows:
Body
weight (kg) Oral dose
<15 Not recommended
⊕15–24 ˚ tablet
25–35 1 tablet
36–50 1˚ tablets
51–65 2 tablets
66–79 2˚ tablets
⊕80 200 µg/kg
Albendazole, 400 mg by mouth
daily for 3 days or thiabendazole,
25 mg/kg by mouth 2 times/day
for 2 days (BIII); maximum dose,
3 g/24 hours
*Sources: Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections [Review]. Infect Dis Clin
North Am 1993;7(3):655–82; and Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidi-
asis and other intestinal helminths. Am J Trop Med Hyg 1989;40:304–9.
Notes: Among immunocompromised patients, multiple courses at 2-week intervals might be required; how-
ever, cure might not be achievable. Safety and efficacy of ivermectin has not been established during preg-
nancy. Albendazole and thiabendazole are contraindicated during pregnancy.
Pathogen: Pneumocystis carinii
Indication First choice Alternatives
Prophylaxis for Pneumocystis
carinii  pneumonia among a) all
allogeneic adult or adolescent
HSCT recipients or b) autologous
adult or adolescent HSCT
recipients with underlying
hematologic malignancies (e.g.,
lymphoma or leukemia) or for
those receiving intense
conditioning regimens or graft
manipulation or for those who
have recently received
fludarabine or 2-
chlorodeoxyadenosine:*
Administer prophylaxis from time
of engraftment for ⊕6 months
after HSCT; continue >6 months
after HSCT for the duration of
immunosuppression for all
persons who a) are receiving
immunosuppressive therapy
(e.g., prednisone or cyclosporine)
or who b) have chronic graft-
versus-host disease
Trimethoprim-sulfamethoxazole,
1 double-strength tablet by
mouth daily or 1 single-strength
tablet by mouth daily or 1
double-strength tablet by mouth
3 times/week (AII); researchers
also recommend administering
prophylaxis for 1–2 weeks before
HSCT (i.e., day –14 to –2) (CIII)
Dapsone, 50 mg by mouth
2 times/day or 100 mg by mouth
daily (BIII) or pentamidine,
300 mg every 3–4 weeks by
Respirgard II™ nebulizer (CIII)
* Source: Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii  pneumonitis after bone marrow transplanta-
tion. Bone Marrow Transplant 1992;10(3):267–72.
Note: Patients who are receiving sulfadiazine-pyrimethamine for toxoplasmosis therapy are protected against
Pneumocystis carinii  and do not need additional prophylaxis.
Pathogen: Toxoplasma gondii
Indication First choice Alternatives
Prophylaxis of Toxoplasma
gondii disease among seroposi-
tive allogeneic adult or adoles-
cent HSCT recipients: Start after
engraftment and administer as
long as patients remain on
immunosuppressive therapy (i.e.,
generally, until 6 months after
HSCT)
Trimethoprim-sulfamethoxazole,
1 double-strength tablet by
mouth daily or 1 single-strength
tablet by mouth daily or 1
double-strength table by mouth
3 times/week (AII)
For those persons who are
intolerant of trimethoprim-
sulfamethoxazole, the following
drugs can be substituted:
Clindamycin, 300–450 mg by
mouth every 6–8 hours; plus
pyrimethamine, 25–75 mg by
mouth daily; plus leucovorin, 10–
25 mg by mouth 4 times/day (CIII)
Note: Among allogeneic HSCT recipients, clinical toxoplasmosis has occurred despite the use of trimethoprim-
sulfamethoxazole for Pneumocystis carinii  prophylaxis (Source: Slavin MA, Meyers JD, Remington JS, Hack-
man RC. Toxoplasma gondii infection in marrow transplant recipients: a 20 year experience. Bone Marrow
Transplant 1994;13[5]:549–57).
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Pathogen: Traveler’s diarrhea
Indication First choice Alternatives
Prophylaxis among adult or
adolescent HSCT recipients who
are immunocompromised and
who plan to travel in developing
countries
Ciprofloxacin, 500 mg by mouth
daily for the duration of stay in
developing countries (BIII) or
bismuth subsalicylate, 2 oz by
mouth 4 times/day or 2 tablets by
mouth 4 times/day; can be
administered for ≤3 weeks to
prevent travelers’ diarrhea in
adults aged >18 years only
Trimethoprim-sulfamethoxazole,
1 double-strength tablet by
mouth daily for the duration of
stay in developing country (CIII)
Notes: Use of aspirin-containing products including bismuth subsalicylate is contraindicated in persons aged
<18 years unless prescribed by a physician because these products have been associated with Reye’s syndrome
(Source: Belay E, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s syndrome in the United
States from 1981 through 1997. New Engl J Med 1999;340[18]:1377–82). Ciprofloxacin, norfloxacin, and ofloxacin
are not approved for use among children aged <18 years.
Pathogen: Mycobacteria tuberculosis
Indication First choice Alternatives
Prevention of Mycobacteria
tuberculosis  among a) highly
immunocompromised adult or
adolescent HSCT recipients or
candidates who have been
substantially exposed to
someone with active, infectious
(e.g., sputum smear positive)
pulmonary or laryngeal
tuberculosis, regardless of the
HSCT recipient’s or candidate’s
tuberculin skin test status, or b)
adult or adolescent HSCT
recipients or candidates with a
positive tuberculin skin test and
who were not previously treated
and have no evidence of active
tuberculosis disease
Isoniazid, 5 mg/kg/day by mouth
or intramuscularly for 9 months
(i.e., for ⊕270 doses);* maximum
dose, 300 mg/day, and pyridoxine
(vitamin B6), 25–50 mg by mouth
daily for 9 months; administer to
nutritionally deficient HSCT
recipients and candidates while
on isoniazid preventive therapy
to reduce the occurrence of
isoniazid-induced neuropathy*
(BIII)
None
*Source: CDC. Prevention and treatment of tuberculosis among patients infected with human immunodefi-
ciency virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20):1–58.
Notes: A twice-weekly schedule of isoniazid and pyridoxine can be administered (CIII). The twice-weekly iso-
niazid dose is 15 mg/kg by mouth or intramuscularly (maximum dose, 900 mg). The twice-weekly pyridoxine
dose is 50–100 mg by mouth. A 2-month pyrazinamide/rifampin preventive therapy regimen can be used for
HSCT candidates who are not at risk for serious rifampin drug interactions and whose HSCT is not scheduled
until ⊕2 weeks after the 2-month course is completed (Sources: CDC. Notice to readers: use of short-course
tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR 1998;47[42]:911–2; and CDC.
Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: prin-
ciples of therapy and revised recommendations. MMWR 1998;47[No. RR-20]:1–58) (CIII). The usual pyrazina-
mide dose is 15–30 mg/kg/day by mouth or 50–70 mg/kg/dose by mouth 2 times/week (maximum daily pyrazina-
mide dose, 2.0 gm; maximum twice-weekly dose, 3.5 gm). Rifampin dose is 10 mg/kg/day by mouth or intrave-
nously or 10 mg/kg/dose administered 2 times/week by mouth or intravenously (maximum rifampin dose, 600
mg). Routine use of a 2-month pyrazinamide/rifampin preventive therapy regimen is not recommended after
HSCT because of the risk for serious rifampin drug interactions (DIII). Persons who have been exposed to rifampin-
and isoniazid-resistant tuberculosis should be placed on preventive therapy regimens that involve ⊕2 antituber-
culosis drugs to which the infecting strain is susceptible, and a tuberculosis specialist should be consulted
(Source: CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency
virus: principles of therapy and revised recommendations. MMWR 1998;47[No. RR-20]:1–58) (BIII). A tuberculo-
sis specialist should also be consulted for patients who are intolerant to isoniazid (AIII). All intermittent dosing
strategies should be administered as directly observed therapy (AIII).
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II. Preventive regimens for pediatric hematopoietic stem cell transplant (HSCT) recipients
Pathogen: Cytomegalovirus
Indication First choice Alternatives
Universal prophylaxis for
cytomegalovirus disease among
all allogeneic pediatric HSCT
recipients at risk throughout
phase II (i.e., from engraftment to
day 100 after HSCT)
Or preemptive cytomegalovirus
treatment administered <100
days after HSCT to all allogeneic
pediatric HSCT recipients at risk:
Start ganciclovir when the patient
experiences any level of
cytomegalovirus antigenemia or
viremia or has ⊕2 consecutively
positive cytomegalovirus-DNA
polymerase chain reaction tests
Preemptive treatment for
cytomegalovirus seropositive
autologous pediatric HSCT
recipients at <100 days after
HSCT: Start ganciclovir when
antigenemia is ⊕5 cells/slide, but
CD34+-selected patients should
be treated at any level of
antigenemia*
Preemptive treatment of
allogeneic pediatric HSCT
recipients >100 days after HSCT:
Start ganciclovir when a)
antigenemia is ⊕5 cells/slide or
b) the patient has had ⊕2
consecutively positive viremia or
polymerase chain reaction tests
(e.g., in a person receiving
steroids for graft-versus-host
disease or who received
ganciclovir or foscarnet at
<100 days after HSCT)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
5–7 days, followed by 5 mg/kg/
dose intravenously daily for
5 days/week from engraftment
until day 100 after HSCT (AI)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7–14 days, followed by 5 mg/kg/
day for 5 days/week until day 100
after HSCT or for a minimum of
3 weeks, whichever is longer (AI);
or administer ganciclovir for a
total of 3–6 weeks; antigen or
polymerase chain reaction tests
should be negative when
ganciclovir is stopped; reinstitute
ganciclovir if subsequent weekly
cytomegalovirus antigenemia
screening tests become positive
(BI)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7 days, followed by 5 mg/kg/day
intravenously for 5 days/week for
2 weeks (BII)
Ganciclovir, 5 mg/kg/dose
intravenously every 12 hours for
7 days, followed by 5 mg/kg/day
intravenously for 5 days/week for
2 weeks (BIII)
Foscarnet, 60 mg/kg intravenously
every 12 hours for 14 days, followed
by 90–120 mg/kg/day until day 100
after HSCT (CIII)
* Source: Holmberg LA, Boeckh M, Hooper H, et al. Increased incidence of cytomegalovirus disease after au-
tologous CD34-selected peripheral blood stem cell transplantation [Clinical observations, interventions, and
therapeutic trials]. Blood 1999;94(12):4029–35.
Notes: Patients who do not tolerate standard doses of ganciclovir should be administered foscarnet. Ganciclovir
and foscarnet doses should be modified for renal impairment. Prehydration is required for foscarnet administra-
tion.
Pathogen: Herpes simplex virus
Indication First choice Alternatives
Prevention of herpes simplex
virus reactivation among
seropositive pediatric HSCT
recipients: Start acyclovir at the
beginning of conditioning
therapy and continue until
engraftment or until mucositis
resolves (i.e., approximately
30 days after HSCT for allogeneic
HSCT recipients)
Acyclovir, 250 mg/m2/dose
intravenously every 8 hours (BIII)
or 125 mg/m2/dose intravenously
every 6 hours (CIII)
Acyclovir 600–1,000 mg/24 hours
by mouth, divided in 3–5 doses/
day
Note: For patients requiring prophylaxis for cytomegalovirus and herpes simplex virus after engraftment,
ganciclovir alone provides effective prophylaxis for both pathogens. Valacyclovir is not approved for use among
children.
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Pathogen: Varicella-zoster virus
Indication First choice Alternatives
Prevention of varicella-zoster
virus disease after exposure
among pediatric HSCT recipients
who are at <24 months after
HSCT or who are at ⊕24 months
after HSCT and on immunosup-
pressive therapy or have chronic
graft-versus-host disease: Ideally,
administer prophylaxis within
96 hours (preferably, within
48 hours) after close contact with
a person who has chickenpox or
shingles
Varicella-zoster immunoglobulin,
125 units (1.25 ml)/10 kg (22 lbs)
of body weight administered
intramuscularly; maximum dose,
625 units or 5 vials (AII); doses
administered as follows:
Body
weight Number
(kg) Dose of vials
0–10 125 units 1
10.1–20 250 units 2
20.1–30 375 units 3
30.1–40 500 units 4
>40 kg 625 units 5
Limited data demonstrate
that a 1-week course of high-
dose acyclovir might prevent
varicella
Pathogen: Influenza
Indication First choice Alternatives
Lifelong annual seasonal (i.e.,
October–May) influenza vaccination
before HSCT and resuming ⊕6
months after HSCT (BIII); doses
administered as follows:
Type of
Number influenza
Age of doses vaccine
6–35 mo 0.25 ml Split-virus*
3–8 years 0.5 ml Split-virus*
9–12 years 0.5 ml Split-virus
>12 years 0.5 ml Whole- or
split-virus
Rimantadine, for children aged 1–9
years, 5 mg/kg/day once daily or
divided in 2 doses (CIII); maximum
daily dose, 150 mg; for children
aged ⊕10 years (weight, <40 kg), 5
mg/kg/day by mouth, divided in 2
doses; for children aged ⊕10 years
(weight, ⊕40 kg), 100 mg by mouth
2 times/day
Prevention of influenza A and B
among pediatric HSCT recipients
Prophylaxis and preemptive
treatment of influenza A among
pediatric HSCT recipients during
nosocomial or community
influenza A outbreaks
None
Amantadine, for children aged 1–
9 years, 5 mg/kg/day; maximum
daily dose, 150 mg; for children
aged ⊕10 years (weight, <40 kg),
5 mg/kg/day by mouth, divided in
2 doses; for children aged ⊕10
years (weight, ⊕40 kg), 100 mg
by mouth 2 times/day; maximum
daily dose, 200 mg
* Children aged <9 years receiving influenza vaccination for the first time require 2 doses of vaccine spaced
⊕1months apart.
Notes: Neither rimantadine nor amantadine are Federal Drug Administration-approved for children aged
<1 year. Rimantadine and amantadine doses should be reduced for patients with impaired renal function.
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Pathogen: Respiratory syncytial virus
Indication First choice Alternatives
Prophylaxis for respiratory
syncytial virus (RSV) lower
respiratory infection among
hypogammaglobulinemic
pediatric HSCT recipients
Preemptive treatment of RSV
upper respiratory infection or
early lower respiratory infection
among pediatric HSCT recipients
RSV intravenous immunoglobu-
lin can be administered in place
of intravenous immunoglobulin
during RSV season (i.e.,
November–April in the United
States) for pediatric HSCT
recipients who are on routine
intravenous immunoglobulin
therapy* (e.g., those with
hypogammaglobulinemia) (CIII);
usual RSV intravenous immuno-
globulin dose is 750 mg/kg/
month or a 1-mg/1-mg dosing
substitution of RSV intravenous
immunoglobulin for intravenous
immunoglobulin can be used for
patients who normally require
high intravenous immunoglobu-
lin doses to maintain serum
immunoglobulin G > 400 mg/dl;
can administer more frequently
than monthly as needed to keep
serum immunoglobulin G
> 400 mg/dl
Aerosolized ribavirin,* 6 g/300 ml
sterile water to make a concentra-
tion of 20 mg/ml; administer
18 hours/day for 10 days in a tent
(CIII); for HSCT recipients with
lower respiratory infections who
cannot tolerate a tent or who
have RSV upper respiratory
infection, administer ribavirin as
2 g for 2 hours every 8 hours by
face mask for 10 days; use small
particle aerosol generator model
SPAG-2
None
*Source: American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. 2000 red book: re-
port of the Committee on Infectious Disease. 25th ed. Elk Grove Village, IL: American Academy of Pediat-
rics;2000:483–7.
Notes: RSV intravenous immunoglobulin is contraindicated among patients with immunoglobulin A deficiency
or who might have allergic reactions or anaphylaxis when receiving blood products containing immunoglobulin
A (DIII). RSV monoclonal antibody is under investigational use among HSCT recipients for treatment with ribavirin
but not for prophylaxis.
Pathogen: Bacterial infections, general prophylaxis
Indication First choice Alternatives
Prevention of bacterial infections
among allogeneic pediatric HSCT
recipients with severe
hypogammaglobulinemia (i.e.,
serum immunoglobulin G level
< 400 mg/dl) at <100 days after
HSCT
Intravenous immunoglobulin
400 mg/kg/month; increase dose
or frequency as needed to keep
serum immunoglobulin G levels
> 400 mg/dl (CIII)
None
Notes: Patients with immunoglobulin E anti-immunoglobulin A antibodies are at high risk for experiencing
anaphylaxis from immunoglobulin administration (Source: Burks AW, Sampson HA, Buckley RH. Anaphylactic
reactions after gamma globulin administration in patients with hypogammaglobulinemia. New Engl J Med
1986;314[9]:560–4). Therefore, persons with immunoglobulin A deficiency should not receive standard immu-
noglobulin products (Source: Siberry GK, Iannone R, eds. Harriet Lane handbook: a manual for pediatric house
officers. 15th ed.; St. Louis, MO: Mosby, Inc., 2000:339;739) (DIII). However, researchers report that use of immu-
noglobulin A-depleted immunoglobulin preparations can be used with caution in these persons (Sources: Burks
AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with
hypogammaglobulinemia. New Engl J Med 1986;314[9]:560–4; Siberry GK, Iannone R, eds. Harriet Lane hand-
book: a manual for pediatric house officers. 15th ed.; St. Louis, MO: Mosby, Inc., 2000:339;739; Stiehm ER. Human
intravenous immunoglobulin in primary and secondary antibody deficiencies [Review]. Pediatr Infect Dis J
1997;16[7]:696–707; American Academy of Pediatrics. Passive immunization. In: Pickering LK, ed. 2000 red book:
report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediat-
rics;2000:41–53). Researchers also propose checking serum immunoglobulin G levels every 2 weeks for patients
receiving intravenous immunoglobulin replacement therapy.
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Pathogen: Haemophilus influenzae  type b
Indication First choice Alternatives
Prevention of invasive
Haemophilus
influenzae  type b (Hib) disease
among pediatric HSCT recipients
Generally, pediatric HSCT
recipients who are household
contacts of a person with Hib
disease should be administered
rifampin prophylaxis* (BIII);
however, prophylaxis is not
needed for pediatric HSCT
recipients who are household
contacts of a person with Hib
disease if all household contacts
aged <4 years are fully vacci-
nated
Hib conjugate vaccine administered
at 12, 14, and 24 months after HSCT
(BII)
Rifampin, administered as follows:
Age Dose
0–1 mo 10 mg/kg by mouth daily
for 4 days
>1 mo 20mg/kg by mouth daily
for 4 days
Maximum dose, 600 mg/day (BIII)
None
None
* Source: American Academy of Pediatrics. Haemophilus influenzae  infections. In: Pickering LK, ed. 2000 red
book: report of the Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of
Pediatrics;2000:262–72.
Pathogen: Methicillin-resistant Staphylococcus aureus
Indication First choice Alternatives
Elimination of methicillin-
resistant Staphylococcus aureus
carrier state among pediatric
patients to prevent this disease
among chronic carriers
Mupirocin calcium ointment 2%;
use a cotton-tipped applicator or
equivalent to apply to nares
2 times/day for 5 days or to
wounds daily for 2 weeks*
Bacitracin is regarded safe for
use among children, and the
dose is the same as for
mupirocin; however, no
standardized protocol has been
evaluated
* Safety of mupirocin calcium ointment 2% use among children aged <12 years has not be established.
Pathogen: Streptococcus pneumoniae
Indication First choice Alternatives
Prevention of pneumococcal
disease among pediatric HSCT
recipients
23-valent pneumococcal
polysaccharide vaccine at 12 and
24 months after HSCT (BIII)
None
Notes: The 23-valent pneumococcal polysaccharide vaccine should not be administered to children aged <2
years because of lack of efficacy (DI). Penicillin-resistant Streptococcus pneumoniae  is increasing in the United
States.
Pathogen: Candida  species
Indication First choice Alternatives
Prophylaxis for disease from
fluconazole-susceptible Candida
species among a) allogeneic
pediatric HSCT recipients or b)
autologous pediatric HSCT
recipients with lymphoma or
leukemia and who have or will
have prolonged neutropenia and
mucosal damage from intense
conditioning regimens or graft
manipulation or who have
recently received fludarabine or
2-chlorodeoxyadenosine:
Administer prophylaxis from the
day of transplantation (i.e., day 0)
until engraftment (i.e., approxi-
mately 30 days after HSCT) or
until 7 days after the absolute
neutrophil count > 1,000 cells/
mm3
Fluconazole, for children aged
6 months–13 years, administer
3–6 mg/kg/day by mouth or
intravenously (AI); maximum
dose, 600 mg/day; for children
aged >13 years, administer 400
mg by mouth or intravenously
daily (AI)
None
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Pathogen: Pneumocystis carinii
Indication First choice Alternatives
Prophylaxis for Pneumocystis
carinii  pneumonia among a) all
allogeneic pediatric HSCT
recipients or b) autologous
pediatric HSCT recipients with
underlying hematologic
malignancies (e.g., lymphoma or
leukemia) or for those receiving
intense conditioning regimens or
graft manipulation or for those
who have recently received
fludarabine or 2-
chlorodeoxyadenosine:*
Administer prophylaxis from time
of engraftment for ⊕6 months
after HSCT; continue >6 months
after HSCT for the duration of
immunosuppression for all
persons who a) are receiving
immunosuppressive therapy
(e.g., prednisone or cyclosporine)
or who b) have chronic graft-
versus-host disease
Trimethoprim-sulfamethoxazole,
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by
mouth in 2 divided doses 3 times/
week on consecutive days (AII);
or a single dose by mouth
3 times/week on consecutive
days; or by mouth in 2 divided
doses daily for 7 days; or by
mouth in 2 divided doses 3 times/
week on alternate days;
researchers also report
administering prophylaxis for 1–2
weeks before HSCT (i.e., day –14
to –2) (CIII)
Dapsone, for HSCT recipients
aged ⊕1 months, 2 mg/kg
(maximum dose, 100 mg) by
mouth daily (BIII); or intravenous
pentamidine, 4 mg/kg every 2–4
weeks; or aerosolized pentami-
dine, for HSCT recipients aged
≤5 years, 9 mg/kg/dose; or for
HSCT recipients aged >5 years,
300 mg; should be administered
every month by Respirgard II™
nebulizer (CIII)
* Source: Tuan IZ, Dennison D, Weisdorf DJ. Pneumocystis carinii  pneumonitis after bone marrow transplanta-
tion. Bone Marrow Transplant 1992;10(3):267–72.
Notes: Trimethoprim-sulfamethoxazole is not recommended for patients aged <2 months because of risk for
kernicterus. Patients who are receiving sulfadiazine-pyrimethamine for toxoplasmosis therapy are protected
against Pneumocystis carinii  and do not need additional prophylaxis.
Pathogen: Strongyloides  species
Indication First choice Alternatives
Prevention of strongyloidiasis
hyperinfection among pediatric
HSCT candidates whose HSCT
screening tests are positive for
Strongyloides  species or who
have an unexplained eosinophilia
and a travel or residence history
suggestive of exposure to
Strongyloides stercoralis:
Administer prophylaxis before
HSCT
Thiabendazole, 25 mg/kg 2 times
daily for 2 days; maximum dose,
3 g/24 hours
Ivermectin, 200 µg/kg by mouth
daily for 2 consecutive days*
(BIII); 1 tablet = 6 mg; doses
administered as follows:
Body
weight (kg) Oral dose
<15 Not recom-
mended
⊕15–24 ˚ tablet
25–35 1 tablet
36–50 1˚ tablets
51–65 2 tablets
66–79 2˚ tablets
⊕80 200 µg/kg
* Sources: Liu LX, Weller PF. Strongyloidiasis and other intestinal nematode infections [Review]. Infect Dis Clin
North Am 1993;7(3):655–82; and Naquira C, Jimenez G, Guerra JG, et al. Ivermectin for human strongyloidi-
asis and other intestinal helminths. Am J Trop Med Hyg 1989;40:304–9.
Notes: Ivermectin safety among children weighing <15 kg has not been established. Among
immunocompromised patients, multiple courses of ivermectin at 2-week intervals might be required; however,
cure might not be achievable. Safety and efficacy of ivermectin has not been established during pregnancy.
Thiabendazole is contraindicated during pregnancy.
Pathogen: Toxoplasma gondii
Indication First choice Alternatives
Prophylaxis of Toxoplasma
gondii  disease among seroposi-
tive allogeneic pediatric HSCT
recipients: Start after engraftment
and administer as long as
patients remain on immunosup-
pressive therapy (i.e., generally,
until 6 months after HSCT)
Trimethoprim-sulfamethoxazole,
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by
mouth in 2 divided doses 3 times/
week on consecutive days (AII);
or a single dose by mouth 3
times/week on consecutive days;
or by mouth in 2 divided doses
daily for 7 days; or by mouth in 2
divided doses 3 times/weekly on
alternate days
For those persons who are
intolerant of trimethoprim-
sulfamethoxazole, the following
drugs can be substituted:
Clindamycin, 20–30 mg/kg/day by
mouth, divided in 4 divided doses
daily; plus pyrimethamine, 1 mg/
kg by mouth daily; plus
leucovorin, 5 mg by mouth every
3 days (CIII)
Note: Trimethoprim-sulfamethoxazole is not recommended for patients aged <2 months because of risk for
kernicterus. Among allogeneic HSCT recipients, clinical toxoplasmosis has occurred despite the use of
trimethoprim-sulfamethoxazole for Pneumocystis carinii  prophylaxis (Source: Slavin MA, Meyers JD, Remington
JS, Hackman RC. Toxoplasma gondii  infection in marrow transplant recipients: a 20 year experience. Bone
Marrow Transplant 1994;13[5]:549–57).
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Pathogen: Traveler’s diarrhea
Indication First choice Alternatives
Prophylaxis among pediatric
HSCT recipients who are
immunocompromised and who
plan to travel in developing
countries
Trimethoprim-sulfamethoxazole,
150 mg trimethoprim/750 mg
sulfamethoxazole/m2/day by
mouth, divided in 2 doses 3
times/week on consecutive days
(CIII); can be administered for
duration of stay in developing
country
Trimethoprim-sulfamethoxazole,
single dose by mouth 3 times/
week on consecutive days
Notes: Use of aspirin-containing products including bismuth subsalicylate is contraindicated in persons aged
<18 years unless prescribed by a physician because these products have been associated with Reye’s syndrome
(Source: Belay E, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB. Reye’s syndrome in the United
States from 1981 through 1997. New Engl J Med 1999;340[18]:1377–82). Trimethoprim-sulfamethoxazole is not
recommended for patients aged <2 months because of risk for kernicterus. Resistance to trimethoprim-
sulfamethoxazole is common in tropical areas. Usual doses of trimethoprim-sulfamethoxazole for Pneumocystis
carinii  pneumonia prophylaxis should provide limited protection against traveler’s diarrhea.
Pathogen: Mycobacteria tuberculosis
Indication First choice Alternatives
Prevention of Mycobacteria
tuberculosis  among a) highly
immunocompromised pediatric
HSCT recipients or candidates
who have been exposed to
someone with active, infectious
(e.g., sputum smear positive)
pulmonary or laryngeal
tuberculosis, regardless of the
HSCT recipient’s or candidate’s
tuberculin skin test status, or b)
pediatric HSCT recipients or
candidates with a positive
tuberculin skin test and who were
not previously treated and have
no evidence of active tuberculo-
sis disease
Isoniazid, 10–20 mg/kg/day by
mouth or intramuscularly for
9 months (i.e., for ⊕270 doses);*
maximum dose, 300 mg/day, and
pyridoxine (vitamin B6), 1–2 mg/
kg/day by mouth daily for 9
months; dose required might
vary by age and condition;†
administer to nutritionally
deficient HSCT recipients and
candidates while on isoniazid
preventive therapy to reduce the
occurrence of isoniazid-induced
neuropathy* (BIII)
None
* Sources: American Academy of Pediatrics. Tuberculosis. In: Pickering LK, ed. 2000 red book: report of the
Committee on Infectious Diseases. 25th ed. Elk Grove Village, IL: American Academy of Pediatrics;2000:593–
613; CDC. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency
virus: principles of therapy and revised recommendations. MMWR 1998;47(No. RR-20):1–58; and CDC. Notice
to readers: use of short-course tuberculosis preventive therapy regimens in HIV-seronegative persons. MMWR
1998;47(42):911–2.
† Source: Siberry GK, Iannone R, eds. Harriet Lane handbook: a manual for pediatric house officers. 15th ed.; St.
Louis, MO: Mosby, Inc., 2000:834–5.
Notes: A twice-weekly schedule of isoniazid and pyridoxine can be administered (CIII). The twice-weekly iso-
niazid dose is 20–40 mg/kg by mouth or intramuscularly (maximum dose, 900 mg). A 2-month pyrazinamide/
rifampin preventive therapy regimen can be used for HSCT candidates who are not at risk for serious rifampin
drug interactions and whose HSCT is not scheduled until ⊕2 weeks after the 2-month course is completed.
Rifampin dose is 10–20 mg/kg/day by mouth or intravenously or 10–20 mk/kg/dose by mouth or intravenously,
administered 2 times/week (maximum pyrazinamide dose, 3.5 g; maximum rifampin dose, 600 mg) (Sources:
CDC. Notice to readers: use of short-course tuberculosis preventive therapy regimens in HIV-seronegative per-
sons. MMWR 1998;47[42]:911–2; and CDC. Prevention and treatment of tuberculosis among patients infected
with human immunodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47[No.
RR-20]:1–58.) (CIII). The usual pyrazinamide dose is 15–30 mg/kg/day by mouth or 50–70 mg/kg/dose by mouth 2
times/week (maximum) (maximum daily pyrazinamide dose, 2 g). Routine use of a 2-month pyrazinamide/
rifampin preventive therapy regimen is not recommended after HSCT because of the risk for serious rifampin
drug interactions (DIII). Persons who have been exposed to rifampin- and isoniazid-resistant tuberculosis should
be placed on preventive therapy regimens that involve ⊕2 antituberculosis drugs to which the infecting strain is
susceptible (Source: CDC. Prevention and treatment of tuberculosis among patients infected with human immu-
nodeficiency virus: principles of therapy and revised recommendations. MMWR 1998;47[No. RR-20]:1–58), and
a tuberculosis specialist should be consulted (BIII). A tuberculosis specialist should also be consulted for pa-
tients who are intolerant to isoniazid (AIII). All intermittent dosing strategies should be administered as directly
observed therapy (AIII).
76
     77B B & M T
Recommendations
and
Reports
Continuing Education Activity
Sponsored by CDC
Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell
Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of
America, and the American Society of Blood and Marrow Transplantation
EXPIRATION — OCTOBER 20, 2001
You must complete and return the response form electronically or by mail by October 20, 2001, to receive
continuing education credit. If you answer all of the questions, you will receive an award letter for 4.5 hours
Continuing Medical Education (CME) credit, 0.45 hour Continuing Education Units (CEUs), or 5.3 hours
Continuing Nursing Education (CNE) credit. If you return the form electronically, you will receive educational
credit immediately. If you mail the form, you will receive educational credit in approximately 30 days. No fees
are charged for participating in this continuing education activity.
INSTRUCTIONS
By Internet
1. Read this BBMT (Vol. 6, No 6a), which contains the correct answers to the questions beginning on the next
page.
2. Go to the MMWR Continuing Education Internet site at <http://www.cdc.gov/mmwr/cme/conted.html>.
3. Select which exam you want to take and select whether you want to register for CME, CEU, or CNE credit.
4. Fill out and submit the registration form.
5. Select exam questions. To receive continuing education credit, you must answer all of the questions.
Questions with more than one correct answer will instruct you to “Indicate all that apply.”
6. Submit your answers no later than October 20, 2001.
7. Immediately print your Certificate of Completion for your records.
By Mail
1. Read this BBMT  (Vol. 6, No 6a), which contains the correct answers to the questions beginning on the next
page.
2. Complete all registration information on the response form, including your name, mailing address, phone
number, and e-mail address, if available.
3. Indicate whether you are registering for CME, CEU, or CNE credit.
4. Select your answers to the questions, and mark the corresponding letters on the response form. To receive
continuing education credit, you must answer all of the questions. Questions with more than one correct
answer will instruct you to “Indicate all that apply.”
5. Sign and date the response form or a photocopy of the form and send no later than October 20, 2001, to
Fax: 404-639-4198 Mail: MMWR CE Credit
Office of Scientific and Health Communications
Epidemiology Program Office, MS C-08
Centers for Disease Control and Prevention
1600 Clifton Rd, N.E.
Atlanta, GA 30333
6. Your Certificate of Completion will be mailed to you within 30 days.
ACCREDITATION
Continuing Medical Education (CME). This activity has been planned and implemented in accordance with the Essential
Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CDC, the
Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. CDC is accredited by
the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CDC designates this educational activity for a maximum of 4.5 hours in category 1 credit towards the AMA Physician’s
Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational
activity.
Continuing Education Unit (CEU). CDC has been approved as an authorized provider of continuing education and training
programs by the International Association for Continuing Education and Training and awards 0.45 hour Continuing Education
Units (CEUs).
Continuing Nursing Education (CNE). This activity for 5.3 contact hours is provided by CDC, which is accredited as a provider
of continuing education in nursing by the American Nurses Credentialing Center’s Commission on Accreditation.
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Goals and Objectives
This MMWR  provides guidelines for preventing opportunistic infections (OIs) among hematopoietic stem cell
transplant (HSCT) recipients. The goals of these guidelines are to summarize current data regarding preventing
opportunistic infections among HSCT recipients and provide evidence-based recommended strategies for
preventing these OIs. Upon completion of this educational activity, the reader should be able to identify
strategies for a) preventing exposure and disease from bacterial, viral, fungal, protozoa, and helminth infections
and b) hospital infection control, safe living, vaccinations, and hematopoietic stem cell safety.
To receive continuing education credit, please answer all of the following questions.
1. What are the three phases of immune system recovery after HSCT?
A. Phase I, –45–21 days; phase II, 30–100 days; and phase III, >100 days.
B. Phase I, 0–21 days; phase II, 30–90 days; and phase III, >90 days.
C. Phase I, 0–30 days; phase II, 30–120 days; and phase III, >120–365 days.
D. Phase I, <30 days; phase II, 30–100 days; and phase III, >100 days.
E. None of the above.
2. Which opportunistic infections commonly occur during phase I?
A. Cytomegalovirus, Pneumocystis carinii  pneumonia, and aspergillosis.
B. Cytomegalovirus, Pneumocystis carinii  pneumonia, and varicella-zoster virus.
C. Herpes simplex virus, cytomegalovirus, and Candida  species.
D. Herpes simplex virus, Candida  species, and aspergillosis.
E. Herpes simplex virus, aspergillosis, and varicella-zoster virus.
3. HSCT recipients should avoid eating which of the following foods?
A. Raw or undercooked meat.
B. Unpasteurized dairy products.
C. Vegetable sprouts.
D. Soft cheese.
E. All of the above.
4. Which of the following statements is true regarding vaccinations that HSCT recipients should receive?
A. Diphtheria and tetanus toxoids at 12, 14, and 24 months after HSCT.
B. Measles, mumps, rubella vaccinations at 12 and 24 months after HSCT.
C. Pneumococcal vaccinations at 12, 14, and 24 months after HSCT.
D. Varicella-zoster immunoglobulin at 24 months after HSCT.
E. Oral polio vaccine at 12, 14, and 24 months after HSCT.
5. Recommended aspergillosis prophylaxis is . . .
A. Fluconazole, 400 mg by mouth or intravenously daily.
B. Fluconazole, 200 mg by mouth or intravenously daily.
C. Amphotericin B, 1 mg/kg/day intravenously.
D. Itraconazole capsules, 200 mg by mouth daily.
E. None of the above.
6. Which of the following statements is not true regarding use of laminar air flow rooms in HSCT centers?
A. Substantial survival benefit has been reported for all HSCT recipients.
B. Substantial survival benefit has been reported for allogeneic HSCT recipients with aplastic anemia
and human lymphocyte antigen-identical sibling donors.
C. Patients are protected from infection during aspergillosis outbreaks related to hospital construction.
D. Use of laminar air flow rooms for HSCT recipients is optional.
7. The number of recommended air exchanges per hour in an HSCT recipient’s hospital room is . . .
A. <6.
B. <8.
C. <10.
D. >12.
E. ⊕15.
8. Patient rooms in HSCT centers should have negative air pressure when compared with hallways and
anterooms.
A. True.
B. False.
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9. HSCT recipients should be cared for routinely by using . . .
A. standard precautions.
B. airborne precautions.
C. droplet precautions.
D. contact precautions.
E. all of the above.
10. The single-most critical and effective procedure for preventing nosocomial infection
is . . .
A. following isolation precautions.
B. following ventilation precautions.
C. hand washing.
D. environmental disinfection.
E. excluding visitors experiencing illness from the HSCT center.
11. An HSCT recipient can be exposed safely to visitors with . . .
A. an upper respiratory infection.
B. a covered shingles rash.
C. a varicella-zoster virus-like rash occurring ≤4 weeks after the person has received a varicella-zoster
virus vaccination.
D. a history of oral polio vaccination within the previous 3–6 weeks.
E. a history of vaccination with inactivated polio vaccine within the previous 3–6 weeks.
12. When constructing cooling towers for a new hospital with an HSCT center, all of the following should be
done to prevent legionellosis except . . .
A. installing drift eliminators.
B. regularly using an effective biocide.
C. maintaining the cooling towers according to the manufacturer’s directions.
D. locating the cooling towers so that drift is directed towards the hospital’s air-intake system.
E. keeping adequate maintenance records.
13. Which of the following animals is a safe pet for HSCT recipients?
A. Reptile.
B. Duckling.
C. Nonhuman primate.
D. Cat aged ⊕6 months.
E. Stray dog.
In questions 14–17, match the recommended prophylaxis drug with the pathogen it protects
against.
14. Acyclovir. A. Candida  species.
15. Foscarnet. B. Aspergillus  species.
16. Dapsone. C. Herpes simplex virus.
17. Fluconazole. D. Cytomegalovirus.
E. Pneumocystis carinii.
18. Indicate your work setting.
A. State/local health department.
B. Other public health setting.
C. Hospital clinic/private practice.
D. Managed care organization.
E. Academic institution.
F. Other.
Correct answers for questions 1–17.
1. D; 2. D; 3. E; 4. A; 5. E; 6. A; 7. D; 8. B; 9. A; 10. C; 11. E; 12. D; 13. D; 14. C; 15. D; 16. E; 17. A.
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19. Which best describes your professional activities?
A. Patient care — emergency/urgent care department.
B. Patient care — inpatient.
C. Patient care — primary-care clinic or office.
D. Laboratory/pharmacy.
E. Public health.
F. Other.
20. I plan to use these recommendations as the basis for . . . (Indicate all that apply. )
A. health education materials.
B. insurance reimbursement policies.
C. local practice guidelines.
D. public policy.
E. other.
21. Each month, approximately how many patients do you see?
A. None.
B. 1–5.
C. 6–20.
D. 21–50.
E. 51–100.
F. >100.
22. How much time did you spend reading this report and completing the exam?
A. 2–2.5 hours.
B. More than 2.5 hours but fewer than 3 hours.
C. 3–3.5 hours.
D. More than 3.5 hours but fewer than 4 hours.
E. More than 4.5 hours.
23. After reading this report, I am confident I can identify strategies for preventing exposure and disease from
bacterial infections among HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
24. After reading this report, I am confident I can identify strategies for preventing exposure and disease from
viral infections among HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
25. After reading this report, I am confident I can identify strategies for preventing exposure and disease from
fungal infections among HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
26. After reading this report, I am confident I can identify strategies for preventing exposure and disease from
protozoa infections among HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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27. After reading this report, I am confident I can identify strategies for preventing exposure and
disease from helminth infections among HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
28. After reading this report, I am confident I can identify strategies for hospital infection control for HSCT
recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
29. After reading this report, I am confident I can identify strategies for safe living for HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
30. After reading this report, I am confident I can identify strategies for vaccinations for HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
31. After reading this report, I am confident I can identify strategies for hematopoietic stem cell safety for
HSCT recipients.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
32. The objectives are relevant to the goal of this report.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
33. The figure, tables, and appendix are useful.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
34. Overall, the presentation of the report enhanced my ability to understand the material.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
35. These recommendations will affect my practice.
A. Strongly agree.
B. Agree.
C. Neither agree nor disagree.
D. Disagree.
E. Strongly disagree.
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CEU Credit
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Fill in the appropriate blocks to indicate your answers. Remember, you must answer all of the questions to
receive continuing education credit!
1. [ ] A [ ] B [ ] C [ ] D [ ] E
2. [ ] A [ ] B [ ] C [ ] D [ ] E
3. [ ] A [ ] B [ ] C [ ] D [ ] E
4. [ ] A [ ] B [ ] C [ ] D [ ] E
5. [ ] A [ ] B [ ] C [ ] D [ ] E
6. [ ] A [ ] B [ ] C [ ] D
7. [ ] A [ ] B [ ] C [ ] D [ ] E
8. [ ] A [ ] B
9. [ ] A [ ] B [ ] C [ ] D [ ] E
10. [ ] A [ ] B [ ] C [ ] D [ ] E
11. [ ] A [ ] B [ ] C [ ] D [ ] E
12. [ ] A [ ] B [ ] C [ ] D [ ] E
13. [ ] A [ ] B [ ] C [ ] D [ ] E
14. [ ] A [ ] B [ ] C [ ] D [ ] E
15. [ ] A [ ] B [ ] C [ ] D [ ] E
16. [ ] A [ ] B [ ] C [ ] D [ ] E
17. [ ] A [ ] B [ ] C [ ] D [ ] E
18. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
19. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
20. [ ] A [ ] B [ ] C [ ] D [ ] E
21. [ ] A [ ] B [ ] C [ ] D [ ] E [ ] F
22. [ ] A [ ] B [ ] C [ ] D [ ] E
23. [ ] A [ ] B [ ] C [ ] D [ ] E
24. [ ] A [ ] B [ ] C [ ] D [ ] E
25. [ ] A [ ] B [ ] C [ ] D [ ] E
26. [ ] A [ ] B [ ] C [ ] D [ ] E
27. [ ] A [ ] B [ ] C [ ] D [ ] E
28. [ ] A [ ] B [ ] C [ ] D [ ] E
29. [ ] A [ ] B [ ] C [ ] D [ ] E
30. [ ] A [ ] B [ ] C [ ] D [ ] E
31. [ ] A [ ] B [ ] C [ ] D [ ] E
32. [ ] A [ ] B [ ] C [ ] D [ ] E
33. [ ] A [ ] B [ ] C [ ] D [ ] E
34. [ ] A [ ] B [ ] C [ ] D [ ] E
35. [ ] A [ ] B [ ] C [ ] D [ ] E
 Response Form for Continuing Education Credit
Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell
Transplant Recipients: Recommendations of CDC, the Infectious Disease Society of
America, and the American Society of Blood and Marrow Transplantation
To receive continuing education credit, you must
1. provide your contact information;
2. indicate your choice of CME, CEU, or CNE credit;
3. answer all of the test questions;
4. sign and date this form or a photocopy;
5. submit your answer form by October 20, 2001.
Failure to complete these items can result in a delay or rejection of
your application for continuing education credit.
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References to non-CDC sites on the Internet are provided as a service to MMWR
readers and do not constitute or imply endorsement of these organizations or
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CDC is not responsible for the content of pages found at these sites.
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